PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
33806161-7	2021	Treatment of evodiamine also induced downregulation of urease and diminished translocation of cytotoxin-associated antigen A (CagA) and vacuolating cytotoxin A (VacA) proteins into gastric adenocarcinoma (AGS) cells.	evodiamine	13-23	S100 calcium binding protein A8	Homo sapiens	126-130
9395722-3	1997	This stimulatory effect of evodiamine was abolished by omission of Ca2+ from the perfusion fluid.	evodiamine	27-37	carbonic anhydrase 2	Bos taurus	67-70
33762570-0	2021	Retracted: Evodiamine Induces Apoptosis, G2/M Cell Cycle Arrest, and Inhibition of Cell Migration and Invasion in Human Osteosarcoma Cells via Raf/MEK/ERK Signalling Pathway.	evodiamine	11-21	mitogen-activated protein kinase kinase 7	Homo sapiens	147-150
33762570-0	2021	Retracted: Evodiamine Induces Apoptosis, G2/M Cell Cycle Arrest, and Inhibition of Cell Migration and Invasion in Human Osteosarcoma Cells via Raf/MEK/ERK Signalling Pathway.	evodiamine	11-21	mitogen-activated protein kinase 1	Homo sapiens	151-154
33762570-2	2021	Reference: Yuelai Zhou, Jinlong Hu: Evodiamine Induces Apoptosis, G2/M Cell Cycle Arrest, and Inhibition of Cell Migration and Invasion in Human Osteosarcoma Cells via Raf/MEK/ERK Signalling Pathway.	evodiamine	36-46	mitogen-activated protein kinase kinase 7	Homo sapiens	172-175
33762570-2	2021	Reference: Yuelai Zhou, Jinlong Hu: Evodiamine Induces Apoptosis, G2/M Cell Cycle Arrest, and Inhibition of Cell Migration and Invasion in Human Osteosarcoma Cells via Raf/MEK/ERK Signalling Pathway.	evodiamine	36-46	mitogen-activated protein kinase 1	Homo sapiens	176-179
33806161-9	2021	In particular, evodiamine inhibited the activation of signaling proteins such as the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappaB) and the mitogen-activated protein kinase (MAPK) pathway induced by H. pylori infection.	evodiamine	15-25	nuclear factor kappa B subunit 1	Homo sapiens	149-158
34942456-12	2022	CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer.	evodiamine	180-190	cyclin dependent kinase inhibitor 1A	Homo sapiens	233-239
34401976-0	2022	Evodiamine Relieve LPS-Induced Mastitis by Inhibiting AKT/NF-kappaB p65 and MAPK Signaling Pathways.	evodiamine	0-10	thymoma viral proto-oncogene 1	Mus musculus	54-57
34401976-5	2022	The results showed that evodiamine could significantly relieve the pathological injury of breast tissue and the production of pro-inflammatory cytokines and inhibit the activation of inflammation-related pathways such as AKT, NF-kappaB p65, ERK1/2, p38, and JNK.	evodiamine	24-34	thymoma viral proto-oncogene 1	Mus musculus	221-224
34401976-5	2022	The results showed that evodiamine could significantly relieve the pathological injury of breast tissue and the production of pro-inflammatory cytokines and inhibit the activation of inflammation-related pathways such as AKT, NF-kappaB p65, ERK1/2, p38, and JNK.	evodiamine	24-34	mitogen-activated protein kinase 3	Mus musculus	241-247
34401976-5	2022	The results showed that evodiamine could significantly relieve the pathological injury of breast tissue and the production of pro-inflammatory cytokines and inhibit the activation of inflammation-related pathways such as AKT, NF-kappaB p65, ERK1/2, p38, and JNK.	evodiamine	24-34	mitogen-activated protein kinase 14	Mus musculus	249-252
34401976-5	2022	The results showed that evodiamine could significantly relieve the pathological injury of breast tissue and the production of pro-inflammatory cytokines and inhibit the activation of inflammation-related pathways such as AKT, NF-kappaB p65, ERK1/2, p38, and JNK.	evodiamine	24-34	mitogen-activated protein kinase 8	Mus musculus	258-261
34401976-9	2022	All the results suggested that evodiamine inhibited inflammation by inhibiting the phosphorylation of AKT, NF-kappaBp65, ERK1/2, p38, and JNK thus the LPS-induced mastitis was ameliorated.	evodiamine	31-41	thymoma viral proto-oncogene 1	Mus musculus	102-105
34401976-9	2022	All the results suggested that evodiamine inhibited inflammation by inhibiting the phosphorylation of AKT, NF-kappaBp65, ERK1/2, p38, and JNK thus the LPS-induced mastitis was ameliorated.	evodiamine	31-41	mitogen-activated protein kinase 3	Mus musculus	121-127
34401976-9	2022	All the results suggested that evodiamine inhibited inflammation by inhibiting the phosphorylation of AKT, NF-kappaBp65, ERK1/2, p38, and JNK thus the LPS-induced mastitis was ameliorated.	evodiamine	31-41	mitogen-activated protein kinase 14	Mus musculus	129-132
34401976-9	2022	All the results suggested that evodiamine inhibited inflammation by inhibiting the phosphorylation of AKT, NF-kappaBp65, ERK1/2, p38, and JNK thus the LPS-induced mastitis was ameliorated.	evodiamine	31-41	mitogen-activated protein kinase 8	Mus musculus	138-141
34942456-12	2022	CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer.	evodiamine	180-190	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	260-263
34942456-12	2022	CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer.	evodiamine	180-190	cyclin dependent kinase 2	Homo sapiens	265-269
34942456-12	2022	CONCLUSIONS: In summary, combined network pharmacology and biological experiments proved that the main ingredients of ZJC such as quercetin, (R)-Canadine, palmatine, rutaecarpine, evodiamine, beta-sitosterol and berberine can target CDKN1A, Bcl2, E2F1, PRKCB, MYC, CDK2 and MMP9 to combat colorectal cancer.	evodiamine	180-190	matrix metallopeptidase 9	Homo sapiens	274-278
34808100-0	2022	Evodiamine induces ROS-Dependent cytotoxicity in human gastric cancer cells via TRPV1/Ca2+ pathway.	evodiamine	0-10	transient receptor potential cation channel subfamily V member 1	Homo sapiens	80-85
34808100-2	2022	Our study aims to explain the underlying role of TRPV1/Ca2+ in EVO-induced cytotoxicity in human gastric cancer cells.	evodiamine	63-66	transient receptor potential cation channel subfamily V member 1	Homo sapiens	49-54
34808100-17	2022	Pharmacological and genetic inhibition of TRPV1 could significantly attenuate Ca2+ influx, ROS generation and apoptotic cell death induced by EVO exposure, while exogenous TRPV1 overexpression could augment the EVO-induced cytotoxicity.	evodiamine	142-145	transient receptor potential cation channel subfamily V member 1	Homo sapiens	42-47
34808100-17	2022	Pharmacological and genetic inhibition of TRPV1 could significantly attenuate Ca2+ influx, ROS generation and apoptotic cell death induced by EVO exposure, while exogenous TRPV1 overexpression could augment the EVO-induced cytotoxicity.	evodiamine	211-214	transient receptor potential cation channel subfamily V member 1	Homo sapiens	172-177
34808100-19	2022	EVO exposure induced endoplasmic reticulum (ER) stress demonstrated by the activation of PERK/CHOP in cells exposed to EVO, and PERK/CHOP activation was depleted by EUK134 pre-treatment.	evodiamine	0-3	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	89-93
34808100-19	2022	EVO exposure induced endoplasmic reticulum (ER) stress demonstrated by the activation of PERK/CHOP in cells exposed to EVO, and PERK/CHOP activation was depleted by EUK134 pre-treatment.	evodiamine	0-3	DNA damage inducible transcript 3	Homo sapiens	94-98
34808100-20	2022	Our results support the concept that EVO induces ROS-dependent cytotoxicity via TRPV1/Ca2+ Pathway.	evodiamine	37-40	transient receptor potential cation channel subfamily V member 1	Homo sapiens	80-85
34944525-5	2021	Evodiamine, berberine, genipin, palmitic acid, genistein, and quercetin were shown to regulate adipocytokine signaling pathway proteins which mainly involved tumor necrosis factor receptor 1, leptin receptor.	evodiamine	0-10	leptin receptor	Homo sapiens	192-207
34886886-0	2021	Roles of reactive oxygen species, mitochondrial membrane potential, and p53 in evodiamine-induced apoptosis and G2/M arrest of human anaplastic thyroid carcinoma cells.	evodiamine	79-89	tumor protein p53	Homo sapiens	72-75
34886886-8	2021	Mechanistic studies showed that increased p53 and its downstream proteins, and disrupted MMP with increased intracellular peroxide production participated in EVO-induced apoptosis and G2/M arrest of SW1736 cells.	evodiamine	158-161	tumor protein p53	Homo sapiens	42-45
34886886-11	2021	CONCLUSION: Evidence indicated that the endogenous p53 status affected the sensitivity of ATC cells to EVO-induced apoptosis and G2/M arrest, revealing the potential role of p53 related to increased ROS production and disrupted MMP in the anticancer actions of EVO, and alkylation at position 14 of EVO is a critical substitution for apoptosis of ATC cells.	evodiamine	103-106	tumor protein p53	Homo sapiens	51-54
34886886-11	2021	CONCLUSION: Evidence indicated that the endogenous p53 status affected the sensitivity of ATC cells to EVO-induced apoptosis and G2/M arrest, revealing the potential role of p53 related to increased ROS production and disrupted MMP in the anticancer actions of EVO, and alkylation at position 14 of EVO is a critical substitution for apoptosis of ATC cells.	evodiamine	103-106	tumor protein p53	Homo sapiens	174-177
34886886-11	2021	CONCLUSION: Evidence indicated that the endogenous p53 status affected the sensitivity of ATC cells to EVO-induced apoptosis and G2/M arrest, revealing the potential role of p53 related to increased ROS production and disrupted MMP in the anticancer actions of EVO, and alkylation at position 14 of EVO is a critical substitution for apoptosis of ATC cells.	evodiamine	261-264	tumor protein p53	Homo sapiens	51-54
34886886-11	2021	CONCLUSION: Evidence indicated that the endogenous p53 status affected the sensitivity of ATC cells to EVO-induced apoptosis and G2/M arrest, revealing the potential role of p53 related to increased ROS production and disrupted MMP in the anticancer actions of EVO, and alkylation at position 14 of EVO is a critical substitution for apoptosis of ATC cells.	evodiamine	261-264	tumor protein p53	Homo sapiens	174-177
34886886-11	2021	CONCLUSION: Evidence indicated that the endogenous p53 status affected the sensitivity of ATC cells to EVO-induced apoptosis and G2/M arrest, revealing the potential role of p53 related to increased ROS production and disrupted MMP in the anticancer actions of EVO, and alkylation at position 14 of EVO is a critical substitution for apoptosis of ATC cells.	evodiamine	299-302	tumor protein p53	Homo sapiens	51-54
34844412-2	2021	Herein, we report using a scaffold-hopping approach to identify a series of novel polycyclic heterocyclic derivatives based on Evo as the topoisomerase I (Top1) inhibitor for the treatment of triple-negative breast cancer (TNBC), which is an aggressive subtype of breast cancer with limited treatment options.	evodiamine	127-130	DNA topoisomerase I	Homo sapiens	155-159
34902249-0	2021	Evodiamine Lowers Blood Lipids by Up-Regulating the PPARgamma/ABCG1 Pathway in High-Fat-Diet-Fed Mice.	evodiamine	0-10	peroxisome proliferator activated receptor gamma	Mus musculus	52-61
34902249-0	2021	Evodiamine Lowers Blood Lipids by Up-Regulating the PPARgamma/ABCG1 Pathway in High-Fat-Diet-Fed Mice.	evodiamine	0-10	ATP binding cassette subfamily G member 1	Mus musculus	62-67
34902249-5	2021	Mechanistically, evodiamine increased ATP-binding cassette transporter G1 (ABCG1) mRNA and protein expression and up-regulated peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver.	evodiamine	17-27	ATP binding cassette subfamily G member 1	Mus musculus	38-73
34902249-5	2021	Mechanistically, evodiamine increased ATP-binding cassette transporter G1 (ABCG1) mRNA and protein expression and up-regulated peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver.	evodiamine	17-27	ATP binding cassette subfamily G member 1	Mus musculus	75-80
34902249-5	2021	Mechanistically, evodiamine increased ATP-binding cassette transporter G1 (ABCG1) mRNA and protein expression and up-regulated peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver.	evodiamine	17-27	peroxisome proliferator activated receptor gamma	Mus musculus	127-175
34902249-5	2021	Mechanistically, evodiamine increased ATP-binding cassette transporter G1 (ABCG1) mRNA and protein expression and up-regulated peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver.	evodiamine	17-27	peroxisome proliferator activated receptor gamma	Mus musculus	177-186
34902249-6	2021	Taken together, the natural product evodiamine lowers blood lipids in HFD-fed mice likely through promoting the PPARgamma-ABCG1 signaling pathway.	evodiamine	36-46	peroxisome proliferator activated receptor gamma	Mus musculus	112-121
34902249-6	2021	Taken together, the natural product evodiamine lowers blood lipids in HFD-fed mice likely through promoting the PPARgamma-ABCG1 signaling pathway.	evodiamine	36-46	ATP binding cassette subfamily G member 1	Mus musculus	122-127
34916690-10	2021	After exposure to EVO (0.2, 1 and 5 mumol/L) for 48 h, the ALT, AST, LDH, ALP activities and TBIL content in the HepG2 cell culture supernatant, and the MDA content in the cells were increased, and SOD enzyme activity was decreased.	evodiamine	18-21	solute carrier family 17 member 5	Homo sapiens	64-67
34916690-10	2021	After exposure to EVO (0.2, 1 and 5 mumol/L) for 48 h, the ALT, AST, LDH, ALP activities and TBIL content in the HepG2 cell culture supernatant, and the MDA content in the cells were increased, and SOD enzyme activity was decreased.	evodiamine	18-21	alkaline phosphatase, placental	Homo sapiens	74-77
34916690-10	2021	After exposure to EVO (0.2, 1 and 5 mumol/L) for 48 h, the ALT, AST, LDH, ALP activities and TBIL content in the HepG2 cell culture supernatant, and the MDA content in the cells were increased, and SOD enzyme activity was decreased.	evodiamine	18-21	superoxide dismutase 1	Homo sapiens	198-201
34916690-11	2021	Molecular docking results showed that EVO interacted with apoptosis-associated proteins (caspase-9 and caspase-3) better.	evodiamine	38-41	caspase 9	Homo sapiens	89-98
34916690-11	2021	Molecular docking results showed that EVO interacted with apoptosis-associated proteins (caspase-9 and caspase-3) better.	evodiamine	38-41	caspase 3	Homo sapiens	103-112
34916690-12	2021	JC-10 and Annexin V-FITC/PI staining assays demonstrated that EVO could decrease MMP and promote apoptosis in the HepG2 cells.	evodiamine	62-65	annexin A5	Homo sapiens	10-19
34916690-13	2021	Western blot results indicated that the protein expressions of cleaved caspase-9 and cleaved caspase-3 were upregulated in the HepG2 cell treated with EVO for 48 h. In contrast, the protein expressions of pro-caspase-3, BSEP and MRP2 were downregulated.	evodiamine	151-154	caspase 9	Homo sapiens	71-80
34916690-13	2021	Western blot results indicated that the protein expressions of cleaved caspase-9 and cleaved caspase-3 were upregulated in the HepG2 cell treated with EVO for 48 h. In contrast, the protein expressions of pro-caspase-3, BSEP and MRP2 were downregulated.	evodiamine	151-154	caspase 3	Homo sapiens	93-102
34916690-13	2021	Western blot results indicated that the protein expressions of cleaved caspase-9 and cleaved caspase-3 were upregulated in the HepG2 cell treated with EVO for 48 h. In contrast, the protein expressions of pro-caspase-3, BSEP and MRP2 were downregulated.	evodiamine	151-154	caspase 3	Homo sapiens	205-218
34916690-13	2021	Western blot results indicated that the protein expressions of cleaved caspase-9 and cleaved caspase-3 were upregulated in the HepG2 cell treated with EVO for 48 h. In contrast, the protein expressions of pro-caspase-3, BSEP and MRP2 were downregulated.	evodiamine	151-154	ATP binding cassette subfamily B member 11	Homo sapiens	220-224
34916690-13	2021	Western blot results indicated that the protein expressions of cleaved caspase-9 and cleaved caspase-3 were upregulated in the HepG2 cell treated with EVO for 48 h. In contrast, the protein expressions of pro-caspase-3, BSEP and MRP2 were downregulated.	evodiamine	151-154	ATP binding cassette subfamily C member 2	Homo sapiens	229-233
34808100-19	2022	EVO exposure induced endoplasmic reticulum (ER) stress demonstrated by the activation of PERK/CHOP in cells exposed to EVO, and PERK/CHOP activation was depleted by EUK134 pre-treatment.	evodiamine	0-3	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	128-132
34808100-19	2022	EVO exposure induced endoplasmic reticulum (ER) stress demonstrated by the activation of PERK/CHOP in cells exposed to EVO, and PERK/CHOP activation was depleted by EUK134 pre-treatment.	evodiamine	0-3	DNA damage inducible transcript 3	Homo sapiens	133-137
34808100-19	2022	EVO exposure induced endoplasmic reticulum (ER) stress demonstrated by the activation of PERK/CHOP in cells exposed to EVO, and PERK/CHOP activation was depleted by EUK134 pre-treatment.	evodiamine	119-122	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	89-93
34808100-19	2022	EVO exposure induced endoplasmic reticulum (ER) stress demonstrated by the activation of PERK/CHOP in cells exposed to EVO, and PERK/CHOP activation was depleted by EUK134 pre-treatment.	evodiamine	119-122	DNA damage inducible transcript 3	Homo sapiens	94-98
34477479-0	2021	The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway.	evodiamine	26-36	renin binding protein	Homo sapiens	128-131
34477479-0	2021	The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway.	evodiamine	26-36	advanced glycosylation end-product specific receptor	Homo sapiens	135-179
34477479-0	2021	The anti-tumor effects of evodiamine on oral squamous cell carcinoma (OSCC) through regulating advanced glycation end products (AGE) / receptor for advanced glycation end products (RAGE) pathway.	evodiamine	26-36	advanced glycosylation end-product specific receptor	Homo sapiens	181-185
34477479-6	2021	Further experiments revealed that the RAGE overexpression was able to markedly block the effects of EVO on cell proliferation and invasion, and tube formation.	evodiamine	100-103	advanced glycosylation end-product specific receptor	Homo sapiens	38-42
34477479-7	2021	By analyzing the expression of High-Mobility Group Box 1 (HMGB1) and RAGE in HSC-4 cells, the result showed that EVO slightly reduced HMBG1 levels and dramatically decreased RAGE levels, while RAGE overexpression did have no marked influences on HMBG1 levels.	evodiamine	113-116	high mobility group box 1	Homo sapiens	31-56
34477479-7	2021	By analyzing the expression of High-Mobility Group Box 1 (HMGB1) and RAGE in HSC-4 cells, the result showed that EVO slightly reduced HMBG1 levels and dramatically decreased RAGE levels, while RAGE overexpression did have no marked influences on HMBG1 levels.	evodiamine	113-116	high mobility group box 1	Homo sapiens	58-63
34477479-7	2021	By analyzing the expression of High-Mobility Group Box 1 (HMGB1) and RAGE in HSC-4 cells, the result showed that EVO slightly reduced HMBG1 levels and dramatically decreased RAGE levels, while RAGE overexpression did have no marked influences on HMBG1 levels.	evodiamine	113-116	advanced glycosylation end-product specific receptor	Homo sapiens	69-73
34477479-7	2021	By analyzing the expression of High-Mobility Group Box 1 (HMGB1) and RAGE in HSC-4 cells, the result showed that EVO slightly reduced HMBG1 levels and dramatically decreased RAGE levels, while RAGE overexpression did have no marked influences on HMBG1 levels.	evodiamine	113-116	advanced glycosylation end-product specific receptor	Homo sapiens	174-178
34477479-9	2021	Remarkable anti-tumor effects of EVO were also demonstrated, as presented by reduced tumor size and levels of HMBG1 and RAGE in tumor tissue of mouse oral squamous cell carcinoma xenograft models.	evodiamine	33-36	advanced glycosylation end product-specific receptor	Mus musculus	120-124
34477479-10	2021	The results demonstrated that EVO has a direct binding effect on HMGB1, but it may be involved in degrading the protein.	evodiamine	30-33	high mobility group box 1	Mus musculus	65-70
34477479-12	2021	To conclude, EVO inhibited proliferation, invasion and angiogenesis of OSCC through affecting the downstream signal transduction system of AGE/RAGE by targeting RAGE.	evodiamine	13-16	renin binding protein	Homo sapiens	139-142
34477479-12	2021	To conclude, EVO inhibited proliferation, invasion and angiogenesis of OSCC through affecting the downstream signal transduction system of AGE/RAGE by targeting RAGE.	evodiamine	13-16	advanced glycosylation end product-specific receptor	Mus musculus	143-147
34477479-12	2021	To conclude, EVO inhibited proliferation, invasion and angiogenesis of OSCC through affecting the downstream signal transduction system of AGE/RAGE by targeting RAGE.	evodiamine	13-16	advanced glycosylation end product-specific receptor	Mus musculus	161-165
33577738-0	2021	Evodiamine protects against airway remodelling and inflammation in asthmatic rats by modulating the HMGB1/NF-kappaB/TLR-4 signalling pathway.	evodiamine	0-10	high mobility group box 1	Rattus norvegicus	100-105
33577738-0	2021	Evodiamine protects against airway remodelling and inflammation in asthmatic rats by modulating the HMGB1/NF-kappaB/TLR-4 signalling pathway.	evodiamine	0-10	toll-like receptor 4	Rattus norvegicus	116-121
33577738-9	2021	Evodiamine treatment reduced IgE and IFN-gamma levels as well as the inflammatory cell infiltrate in the lung tissue of asthmatic rats.	evodiamine	0-10	interferon gamma	Rattus norvegicus	37-46
33577738-11	2021	Lower levels of TLR-4, MyD88, NF-kappaB, and HMGB1 mRNA in lung tissue were measured in the evodiamine-treated group than in the asthma group.	evodiamine	92-102	toll-like receptor 4	Rattus norvegicus	16-21
33577738-11	2021	Lower levels of TLR-4, MyD88, NF-kappaB, and HMGB1 mRNA in lung tissue were measured in the evodiamine-treated group than in the asthma group.	evodiamine	92-102	MYD88, innate immune signal transduction adaptor	Rattus norvegicus	23-28
33577738-11	2021	Lower levels of TLR-4, MyD88, NF-kappaB, and HMGB1 mRNA in lung tissue were measured in the evodiamine-treated group than in the asthma group.	evodiamine	92-102	high mobility group box 1	Rattus norvegicus	45-50
33577738-12	2021	DISCUSSION AND CONCLUSION: The effect of evodiamine treatment protects the asthma, as evodiamine reduces airway inflammation and remodelling in the lung tissue by downregulating the HMGB1/NF-kappaB/TLR-4 pathway in asthma.	evodiamine	41-51	high mobility group box 1	Rattus norvegicus	182-187
33577738-12	2021	DISCUSSION AND CONCLUSION: The effect of evodiamine treatment protects the asthma, as evodiamine reduces airway inflammation and remodelling in the lung tissue by downregulating the HMGB1/NF-kappaB/TLR-4 pathway in asthma.	evodiamine	41-51	toll-like receptor 4	Rattus norvegicus	198-203
33577738-12	2021	DISCUSSION AND CONCLUSION: The effect of evodiamine treatment protects the asthma, as evodiamine reduces airway inflammation and remodelling in the lung tissue by downregulating the HMGB1/NF-kappaB/TLR-4 pathway in asthma.	evodiamine	86-96	high mobility group box 1	Rattus norvegicus	182-187
33577738-12	2021	DISCUSSION AND CONCLUSION: The effect of evodiamine treatment protects the asthma, as evodiamine reduces airway inflammation and remodelling in the lung tissue by downregulating the HMGB1/NF-kappaB/TLR-4 pathway in asthma.	evodiamine	86-96	toll-like receptor 4	Rattus norvegicus	198-203
34824590-11	2021	Mechanistically, the results demonstrated that evodiamine promoted the relative mRNA and protein expression of PTEN and decreased expression of EGF, EGFR, PI3K, AKT, p-AKT, and mTOR.	evodiamine	47-57	AKT serine/threonine kinase 1	Homo sapiens	161-164
34824590-11	2021	Mechanistically, the results demonstrated that evodiamine promoted the relative mRNA and protein expression of PTEN and decreased expression of EGF, EGFR, PI3K, AKT, p-AKT, and mTOR.	evodiamine	47-57	AKT serine/threonine kinase 1	Homo sapiens	168-171
34824590-11	2021	Mechanistically, the results demonstrated that evodiamine promoted the relative mRNA and protein expression of PTEN and decreased expression of EGF, EGFR, PI3K, AKT, p-AKT, and mTOR.	evodiamine	47-57	mechanistic target of rapamycin kinase	Homo sapiens	177-181
34824590-12	2021	Most importantly, evodiamine could effectively increase the mRNA and protein expression of PTEN and decrease the protein expression of EGF/PI3K pathway, indicating that evodiamine downregulated EGF/PI3K through the activation of PTEN pathway.	evodiamine	18-28	phosphatase and tensin homolog	Homo sapiens	91-95
34824590-12	2021	Most importantly, evodiamine could effectively increase the mRNA and protein expression of PTEN and decrease the protein expression of EGF/PI3K pathway, indicating that evodiamine downregulated EGF/PI3K through the activation of PTEN pathway.	evodiamine	18-28	epidermal growth factor	Homo sapiens	135-143
34824590-12	2021	Most importantly, evodiamine could effectively increase the mRNA and protein expression of PTEN and decrease the protein expression of EGF/PI3K pathway, indicating that evodiamine downregulated EGF/PI3K through the activation of PTEN pathway.	evodiamine	18-28	epidermal growth factor	Homo sapiens	194-197
34824590-12	2021	Most importantly, evodiamine could effectively increase the mRNA and protein expression of PTEN and decrease the protein expression of EGF/PI3K pathway, indicating that evodiamine downregulated EGF/PI3K through the activation of PTEN pathway.	evodiamine	18-28	phosphatase and tensin homolog	Homo sapiens	229-233
34824590-12	2021	Most importantly, evodiamine could effectively increase the mRNA and protein expression of PTEN and decrease the protein expression of EGF/PI3K pathway, indicating that evodiamine downregulated EGF/PI3K through the activation of PTEN pathway.	evodiamine	169-179	phosphatase and tensin homolog	Homo sapiens	91-95
34824590-12	2021	Most importantly, evodiamine could effectively increase the mRNA and protein expression of PTEN and decrease the protein expression of EGF/PI3K pathway, indicating that evodiamine downregulated EGF/PI3K through the activation of PTEN pathway.	evodiamine	169-179	epidermal growth factor	Homo sapiens	135-143
34824590-12	2021	Most importantly, evodiamine could effectively increase the mRNA and protein expression of PTEN and decrease the protein expression of EGF/PI3K pathway, indicating that evodiamine downregulated EGF/PI3K through the activation of PTEN pathway.	evodiamine	169-179	epidermal growth factor	Homo sapiens	194-197
34824590-12	2021	Most importantly, evodiamine could effectively increase the mRNA and protein expression of PTEN and decrease the protein expression of EGF/PI3K pathway, indicating that evodiamine downregulated EGF/PI3K through the activation of PTEN pathway.	evodiamine	169-179	phosphatase and tensin homolog	Homo sapiens	229-233
34824590-13	2021	Conclusion: Evodiamine inhibited the directional migration and invasion of GC cells by inhibiting PTEN-mediated EGF/PI3K signaling pathway.	evodiamine	12-22	phosphatase and tensin homolog	Homo sapiens	98-102
34824590-13	2021	Conclusion: Evodiamine inhibited the directional migration and invasion of GC cells by inhibiting PTEN-mediated EGF/PI3K signaling pathway.	evodiamine	12-22	epidermal growth factor	Homo sapiens	112-115
34713388-0	2022	Identification of evodiamine as a suppressor of prostate cancer progression by reducing AR transcriptional activity via targeting Src.	evodiamine	18-28	steroid receptor RNA activator 1	Homo sapiens	130-133
34824590-0	2021	Evodiamine Inhibits Gastric Cancer Cell Proliferation via PTEN-Mediated EGF/PI3K Signaling Pathway.	evodiamine	0-10	phosphatase and tensin homolog	Homo sapiens	58-62
34824590-0	2021	Evodiamine Inhibits Gastric Cancer Cell Proliferation via PTEN-Mediated EGF/PI3K Signaling Pathway.	evodiamine	0-10	epidermal growth factor	Homo sapiens	72-75
34824590-11	2021	Mechanistically, the results demonstrated that evodiamine promoted the relative mRNA and protein expression of PTEN and decreased expression of EGF, EGFR, PI3K, AKT, p-AKT, and mTOR.	evodiamine	47-57	phosphatase and tensin homolog	Homo sapiens	111-115
34824590-11	2021	Mechanistically, the results demonstrated that evodiamine promoted the relative mRNA and protein expression of PTEN and decreased expression of EGF, EGFR, PI3K, AKT, p-AKT, and mTOR.	evodiamine	47-57	epidermal growth factor	Homo sapiens	144-147
34824590-11	2021	Mechanistically, the results demonstrated that evodiamine promoted the relative mRNA and protein expression of PTEN and decreased expression of EGF, EGFR, PI3K, AKT, p-AKT, and mTOR.	evodiamine	47-57	epidermal growth factor receptor	Homo sapiens	149-153
34713388-9	2022	Mechanistically, evodiamine directly targeted Src and reduced DHT-induced Src activation.	evodiamine	17-27	steroid receptor RNA activator 1	Homo sapiens	46-49
34713388-9	2022	Mechanistically, evodiamine directly targeted Src and reduced DHT-induced Src activation.	evodiamine	17-27	steroid receptor RNA activator 1	Homo sapiens	74-77
34713388-11	2022	Furthermore, evodiamine inhibited DHT-induced AR transcriptional activity through targeting Src.	evodiamine	13-23	steroid receptor RNA activator 1	Homo sapiens	92-95
34713388-12	2022	As a conclusion, our findings demonstrate the antitumor property of evodiamine in PCa by blocking AR transcriptional activity through targeting Src and provide a rationale for developing evodiamine as a promising antitumor agent against PCa.	evodiamine	68-78	steroid receptor RNA activator 1	Homo sapiens	144-147
35163776-11	2022	In conclusion, YAP is a critical target in HCC therapy, and evodiamine can be an effective HCC anticancer drug by reducing the YAP level.	evodiamine	60-70	Yes1 associated transcriptional regulator	Homo sapiens	127-130
34378540-4	2021	Evodiamine, as a multi-target natural product, has been found to exert various biological activities such as anti-cancer and anti-hepatic fibrosis via blocking topoisomerase, NF-kappaB, TGF-beta/HGF, and Smad2/3.	evodiamine	0-10	transforming growth factor alpha	Rattus norvegicus	186-194
34378540-4	2021	Evodiamine, as a multi-target natural product, has been found to exert various biological activities such as anti-cancer and anti-hepatic fibrosis via blocking topoisomerase, NF-kappaB, TGF-beta/HGF, and Smad2/3.	evodiamine	0-10	hepatocyte growth factor	Rattus norvegicus	195-198
34378540-4	2021	Evodiamine, as a multi-target natural product, has been found to exert various biological activities such as anti-cancer and anti-hepatic fibrosis via blocking topoisomerase, NF-kappaB, TGF-beta/HGF, and Smad2/3.	evodiamine	0-10	SMAD family member 2	Rattus norvegicus	204-211
34218553-13	2021	Compared with the model group, evodiamine could reduce liver index and serum ALT and AST levels, increase ALB and TP levels (P<0.05) , improve inflammatory cell infiltration and fibrosis degree in liver tissue, and up regulate intestinal flora Shannon and Simpson indexes in liver fibrosis mice (P<0.05) .	evodiamine	31-41	glutamic pyruvic transaminase, soluble	Mus musculus	77-80
34218553-13	2021	Compared with the model group, evodiamine could reduce liver index and serum ALT and AST levels, increase ALB and TP levels (P<0.05) , improve inflammatory cell infiltration and fibrosis degree in liver tissue, and up regulate intestinal flora Shannon and Simpson indexes in liver fibrosis mice (P<0.05) .	evodiamine	31-41	solute carrier family 17 (anion/sugar transporter), member 5	Mus musculus	85-88
34218553-13	2021	Compared with the model group, evodiamine could reduce liver index and serum ALT and AST levels, increase ALB and TP levels (P<0.05) , improve inflammatory cell infiltration and fibrosis degree in liver tissue, and up regulate intestinal flora Shannon and Simpson indexes in liver fibrosis mice (P<0.05) .	evodiamine	31-41	albumin	Mus musculus	106-109
34218553-15	2021	Compared with the model group, evodiamine could reduce the mRNA and protein levels of IL-6, IL-1beta and TNF-alpha in liver tissue of liver fibrosis mice (P<0.05) .	evodiamine	31-41	interleukin 6	Mus musculus	86-90
34218553-15	2021	Compared with the model group, evodiamine could reduce the mRNA and protein levels of IL-6, IL-1beta and TNF-alpha in liver tissue of liver fibrosis mice (P<0.05) .	evodiamine	31-41	interleukin 1 alpha	Mus musculus	92-100
34218553-15	2021	Compared with the model group, evodiamine could reduce the mRNA and protein levels of IL-6, IL-1beta and TNF-alpha in liver tissue of liver fibrosis mice (P<0.05) .	evodiamine	31-41	tumor necrosis factor	Mus musculus	105-114
35385268-8	2022	Moreover, five alkaloids, namely, berberine hydrochloride, caffeine, camptothecin, matrine, and evodiamine, were screened by using neostigmine bromide as a control; berberine hydrochloride exhibited a good inhibitory effect on AChE with an IC50 of 0.94 muM, while the other four had no obvious inhibitory effect.	evodiamine	96-106	acetylcholinesterase (Cartwright blood group)	Homo sapiens	227-231
34081902-1	2021	Evodiamine (EVO) was derivatized to a C10-amino derivative (EVA) using a two-step method suitable for industrializing production.	evodiamine	0-10	myelin protein zero like 2	Homo sapiens	60-63
34081902-1	2021	Evodiamine (EVO) was derivatized to a C10-amino derivative (EVA) using a two-step method suitable for industrializing production.	evodiamine	12-15	myelin protein zero like 2	Homo sapiens	60-63
34081902-9	2021	The interaction between EVO/EVA and the upstream protein PI3K p110 was first investigated with molecular docking.	evodiamine	24-27	myelin protein zero like 2	Homo sapiens	28-31
34081902-9	2021	The interaction between EVO/EVA and the upstream protein PI3K p110 was first investigated with molecular docking.	evodiamine	24-27	endogenous retrovirus group K member 15	Homo sapiens	62-66
34081902-11	2021	The interaction between EVO/EVA and P-gp was also first studied using docking method.	evodiamine	24-27	myelin protein zero like 2	Homo sapiens	28-31
34081902-11	2021	The interaction between EVO/EVA and P-gp was also first studied using docking method.	evodiamine	24-27	phosphoglycolate phosphatase	Homo sapiens	36-40
34081902-13	2021	But EVA might reduce much expression of P-gp than EVO, and ultimately led to reduction of EVA efflux.	evodiamine	50-53	phosphoglycolate phosphatase	Homo sapiens	40-44
35597409-20	2022	Isoquinoline alkaloids, including berberine, jateorhizine, coptisine, epiberberine, columbamine, and palmatine, were substrates of hOCT1 and hOCT2, but not the indole alkaloids evodiamine and rutaecarpine.	evodiamine	177-187	solute carrier family 22 member 1	Homo sapiens	131-136
35597409-20	2022	Isoquinoline alkaloids, including berberine, jateorhizine, coptisine, epiberberine, columbamine, and palmatine, were substrates of hOCT1 and hOCT2, but not the indole alkaloids evodiamine and rutaecarpine.	evodiamine	177-187	POU class 2 homeobox 2	Homo sapiens	141-146
35362542-4	2022	In addition, Evo decreased the number and size of colonic tumors in ApcMinC/Gpt mice.	evodiamine	13-16	glutamic pyruvic transaminase, soluble	Mus musculus	76-79
35362542-6	2022	In vitro, Evo also reduced the viability of the colon cancer cell line SW480, inhibited mitochondrial membrane potential (MMP detection), caused G2/M-phase arrest (cell cycle detection) and suppressed the translocation of phosphorylated-NF-kappaB from the cytoplasm into the nucleus (immunofluorescence of p-NF-kappaB).	evodiamine	10-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	237-246
35362542-6	2022	In vitro, Evo also reduced the viability of the colon cancer cell line SW480, inhibited mitochondrial membrane potential (MMP detection), caused G2/M-phase arrest (cell cycle detection) and suppressed the translocation of phosphorylated-NF-kappaB from the cytoplasm into the nucleus (immunofluorescence of p-NF-kappaB).	evodiamine	10-13	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	308-317
35362542-7	2022	Theoretical evidence (MD simulations) suggest that Evo may bind to the ordered domain (alpha-helix) of NF-kappaB to influence this protein.	evodiamine	51-54	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	103-112
33657655-0	2021	Evodiamine alleviates lipopolysaccharide-induced pulmonary inflammation and fibrosis by activating apelin pathway.	evodiamine	0-10	apelin	Mus musculus	99-105
35388733-11	2022	Immunostaining showed that EVO treatment significantly decreased the expression of Ki-67.	evodiamine	27-30	antigen identified by monoclonal antibody Ki 67	Mus musculus	83-88
33945347-0	2021	Evodiamine Enhanced the Anti-Inflammation Effect of Clindamycin in the BEAS-2B Cells Infected with H5N1 and Pneumoniae D39 Through CREB-C/EBPbeta Signaling Pathway.	evodiamine	0-10	cAMP responsive element binding protein 1	Homo sapiens	131-135
33945347-0	2021	Evodiamine Enhanced the Anti-Inflammation Effect of Clindamycin in the BEAS-2B Cells Infected with H5N1 and Pneumoniae D39 Through CREB-C/EBPbeta Signaling Pathway.	evodiamine	0-10	CCAAT enhancer binding protein alpha	Homo sapiens	136-145
33945347-7	2021	Our results revealed that Evodiamine significantly decreased TNF-alpha, IL-6, and IL-1beta in BEAS-2B cells.	evodiamine	26-36	tumor necrosis factor	Homo sapiens	61-70
33945347-7	2021	Our results revealed that Evodiamine significantly decreased TNF-alpha, IL-6, and IL-1beta in BEAS-2B cells.	evodiamine	26-36	interleukin 6	Homo sapiens	72-76
33945347-7	2021	Our results revealed that Evodiamine significantly decreased TNF-alpha, IL-6, and IL-1beta in BEAS-2B cells.	evodiamine	26-36	interleukin 1 alpha	Homo sapiens	82-90
35163776-0	2022	A Critical YAP in Malignancy of HCC Is Regulated by Evodiamine.	evodiamine	52-62	Yes1 associated transcriptional regulator	Homo sapiens	11-14
35163776-6	2022	In addition, this study examined whether evodiamine (which has anticancer effects) can inhibit YAP and, if so, modulate HCC.	evodiamine	41-51	Yes1 associated transcriptional regulator	Homo sapiens	95-98
35163776-7	2022	Evodiamine significantly reduced both the YAP level and cell growth of HCC in a dose-dependent manner.	evodiamine	0-10	Yes1 associated transcriptional regulator	Homo sapiens	42-45
35163776-10	2022	Migration and invasion analysis showed that evodiamine has anti-metastatic ability on Hep3B and Huh-7 cells and reduces the level of vimentin, an EMT marker.	evodiamine	44-54	vimentin	Homo sapiens	133-141
35163776-11	2022	In conclusion, YAP is a critical target in HCC therapy, and evodiamine can be an effective HCC anticancer drug by reducing the YAP level.	evodiamine	60-70	Yes1 associated transcriptional regulator	Homo sapiens	15-18
33945347-8	2021	Moreover, evodiamine markedly reduced TLR2,3,4 protein expression and the phosphorylated protein of C/EBPbeta and CREB.	evodiamine	10-20	toll like receptor 2	Homo sapiens	38-46
33945347-8	2021	Moreover, evodiamine markedly reduced TLR2,3,4 protein expression and the phosphorylated protein of C/EBPbeta and CREB.	evodiamine	10-20	CCAAT enhancer binding protein alpha	Homo sapiens	100-109
33945347-8	2021	Moreover, evodiamine markedly reduced TLR2,3,4 protein expression and the phosphorylated protein of C/EBPbeta and CREB.	evodiamine	10-20	cAMP responsive element binding protein 1	Homo sapiens	114-118
33945347-10	2021	Taken together, our results demonstrated that evodiamine enhanced the anti-inflammation effect of clindamycin in the BEAS-2B cells infected with H5N1 and pneumoniae D39 through CREB-C/EBPbeta signaling pathway.	evodiamine	46-56	cAMP responsive element binding protein 1	Homo sapiens	177-181
33945347-10	2021	Taken together, our results demonstrated that evodiamine enhanced the anti-inflammation effect of clindamycin in the BEAS-2B cells infected with H5N1 and pneumoniae D39 through CREB-C/EBPbeta signaling pathway.	evodiamine	46-56	CCAAT enhancer binding protein alpha	Homo sapiens	182-191
33657655-8	2021	The results suggest that evodiamine can protect murine macrophages from the LPS-nigericin-induced damages by (a) inhibiting cellular apoptosis, (b) inhibiting inflammatory cytokines releasing, and (c) activating the apelin pathway.	evodiamine	25-35	apelin	Mus musculus	216-222
33657655-12	2021	)for some time, the results of the alveolar lavage fluid and the tissue slices showed that evodiamine treatment alleviated the pulmonary inflammation and fibrosis, stimulated apelin expression and inhibited the inflammatory cytokines.	evodiamine	91-101	apelin	Mus musculus	175-181
33394687-10	2021	Furthermore, Evo reduced the expression of hypoxia-inducible factor 1-alpha (HIF-1alpha), VE-cadherin, VEGF, MMP2, and MMP9.	evodiamine	13-16	vascular endothelial growth factor A	Homo sapiens	103-107
33394687-10	2021	Furthermore, Evo reduced the expression of hypoxia-inducible factor 1-alpha (HIF-1alpha), VE-cadherin, VEGF, MMP2, and MMP9.	evodiamine	13-16	matrix metallopeptidase 2	Homo sapiens	109-113
33394687-10	2021	Furthermore, Evo reduced the expression of hypoxia-inducible factor 1-alpha (HIF-1alpha), VE-cadherin, VEGF, MMP2, and MMP9.	evodiamine	13-16	matrix metallopeptidase 9	Homo sapiens	119-123
33394687-12	2021	Our study demonstrates that Evo could inhibit VM in CRC cells HCT116 and reduce the expression of HIF-1alpha, VE-cadherin, VEGF, MMP2, and MMP9.	evodiamine	28-31	hypoxia inducible factor 1 subunit alpha	Homo sapiens	98-108
33394687-12	2021	Our study demonstrates that Evo could inhibit VM in CRC cells HCT116 and reduce the expression of HIF-1alpha, VE-cadherin, VEGF, MMP2, and MMP9.	evodiamine	28-31	cadherin 5	Homo sapiens	110-121
33394687-0	2021	Evodiamine inhibits vasculogenic mimicry in HCT116 cells by suppressing hypoxia-inducible factor 1-alpha-mediated angiogenesis.	evodiamine	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	72-104
33394687-12	2021	Our study demonstrates that Evo could inhibit VM in CRC cells HCT116 and reduce the expression of HIF-1alpha, VE-cadherin, VEGF, MMP2, and MMP9.	evodiamine	28-31	vascular endothelial growth factor A	Homo sapiens	123-127
33394687-12	2021	Our study demonstrates that Evo could inhibit VM in CRC cells HCT116 and reduce the expression of HIF-1alpha, VE-cadherin, VEGF, MMP2, and MMP9.	evodiamine	28-31	matrix metallopeptidase 2	Homo sapiens	129-133
33394687-10	2021	Furthermore, Evo reduced the expression of hypoxia-inducible factor 1-alpha (HIF-1alpha), VE-cadherin, VEGF, MMP2, and MMP9.	evodiamine	13-16	hypoxia inducible factor 1 subunit alpha	Homo sapiens	43-75
33394687-12	2021	Our study demonstrates that Evo could inhibit VM in CRC cells HCT116 and reduce the expression of HIF-1alpha, VE-cadherin, VEGF, MMP2, and MMP9.	evodiamine	28-31	matrix metallopeptidase 9	Homo sapiens	139-143
33394687-10	2021	Furthermore, Evo reduced the expression of hypoxia-inducible factor 1-alpha (HIF-1alpha), VE-cadherin, VEGF, MMP2, and MMP9.	evodiamine	13-16	hypoxia inducible factor 1 subunit alpha	Homo sapiens	77-87
32874829-0	2020	Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity.	evodiamine	0-10	histone deacetylase 1	Homo sapiens	39-60
33394687-10	2021	Furthermore, Evo reduced the expression of hypoxia-inducible factor 1-alpha (HIF-1alpha), VE-cadherin, VEGF, MMP2, and MMP9.	evodiamine	13-16	cadherin 5	Homo sapiens	90-101
33179114-6	2021	Rutaecarpine, capsaicin and its derivatives, such as evodiamine, decrease gastric mucosal damage induced by several factors, including increased synthesis and release of CGRP.	evodiamine	53-63	calcitonin related polypeptide alpha	Homo sapiens	170-174
33456581-8	2021	Evo administration decreased the multiplicity, volume, and load of lung tumors in Kras G12D/+ transgenic mice and the growth of cancer cell line- and PDX-derived tumors without detectable toxicity.	evodiamine	0-3	Kirsten rat sarcoma viral oncogene homolog	Mus musculus	82-86
33456581-9	2021	Mechanistically, Evo disrupted the HSP system by binding the N-terminal ATP-binding pocket of HSP70 and causing its ubiquitin-mediated degradation.	evodiamine	17-20	heat shock protein 90 beta family member 2, pseudogene	Homo sapiens	35-38
33456581-9	2021	Mechanistically, Evo disrupted the HSP system by binding the N-terminal ATP-binding pocket of HSP70 and causing its ubiquitin-mediated degradation.	evodiamine	17-20	heat shock protein family A (Hsp70) member 4	Homo sapiens	94-99
33240089-0	2020	Evodiamine Attenuates Experimental Colitis Injury Via Activating Autophagy and Inhibiting NLRP3 Inflammasome Assembly.	evodiamine	0-10	NLR family, pyrin domain containing 3	Mus musculus	90-95
33240089-5	2020	We also observed that evodiamine restrained the formation of the NLRP3 inflammasome by inhibiting the apoptosis-associated speck-like protein oligomerization and caspase-1 activity in THP-1 macrophages.	evodiamine	22-32	NLR family, pyrin domain containing 3	Mus musculus	65-70
33240089-5	2020	We also observed that evodiamine restrained the formation of the NLRP3 inflammasome by inhibiting the apoptosis-associated speck-like protein oligomerization and caspase-1 activity in THP-1 macrophages.	evodiamine	22-32	caspase 1	Mus musculus	162-171
33240089-6	2020	Our results demonstrated evodiamine inhibit NLRP3 inflammasome activation via the induction of autophagosome-mediated degradation of inflammasome and the inhibition of NFkappaB pathway, which synergistically contribute to the effect of evodiamine in colitis.	evodiamine	25-35	NLR family, pyrin domain containing 3	Mus musculus	44-49
33240089-6	2020	Our results demonstrated evodiamine inhibit NLRP3 inflammasome activation via the induction of autophagosome-mediated degradation of inflammasome and the inhibition of NFkappaB pathway, which synergistically contribute to the effect of evodiamine in colitis.	evodiamine	25-35	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	168-176
33240089-6	2020	Our results demonstrated evodiamine inhibit NLRP3 inflammasome activation via the induction of autophagosome-mediated degradation of inflammasome and the inhibition of NFkappaB pathway, which synergistically contribute to the effect of evodiamine in colitis.	evodiamine	236-246	NLR family, pyrin domain containing 3	Mus musculus	44-49
32863934-6	2020	The results also revealed that EVO exposure induced the activation of caspase-3, caspase-9 and poly (ADP-ribose) polymerase 1, as well as mitochondrial membrane potential dissipation in a time-dependent manner, indicating that EVO induced intrinsic apoptosis in A-375 cells.	evodiamine	31-34	caspase 3	Homo sapiens	70-79
32863934-6	2020	The results also revealed that EVO exposure induced the activation of caspase-3, caspase-9 and poly (ADP-ribose) polymerase 1, as well as mitochondrial membrane potential dissipation in a time-dependent manner, indicating that EVO induced intrinsic apoptosis in A-375 cells.	evodiamine	31-34	caspase 9	Homo sapiens	81-90
32863934-6	2020	The results also revealed that EVO exposure induced the activation of caspase-3, caspase-9 and poly (ADP-ribose) polymerase 1, as well as mitochondrial membrane potential dissipation in a time-dependent manner, indicating that EVO induced intrinsic apoptosis in A-375 cells.	evodiamine	31-34	poly(ADP-ribose) polymerase 1	Homo sapiens	95-125
32863934-6	2020	The results also revealed that EVO exposure induced the activation of caspase-3, caspase-9 and poly (ADP-ribose) polymerase 1, as well as mitochondrial membrane potential dissipation in a time-dependent manner, indicating that EVO induced intrinsic apoptosis in A-375 cells.	evodiamine	227-230	caspase 9	Homo sapiens	81-90
32863934-6	2020	The results also revealed that EVO exposure induced the activation of caspase-3, caspase-9 and poly (ADP-ribose) polymerase 1, as well as mitochondrial membrane potential dissipation in a time-dependent manner, indicating that EVO induced intrinsic apoptosis in A-375 cells.	evodiamine	227-230	poly(ADP-ribose) polymerase 1	Homo sapiens	95-125
32863934-7	2020	Furthermore, the results revealed that receptor-interacting serine/threonine kinase (RIP) and RIP3 were sequentially activated, suggesting that necroptosis may also be involved in EVO-induced cell death in A-375 cells.	evodiamine	180-183	receptor interacting serine/threonine kinase 1	Homo sapiens	85-88
32863934-7	2020	Furthermore, the results revealed that receptor-interacting serine/threonine kinase (RIP) and RIP3 were sequentially activated, suggesting that necroptosis may also be involved in EVO-induced cell death in A-375 cells.	evodiamine	180-183	receptor interacting serine/threonine kinase 3	Homo sapiens	94-98
32794708-0	2020	Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket.	evodiamine	13-23	phosphodiesterase 5A	Homo sapiens	56-60
32794708-2	2020	Herein, a unique allosteric pocket of PDE5 is identified by molecular modeling and structural biology, which enables the discovery of highly selective PDE5 inhibitors from natural product evodiamine (EVO).	evodiamine	188-198	phosphodiesterase 5A	Homo sapiens	38-42
32794708-2	2020	Herein, a unique allosteric pocket of PDE5 is identified by molecular modeling and structural biology, which enables the discovery of highly selective PDE5 inhibitors from natural product evodiamine (EVO).	evodiamine	188-198	phosphodiesterase 5A	Homo sapiens	151-155
32794708-2	2020	Herein, a unique allosteric pocket of PDE5 is identified by molecular modeling and structural biology, which enables the discovery of highly selective PDE5 inhibitors from natural product evodiamine (EVO).	evodiamine	200-203	phosphodiesterase 5A	Homo sapiens	38-42
32794708-2	2020	Herein, a unique allosteric pocket of PDE5 is identified by molecular modeling and structural biology, which enables the discovery of highly selective PDE5 inhibitors from natural product evodiamine (EVO).	evodiamine	200-203	phosphodiesterase 5A	Homo sapiens	151-155
32794708-3	2020	The crystal structure of PDE5 with bound EVO derivative (S)-7e revealed that binding of (S)-7e to the novel allosteric pocket induced dramatic conformation changes in the H-loop with a maximum 24 A movement of their Calpha atoms.	evodiamine	41-44	phosphodiesterase 5A	Homo sapiens	25-29
33506010-10	2021	Moreover, the TNF-alpha decreased significantly accompanied by the increase of berberine, chlorogenic acid, jatrorrhizine, palmatine, evodin, and evodiamine in serum (negative correlation, p < 0.05).	evodiamine	146-156	tumor necrosis factor	Rattus norvegicus	14-23
32279133-0	2021	Evodiamine Inhibits Lipopolysaccharide (LPS)-Induced Inflammation in BV-2 Cells via Regulating AKT/Nrf2-HO-1/NF-kappaB Signaling Axis.	evodiamine	0-10	thymoma viral proto-oncogene 1	Mus musculus	95-98
32279133-0	2021	Evodiamine Inhibits Lipopolysaccharide (LPS)-Induced Inflammation in BV-2 Cells via Regulating AKT/Nrf2-HO-1/NF-kappaB Signaling Axis.	evodiamine	0-10	nuclear factor, erythroid derived 2, like 2	Mus musculus	99-103
32279133-0	2021	Evodiamine Inhibits Lipopolysaccharide (LPS)-Induced Inflammation in BV-2 Cells via Regulating AKT/Nrf2-HO-1/NF-kappaB Signaling Axis.	evodiamine	0-10	heme oxygenase 1	Mus musculus	104-108
32279133-7	2021	It was found that EV effectively inhibited expression of proinflammatory mediators (cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) via AKT/Nrf2/HO-1 activation and suppressed NF-kappaB p65 phosphorylation.	evodiamine	18-20	prostaglandin-endoperoxide synthase 2	Mus musculus	84-100
32279133-7	2021	It was found that EV effectively inhibited expression of proinflammatory mediators (cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) via AKT/Nrf2/HO-1 activation and suppressed NF-kappaB p65 phosphorylation.	evodiamine	18-20	prostaglandin-endoperoxide synthase 2	Mus musculus	102-107
32279133-7	2021	It was found that EV effectively inhibited expression of proinflammatory mediators (cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) via AKT/Nrf2/HO-1 activation and suppressed NF-kappaB p65 phosphorylation.	evodiamine	18-20	nitric oxide synthase 2, inducible	Mus musculus	110-141
32279133-7	2021	It was found that EV effectively inhibited expression of proinflammatory mediators (cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) via AKT/Nrf2/HO-1 activation and suppressed NF-kappaB p65 phosphorylation.	evodiamine	18-20	nitric oxide synthase 2, inducible	Mus musculus	143-147
32279133-7	2021	It was found that EV effectively inhibited expression of proinflammatory mediators (cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) via AKT/Nrf2/HO-1 activation and suppressed NF-kappaB p65 phosphorylation.	evodiamine	18-20	interleukin 6	Mus musculus	150-163
32279133-7	2021	It was found that EV effectively inhibited expression of proinflammatory mediators (cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) via AKT/Nrf2/HO-1 activation and suppressed NF-kappaB p65 phosphorylation.	evodiamine	18-20	interleukin 6	Mus musculus	165-169
32279133-7	2021	It was found that EV effectively inhibited expression of proinflammatory mediators (cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) via AKT/Nrf2/HO-1 activation and suppressed NF-kappaB p65 phosphorylation.	evodiamine	18-20	tumor necrosis factor	Mus musculus	176-203
32279133-7	2021	It was found that EV effectively inhibited expression of proinflammatory mediators (cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) via AKT/Nrf2/HO-1 activation and suppressed NF-kappaB p65 phosphorylation.	evodiamine	18-20	tumor necrosis factor	Mus musculus	205-214
32279133-7	2021	It was found that EV effectively inhibited expression of proinflammatory mediators (cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) via AKT/Nrf2/HO-1 activation and suppressed NF-kappaB p65 phosphorylation.	evodiamine	18-20	thymoma viral proto-oncogene 1	Mus musculus	221-224
32279133-7	2021	It was found that EV effectively inhibited expression of proinflammatory mediators (cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) via AKT/Nrf2/HO-1 activation and suppressed NF-kappaB p65 phosphorylation.	evodiamine	18-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	225-229
32279133-7	2021	It was found that EV effectively inhibited expression of proinflammatory mediators (cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha)) via AKT/Nrf2/HO-1 activation and suppressed NF-kappaB p65 phosphorylation.	evodiamine	18-20	heme oxygenase 1	Mus musculus	230-234
32279133-9	2021	Hence, these findings demonstrate that EV suppresses neuroinflammation caused by overactivated microglia via regulating the AKT/Nrf2/HO-1/NF-kappaB signaling axis.	evodiamine	39-41	thymoma viral proto-oncogene 1	Mus musculus	124-127
32279133-9	2021	Hence, these findings demonstrate that EV suppresses neuroinflammation caused by overactivated microglia via regulating the AKT/Nrf2/HO-1/NF-kappaB signaling axis.	evodiamine	39-41	nuclear factor, erythroid derived 2, like 2	Mus musculus	128-132
32279133-9	2021	Hence, these findings demonstrate that EV suppresses neuroinflammation caused by overactivated microglia via regulating the AKT/Nrf2/HO-1/NF-kappaB signaling axis.	evodiamine	39-41	heme oxygenase 1	Mus musculus	133-137
32279133-9	2021	Hence, these findings demonstrate that EV suppresses neuroinflammation caused by overactivated microglia via regulating the AKT/Nrf2/HO-1/NF-kappaB signaling axis.	evodiamine	39-41	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	138-147
33277208-14	2021	Further, the IL6/STAT3/P65 signaling pathway was inhibited in the EVO group.	evodiamine	66-69	interleukin 6	Mus musculus	13-16
33277208-14	2021	Further, the IL6/STAT3/P65 signaling pathway was inhibited in the EVO group.	evodiamine	66-69	signal transducer and activator of transcription 3	Mus musculus	17-22
33277208-14	2021	Further, the IL6/STAT3/P65 signaling pathway was inhibited in the EVO group.	evodiamine	66-69	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	23-26
33456581-10	2021	Conclusions: Our findings illustrate HSP70 as a potential target for eliminating CSCs and Evo as an effective HSP70-targeting anticancer drug eradicating both CSCs and non-CSCs with a minimal toxicity.	evodiamine	90-93	heat shock protein family A (Hsp70) member 4	Homo sapiens	110-115
33208183-0	2020	Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis.	evodiamine	0-10	CD8a molecule	Homo sapiens	62-65
33208183-0	2020	Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis.	evodiamine	0-10	CD274 molecule	Homo sapiens	105-110
33208183-4	2020	In the present study, we confirmed that evodiamine downregulates MUC1-C, resulting in modulating PD-L1 expression in non-small cell lung cancer (NSCLC).	evodiamine	40-50	mucin 1, cell surface associated	Homo sapiens	65-69
33208183-4	2020	In the present study, we confirmed that evodiamine downregulates MUC1-C, resulting in modulating PD-L1 expression in non-small cell lung cancer (NSCLC).	evodiamine	40-50	CD274 molecule	Sus scrofa	97-102
33208183-9	2020	The effects of evodiamine treatment on NSCLC sensitivity towards T cells were investigated using human peripheral blood mononuclear cells and Jurkat, apoptosis and IL-2 secretion assays.	evodiamine	15-25	interleukin 2	Homo sapiens	164-168
33208183-13	2020	Evodiamine suppressed IFN-gamma-induced PD-L1 expression in H1975 and H1650.	evodiamine	0-10	interferon gamma	Homo sapiens	22-31
33208183-13	2020	Evodiamine suppressed IFN-gamma-induced PD-L1 expression in H1975 and H1650.	evodiamine	0-10	CD274 antigen	Mus musculus	40-45
33208183-14	2020	MUC1-C mRNA and protein expression were decreased by evodiamine in NSCLC cells as well.	evodiamine	53-63	mucin 1, cell surface associated	Homo sapiens	0-4
33208183-15	2020	Evodiamine could downregulate the PD-L1 expression and diminish the apoptosis of T cells.	evodiamine	0-10	CD274 antigen	Mus musculus	34-39
33208183-18	2020	Evodiamine exhibited anti-tumor activity by elevation of CD8+ T cells in vivo in Lewis lung carcinoma model.	evodiamine	0-10	CD8a molecule	Homo sapiens	57-60
33208183-20	2020	CONCLUSIONS: Evodiamine can suppress NSCLC by elevating of CD8+ T cells and downregulating of the MUC1-C/PD-L1 axis.	evodiamine	13-23	CD8a molecule	Homo sapiens	59-62
33208183-20	2020	CONCLUSIONS: Evodiamine can suppress NSCLC by elevating of CD8+ T cells and downregulating of the MUC1-C/PD-L1 axis.	evodiamine	13-23	mucin 1, cell surface associated	Homo sapiens	98-102
33208183-20	2020	CONCLUSIONS: Evodiamine can suppress NSCLC by elevating of CD8+ T cells and downregulating of the MUC1-C/PD-L1 axis.	evodiamine	13-23	CD274 antigen	Mus musculus	105-110
32874829-0	2020	Evodiamine-inspired dual inhibitors of histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) with potent antitumor activity.	evodiamine	0-10	histone deacetylase 1	Homo sapiens	62-67
32874829-2	2020	Inspired by our previous efforts in designing antitumor evodiamine derivatives, herein selective histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) dual inhibitors were successfully identified, which showed potent in vitro and in vivo antitumor potency.	evodiamine	56-66	histone deacetylase 1	Homo sapiens	97-118
32874829-2	2020	Inspired by our previous efforts in designing antitumor evodiamine derivatives, herein selective histone deacetylase 1 (HDAC1) and topoisomerase 2 (TOP2) dual inhibitors were successfully identified, which showed potent in vitro and in vivo antitumor potency.	evodiamine	56-66	histone deacetylase 1	Homo sapiens	120-125
32874829-5	2020	Taken together, this study highlights the therapeutic advantages of evodiamine-based HDAC1/TOP2 dual inhibitors and provides valuable leads for the development of novel multi-targeting antitumor agents.	evodiamine	68-78	histone deacetylase 1	Homo sapiens	85-90
32147481-0	2020	Evodiamine via targeting nNOS and AMPA receptor GluA1 inhibits nitroglycerin-induced migraine-like response.	evodiamine	0-10	nitric oxide synthase 1	Rattus norvegicus	25-29
32613178-4	2020	Evodiamine, a quinolone alkaloid, has been found to improve learning and memory ability to in the APPswe/PS1 E9 mouse model of dementia.	evodiamine	0-10	presenilin 1	Mus musculus	105-108
32613178-9	2020	The Morris water-maze test was used to detect the effect of evodiamine and its derivatives on improving learning and memory in APPswe/PS1 E9 mice.	evodiamine	60-70	presenilin 1	Mus musculus	134-137
32057900-0	2020	Evodiamine inhibits proliferation and promotes apoptosis of hepatocellular carcinoma cells via the Hippo-Yes-Associated Protein signaling pathway.	evodiamine	0-10	yes-associated protein 1	Mus musculus	99-127
32057900-3	2020	However, the precise influence of Evo on HCC and its potential effects on Hippo-YAP signaling have yet to be ascertained.	evodiamine	34-37	yes-associated protein 1	Mus musculus	80-83
32057900-10	2020	Mechanistically, Evo treatment stimulated the Hippo-YAP signaling pathway.	evodiamine	17-20	yes-associated protein 1	Mus musculus	52-55
32057900-12	2020	SIGNIFICANCE: Our collective results revealed that the anti-HCC effects of Evo were correlated with the Hippo-YAP signaling pathway.	evodiamine	75-78	yes-associated protein 1	Mus musculus	110-113
32056223-7	2020	Furthermore, the numbers of synovial CD3+ or CD68+ inflammatory cells were reduced, and the elevated levels of tumour necrosis factor-alpha, interleukin-1beta (IL-1beta) and IL-6 were restored to control levels by the Evo treatment.	evodiamine	218-221	interleukin 1 beta	Rattus norvegicus	141-158
32056223-8	2020	In addition, Evo therapy regulated the abnormal differentiation of Treg and Th17 cells, decreasing IL-17 production and increasing IL-10 levels.	evodiamine	13-16	interleukin 17A	Rattus norvegicus	99-104
32056223-8	2020	In addition, Evo therapy regulated the abnormal differentiation of Treg and Th17 cells, decreasing IL-17 production and increasing IL-10 levels.	evodiamine	13-16	interleukin 10	Rattus norvegicus	131-136
32056223-9	2020	Finally, Evo inhibited Stat3 phosphorylation and induced Stat5 phosphorylation in rats with AA.	evodiamine	9-12	signal transducer and activator of transcription 3	Rattus norvegicus	23-28
32056223-9	2020	Finally, Evo inhibited Stat3 phosphorylation and induced Stat5 phosphorylation in rats with AA.	evodiamine	9-12	signal transducer and activator of transcription 5A	Rattus norvegicus	57-62
32147481-0	2020	Evodiamine via targeting nNOS and AMPA receptor GluA1 inhibits nitroglycerin-induced migraine-like response.	evodiamine	0-10	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	48-53
32147481-11	2020	Additionally, EVO suppressed serum NO levels and reduced the mRNA/protein expression of c-Fos and nNOS, but not iNOS, in the PAG.	evodiamine	14-17	Fos proto-oncogene, AP-1 transcription factor subunit	Rattus norvegicus	88-93
32147481-11	2020	Additionally, EVO suppressed serum NO levels and reduced the mRNA/protein expression of c-Fos and nNOS, but not iNOS, in the PAG.	evodiamine	14-17	nitric oxide synthase 1	Rattus norvegicus	98-102
32147481-12	2020	Furthermore, EVO suppressed total protein expression of the AMPA receptor GluA1 and its phosphorylation at Ser831 and Ser845.	evodiamine	13-16	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	74-79
32147481-13	2020	CONCLUSIONS: This study showed that EVO inhibits the migraine-like pain response and that this beneficial effect might be attributed to the regulation of nNOS and suppression of the AMPA receptor GluA1.	evodiamine	36-39	nitric oxide synthase 1	Rattus norvegicus	154-158
32147481-13	2020	CONCLUSIONS: This study showed that EVO inhibits the migraine-like pain response and that this beneficial effect might be attributed to the regulation of nNOS and suppression of the AMPA receptor GluA1.	evodiamine	36-39	glutamate ionotropic receptor AMPA type subunit 1	Rattus norvegicus	196-201
32109457-7	2020	We found that the combination of berberine and evodiamine showed synergistic anticancer activity in P-glycoprotein (P-gp)-positive colorectal cancer cells through attenuating the overexpression of P-gp mRNA independent of cell cycle arrest and cell apoptosis.	evodiamine	47-57	ATP binding cassette subfamily B member 1	Homo sapiens	100-114
32109457-7	2020	We found that the combination of berberine and evodiamine showed synergistic anticancer activity in P-glycoprotein (P-gp)-positive colorectal cancer cells through attenuating the overexpression of P-gp mRNA independent of cell cycle arrest and cell apoptosis.	evodiamine	47-57	ATP binding cassette subfamily B member 1	Homo sapiens	116-120
32109457-7	2020	We found that the combination of berberine and evodiamine showed synergistic anticancer activity in P-glycoprotein (P-gp)-positive colorectal cancer cells through attenuating the overexpression of P-gp mRNA independent of cell cycle arrest and cell apoptosis.	evodiamine	47-57	ATP binding cassette subfamily B member 1	Homo sapiens	197-201
32109457-9	2020	Furthermore, berberine attenuated evodiamine-induced cardiotoxicity by regulating extrinsic apoptosis via nuclear factor erythroid-2-related factor 2 (Nrf2)-dependent and reactive oxygen species-independent pathways.	evodiamine	34-44	NFE2 like bZIP transcription factor 2	Homo sapiens	106-149
32109457-9	2020	Furthermore, berberine attenuated evodiamine-induced cardiotoxicity by regulating extrinsic apoptosis via nuclear factor erythroid-2-related factor 2 (Nrf2)-dependent and reactive oxygen species-independent pathways.	evodiamine	34-44	NFE2 like bZIP transcription factor 2	Homo sapiens	151-155
32045841-0	2020	Evodiamine suppresses Notch3 signaling in lung tumorigenesis via direct binding to gamma-secretases.	evodiamine	0-10	notch 3	Mus musculus	22-28
32328100-5	2020	Muscle contractions were studied in an organ bath system to determine whether CCK1R, nitric oxide (NO), and enteric neurons are involved in the relaxant effect of Evo.	evodiamine	163-166	cholecystokinin A receptor	Rattus norvegicus	78-83
32328100-13	2020	The enteric neurons, NO, and CCK1R may be partly related to the inhibitory effect of Evo on colonic motility.	evodiamine	85-88	cholecystokinin A receptor	Rattus norvegicus	29-34
32183146-4	2020	Next, we found that EVO markedly inhibited HGF-induced c-Met/Src/STAT3 phosphorylation and impaired the nuclear translocation of STAT3 protein.	evodiamine	20-23	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	55-60
32183146-4	2020	Next, we found that EVO markedly inhibited HGF-induced c-Met/Src/STAT3 phosphorylation and impaired the nuclear translocation of STAT3 protein.	evodiamine	20-23	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	61-64
32183146-4	2020	Next, we found that EVO markedly inhibited HGF-induced c-Met/Src/STAT3 phosphorylation and impaired the nuclear translocation of STAT3 protein.	evodiamine	20-23	signal transducer and activator of transcription 3	Homo sapiens	65-70
32183146-4	2020	Next, we found that EVO markedly inhibited HGF-induced c-Met/Src/STAT3 phosphorylation and impaired the nuclear translocation of STAT3 protein.	evodiamine	20-23	signal transducer and activator of transcription 3	Homo sapiens	129-134
32183146-5	2020	Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9).	evodiamine	20-23	BCL2 apoptosis regulator	Homo sapiens	140-157
32183146-5	2020	Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9).	evodiamine	20-23	BCL2 apoptosis regulator	Homo sapiens	159-164
32183146-5	2020	Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9).	evodiamine	20-23	BCL2 like 1	Homo sapiens	167-194
32183146-5	2020	Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9).	evodiamine	20-23	BCL2 like 1	Homo sapiens	196-202
32183146-5	2020	Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9).	evodiamine	20-23	cyclin D1	Homo sapiens	205-214
32183146-5	2020	Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9).	evodiamine	20-23	prostaglandin-endoperoxide synthase 2	Homo sapiens	216-232
32183146-5	2020	Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9).	evodiamine	20-23	prostaglandin-endoperoxide synthase 2	Homo sapiens	234-239
32183146-5	2020	Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9).	evodiamine	20-23	vascular endothelial growth factor A	Homo sapiens	252-286
32183146-5	2020	Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9).	evodiamine	20-23	vascular endothelial growth factor A	Homo sapiens	288-292
32183146-5	2020	Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9).	evodiamine	20-23	matrix metallopeptidase 9	Homo sapiens	299-325
32183146-5	2020	Then, we noted that EVO arrested the cell cycle, caused apoptosis, and downregulated the expression of various carcinogenic markers such as B-cell lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), cyclin D1, cyclooxygenase 2 (COX-2), survivin, vascular endothelial growth factor (VEGF), and matrix metallopeptidases 9 (MMP-9).	evodiamine	20-23	matrix metallopeptidase 9	Homo sapiens	327-332
32183146-6	2020	Moreover, it was observed that in cPC-3 and DU145 cells transfected with c-Met small interfering RNA (siRNA), Src/STAT3 activation was also mitigated and led to a decrease in EVO-induced apoptotic cell death.	evodiamine	175-178	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	73-78
32183146-6	2020	Moreover, it was observed that in cPC-3 and DU145 cells transfected with c-Met small interfering RNA (siRNA), Src/STAT3 activation was also mitigated and led to a decrease in EVO-induced apoptotic cell death.	evodiamine	175-178	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	110-113
32183146-6	2020	Moreover, it was observed that in cPC-3 and DU145 cells transfected with c-Met small interfering RNA (siRNA), Src/STAT3 activation was also mitigated and led to a decrease in EVO-induced apoptotic cell death.	evodiamine	175-178	signal transducer and activator of transcription 3	Homo sapiens	114-119
32183146-7	2020	According to our results, EVO can abrogate the activation of the c-Met/Src/STAT3 signaling axis and thus plays a role as a robust suppressor of tumor cell survival, proliferation, and angiogenesis.	evodiamine	26-29	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	65-70
32183146-7	2020	According to our results, EVO can abrogate the activation of the c-Met/Src/STAT3 signaling axis and thus plays a role as a robust suppressor of tumor cell survival, proliferation, and angiogenesis.	evodiamine	26-29	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	71-74
32183146-7	2020	According to our results, EVO can abrogate the activation of the c-Met/Src/STAT3 signaling axis and thus plays a role as a robust suppressor of tumor cell survival, proliferation, and angiogenesis.	evodiamine	26-29	signal transducer and activator of transcription 3	Homo sapiens	75-80
31922213-0	2020	Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells.	evodiamine	11-21	AKT serine/threonine kinase 1	Homo sapiens	30-33
31922213-0	2020	Effects of evodiamine on PI3K/Akt and MAPK/ERK signaling pathways in pancreatic cancer cells.	evodiamine	11-21	mitogen-activated protein kinase 1	Homo sapiens	43-46
31922213-11	2020	EVO decreased LC3II, enhanced P62 and inhibited the expression of Akt, extracellular-signal-regulated protein kinase (ERK)1/2 and p38.	evodiamine	0-3	nucleoporin 62	Homo sapiens	30-33
31922213-11	2020	EVO decreased LC3II, enhanced P62 and inhibited the expression of Akt, extracellular-signal-regulated protein kinase (ERK)1/2 and p38.	evodiamine	0-3	AKT serine/threonine kinase 1	Homo sapiens	66-69
31922213-11	2020	EVO decreased LC3II, enhanced P62 and inhibited the expression of Akt, extracellular-signal-regulated protein kinase (ERK)1/2 and p38.	evodiamine	0-3	mitogen-activated protein kinase 3	Homo sapiens	71-125
31922213-11	2020	EVO decreased LC3II, enhanced P62 and inhibited the expression of Akt, extracellular-signal-regulated protein kinase (ERK)1/2 and p38.	evodiamine	0-3	mitogen-activated protein kinase 1	Homo sapiens	130-133
31922213-13	2020	The tumor expression of phosphorylated AKT, detected using immunohistochemistry, decreased with increasing EVO doses in vivo.	evodiamine	107-110	AKT serine/threonine kinase 1	Homo sapiens	39-42
31922213-14	2020	EVO induced PC cell apoptosis by inhibiting phosphoinositide 3-kinase/AKT and mitogen-activated protein kinase/ERK and inhibiting the phosphorylation of signal transducer and activator of transcription activator 3 in PC cells to inhibit autophagy, suggesting that EVO may be considered as a novel PC treatment.	evodiamine	0-3	AKT serine/threonine kinase 1	Homo sapiens	70-73
31922213-14	2020	EVO induced PC cell apoptosis by inhibiting phosphoinositide 3-kinase/AKT and mitogen-activated protein kinase/ERK and inhibiting the phosphorylation of signal transducer and activator of transcription activator 3 in PC cells to inhibit autophagy, suggesting that EVO may be considered as a novel PC treatment.	evodiamine	0-3	mitogen-activated protein kinase 1	Homo sapiens	111-114
32045841-12	2020	Mechanistic studies indicated that EVO prevented the gamma-secretase cleavage of Notch3 at the cell surface and hence inhibited Notch3 activation.	evodiamine	35-38	notch 3	Mus musculus	81-87
32045841-12	2020	Mechanistic studies indicated that EVO prevented the gamma-secretase cleavage of Notch3 at the cell surface and hence inhibited Notch3 activation.	evodiamine	35-38	notch 3	Mus musculus	128-134
32045841-13	2020	Moreover, EVO notably reduced tumor growth in the mouse model and inhibited Notch3 activity in the tumors.	evodiamine	10-13	notch 3	Mus musculus	76-82
32045841-14	2020	CONCLUSION: This study provides new insights into the anti-NSCLC action of EVO, and suggests that suppressing Notch3 signaling by inhibiting gamma-secretase is a mechanism of action underlying the anti-NSCLC effect of EVO.	evodiamine	75-78	notch 3	Mus musculus	110-116
32045841-14	2020	CONCLUSION: This study provides new insights into the anti-NSCLC action of EVO, and suggests that suppressing Notch3 signaling by inhibiting gamma-secretase is a mechanism of action underlying the anti-NSCLC effect of EVO.	evodiamine	218-221	notch 3	Mus musculus	110-116
31894286-11	2020	BMP9 potentiated the effect of Evo on the upregulation of HIF-1alpha, and enhanced the antitumor effect of Evo in colon cancer, which was clearly reduced by HIF-1alpha silencing.	evodiamine	31-34	hypoxia inducible factor 1 subunit alpha	Homo sapiens	58-68
31894286-11	2020	BMP9 potentiated the effect of Evo on the upregulation of HIF-1alpha, and enhanced the antitumor effect of Evo in colon cancer, which was clearly reduced by HIF-1alpha silencing.	evodiamine	107-110	growth differentiation factor 2	Homo sapiens	0-4
31894286-11	2020	BMP9 potentiated the effect of Evo on the upregulation of HIF-1alpha, and enhanced the antitumor effect of Evo in colon cancer, which was clearly reduced by HIF-1alpha silencing.	evodiamine	107-110	hypoxia inducible factor 1 subunit alpha	Homo sapiens	157-167
31894286-12	2020	In HCT116 cells, Evo increased the phosphorylation of p53, which was enhanced by BMP9 but reduced by BMP9 silencing.	evodiamine	17-20	tumor protein p53	Homo sapiens	54-57
31894286-12	2020	In HCT116 cells, Evo increased the phosphorylation of p53, which was enhanced by BMP9 but reduced by BMP9 silencing.	evodiamine	17-20	growth differentiation factor 2	Homo sapiens	81-85
31894286-12	2020	In HCT116 cells, Evo increased the phosphorylation of p53, which was enhanced by BMP9 but reduced by BMP9 silencing.	evodiamine	17-20	growth differentiation factor 2	Homo sapiens	101-105
31894286-13	2020	Furthermore, the effect of Evo on p53 was potentiated by HIF-1alpha and reduced by HIF-1alpha silencing.	evodiamine	27-30	tumor protein p53	Homo sapiens	34-37
31894286-13	2020	Furthermore, the effect of Evo on p53 was potentiated by HIF-1alpha and reduced by HIF-1alpha silencing.	evodiamine	27-30	hypoxia inducible factor 1 subunit alpha	Homo sapiens	57-67
31894286-13	2020	Furthermore, the effect of Evo on p53 was potentiated by HIF-1alpha and reduced by HIF-1alpha silencing.	evodiamine	27-30	hypoxia inducible factor 1 subunit alpha	Homo sapiens	83-93
32425601-0	2020	Evodiamine Exerts Anticancer Effects Against 143B and MG63 Cells Through the Wnt/beta-Catenin Signaling Pathway.	evodiamine	0-10	catenin beta 1	Homo sapiens	81-93
32425601-13	2020	Mechanistic studies revealed that EVO suppresses metastatic through suppressing epithelial-mesenchymal transition (EMT) as indicated by elevating the expression of epithelial marker E-cadherin and reducing the expression of mesenchymal markers N-cadherin and vimentin, as well as EMT transcription factors Snail and MMPs.	evodiamine	34-37	cadherin 1	Homo sapiens	182-192
32425601-13	2020	Mechanistic studies revealed that EVO suppresses metastatic through suppressing epithelial-mesenchymal transition (EMT) as indicated by elevating the expression of epithelial marker E-cadherin and reducing the expression of mesenchymal markers N-cadherin and vimentin, as well as EMT transcription factors Snail and MMPs.	evodiamine	34-37	cadherin 2	Homo sapiens	244-254
32425601-13	2020	Mechanistic studies revealed that EVO suppresses metastatic through suppressing epithelial-mesenchymal transition (EMT) as indicated by elevating the expression of epithelial marker E-cadherin and reducing the expression of mesenchymal markers N-cadherin and vimentin, as well as EMT transcription factors Snail and MMPs.	evodiamine	34-37	vimentin	Homo sapiens	259-267
32425601-14	2020	Subsequently, EVO induced cell cycle arrest at the G2/M phase that correlated with reduced levels of cyclin D1 protein, while the apoptotic effects of EVO were associated with the upregulation of Bax and Bad and a decrease in Bcl-2 protein levels.	evodiamine	14-17	cyclin D1	Homo sapiens	101-110
32425601-14	2020	Subsequently, EVO induced cell cycle arrest at the G2/M phase that correlated with reduced levels of cyclin D1 protein, while the apoptotic effects of EVO were associated with the upregulation of Bax and Bad and a decrease in Bcl-2 protein levels.	evodiamine	151-154	BCL2 associated X, apoptosis regulator	Homo sapiens	196-199
32425601-14	2020	Subsequently, EVO induced cell cycle arrest at the G2/M phase that correlated with reduced levels of cyclin D1 protein, while the apoptotic effects of EVO were associated with the upregulation of Bax and Bad and a decrease in Bcl-2 protein levels.	evodiamine	151-154	BCL2 apoptosis regulator	Homo sapiens	226-231
32425601-15	2020	Furthermore, EVO exerted the anticancer effects by suppressing Wnt/beta-catenin signal pathway in osteosarcoma cells.	evodiamine	13-16	catenin beta 1	Homo sapiens	67-79
32425601-16	2020	Conclusion: In summary, EVO exhibited potent anticancer effects against human osteosarcoma cells and promoted apoptosis through suppressing Wnt/beta-catenin signaling pathway.	evodiamine	24-27	catenin beta 1	Homo sapiens	144-156
32183146-0	2020	Evodiamine Mitigates Cellular Growth and Promotes Apoptosis by Targeting the c-Met Pathway in Prostate Cancer Cells.	evodiamine	0-10	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	77-82
32183146-1	2020	Evodiamine (EVO) is an indoloquinazoline alkaloid that exerts its various anti-oncogenic actions by blocking phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), c-Met, and nuclear factor kappa B (NF-kappaB) signaling pathways, thus leading to apoptosis of tumor cells.	evodiamine	0-10	protein tyrosine kinase 2 beta	Homo sapiens	139-155
32183146-1	2020	Evodiamine (EVO) is an indoloquinazoline alkaloid that exerts its various anti-oncogenic actions by blocking phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), c-Met, and nuclear factor kappa B (NF-kappaB) signaling pathways, thus leading to apoptosis of tumor cells.	evodiamine	0-10	AKT serine/threonine kinase 1	Homo sapiens	162-165
32183146-1	2020	Evodiamine (EVO) is an indoloquinazoline alkaloid that exerts its various anti-oncogenic actions by blocking phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), c-Met, and nuclear factor kappa B (NF-kappaB) signaling pathways, thus leading to apoptosis of tumor cells.	evodiamine	0-10	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	209-214
32183146-1	2020	Evodiamine (EVO) is an indoloquinazoline alkaloid that exerts its various anti-oncogenic actions by blocking phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), c-Met, and nuclear factor kappa B (NF-kappaB) signaling pathways, thus leading to apoptosis of tumor cells.	evodiamine	0-10	nuclear factor kappa B subunit 1	Homo sapiens	220-242
32183146-1	2020	Evodiamine (EVO) is an indoloquinazoline alkaloid that exerts its various anti-oncogenic actions by blocking phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), c-Met, and nuclear factor kappa B (NF-kappaB) signaling pathways, thus leading to apoptosis of tumor cells.	evodiamine	0-10	nuclear factor kappa B subunit 1	Homo sapiens	244-253
32183146-1	2020	Evodiamine (EVO) is an indoloquinazoline alkaloid that exerts its various anti-oncogenic actions by blocking phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), c-Met, and nuclear factor kappa B (NF-kappaB) signaling pathways, thus leading to apoptosis of tumor cells.	evodiamine	12-15	protein tyrosine kinase 2 beta	Homo sapiens	139-155
32183146-1	2020	Evodiamine (EVO) is an indoloquinazoline alkaloid that exerts its various anti-oncogenic actions by blocking phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), c-Met, and nuclear factor kappa B (NF-kappaB) signaling pathways, thus leading to apoptosis of tumor cells.	evodiamine	12-15	AKT serine/threonine kinase 1	Homo sapiens	162-165
32183146-1	2020	Evodiamine (EVO) is an indoloquinazoline alkaloid that exerts its various anti-oncogenic actions by blocking phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), c-Met, and nuclear factor kappa B (NF-kappaB) signaling pathways, thus leading to apoptosis of tumor cells.	evodiamine	12-15	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	209-214
32183146-1	2020	Evodiamine (EVO) is an indoloquinazoline alkaloid that exerts its various anti-oncogenic actions by blocking phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), c-Met, and nuclear factor kappa B (NF-kappaB) signaling pathways, thus leading to apoptosis of tumor cells.	evodiamine	12-15	nuclear factor kappa B subunit 1	Homo sapiens	220-242
32183146-1	2020	Evodiamine (EVO) is an indoloquinazoline alkaloid that exerts its various anti-oncogenic actions by blocking phosphatidylinositol-3-kinase/protein kinase B (PI3K/Akt), mitogen-activated protein kinase (MAPK), c-Met, and nuclear factor kappa B (NF-kappaB) signaling pathways, thus leading to apoptosis of tumor cells.	evodiamine	12-15	nuclear factor kappa B subunit 1	Homo sapiens	244-253
32183146-2	2020	We investigated the ability of EVO to affect hepatocyte growth factor (HGF)-induced c-Met/Src/STAT3 activation cascades in castration-resistant prostate cancer (CRPC).	evodiamine	31-34	hepatocyte growth factor	Homo sapiens	45-69
32183146-2	2020	We investigated the ability of EVO to affect hepatocyte growth factor (HGF)-induced c-Met/Src/STAT3 activation cascades in castration-resistant prostate cancer (CRPC).	evodiamine	31-34	hepatocyte growth factor	Homo sapiens	71-74
32183146-2	2020	We investigated the ability of EVO to affect hepatocyte growth factor (HGF)-induced c-Met/Src/STAT3 activation cascades in castration-resistant prostate cancer (CRPC).	evodiamine	31-34	MET proto-oncogene, receptor tyrosine kinase	Homo sapiens	84-89
32183146-2	2020	We investigated the ability of EVO to affect hepatocyte growth factor (HGF)-induced c-Met/Src/STAT3 activation cascades in castration-resistant prostate cancer (CRPC).	evodiamine	31-34	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	90-93
32183146-2	2020	We investigated the ability of EVO to affect hepatocyte growth factor (HGF)-induced c-Met/Src/STAT3 activation cascades in castration-resistant prostate cancer (CRPC).	evodiamine	31-34	signal transducer and activator of transcription 3	Homo sapiens	94-99
32183146-4	2020	Next, we found that EVO markedly inhibited HGF-induced c-Met/Src/STAT3 phosphorylation and impaired the nuclear translocation of STAT3 protein.	evodiamine	20-23	hepatocyte growth factor	Homo sapiens	43-46
32045841-6	2020	PURPOSE: We sought to determine the involvement of Notch3 signaling in the anti-NSCLC effects of EVO, and to explore whether EVO suppressed Notch3 signaling by inhibiting gamma-secretase in cultured A549 and H1299 NSCLC cells and in urethane-induced lung cancer FVB mouse model.	evodiamine	125-128	notch receptor 3	Homo sapiens	140-146
31894007-0	2019	[Evodiamine inhibits injury of HUVECs induced by lipopolysaccharide through TLR4/NF-kappaB signaling pathway].	evodiamine	1-11	toll like receptor 4	Homo sapiens	76-80
31894286-0	2020	BMP9 mediates the anticancer activity of evodiamine through HIF-1alpha/p53 in human colon cancer cells.	evodiamine	41-51	growth differentiation factor 2	Homo sapiens	0-4
31894286-0	2020	BMP9 mediates the anticancer activity of evodiamine through HIF-1alpha/p53 in human colon cancer cells.	evodiamine	41-51	hypoxia inducible factor 1 subunit alpha	Homo sapiens	60-70
31894286-0	2020	BMP9 mediates the anticancer activity of evodiamine through HIF-1alpha/p53 in human colon cancer cells.	evodiamine	41-51	tumor protein p53	Homo sapiens	71-74
31894286-7	2020	Bone morphogenetic protein 9 (BMP9) was notably upregulated by Evo in HCT116 cells.	evodiamine	63-66	growth differentiation factor 2	Homo sapiens	0-28
31894286-7	2020	Bone morphogenetic protein 9 (BMP9) was notably upregulated by Evo in HCT116 cells.	evodiamine	63-66	growth differentiation factor 2	Homo sapiens	30-34
31894286-8	2020	Exogenous BMP9 potentiated the anti-cancer activity of Evo, and BMP9 silencing reduced this effect.	evodiamine	55-58	growth differentiation factor 2	Homo sapiens	10-14
31894286-9	2020	In addition, HIF-1alpha was also upregulated by Evo.	evodiamine	48-51	hypoxia inducible factor 1 subunit alpha	Homo sapiens	13-23
31894286-10	2020	The anticancer activity of Evo was enhanced by HIF-1alpha, but was reduced by HIF-1alpha silencing.	evodiamine	27-30	hypoxia inducible factor 1 subunit alpha	Homo sapiens	47-57
31894286-10	2020	The anticancer activity of Evo was enhanced by HIF-1alpha, but was reduced by HIF-1alpha silencing.	evodiamine	27-30	hypoxia inducible factor 1 subunit alpha	Homo sapiens	78-88
31894286-11	2020	BMP9 potentiated the effect of Evo on the upregulation of HIF-1alpha, and enhanced the antitumor effect of Evo in colon cancer, which was clearly reduced by HIF-1alpha silencing.	evodiamine	31-34	growth differentiation factor 2	Homo sapiens	0-4
31920329-7	2019	Evo treatment significantly activated caspase-3 and -9 in MM cells.	evodiamine	0-3	caspase 3	Homo sapiens	38-54
31920329-8	2019	Evo also increased cytochrome C expression and ROS production in cytosol in a dose-dependent manner, which was abolished by MitoTEMPO cotreatment.	evodiamine	0-3	cytochrome c, somatic	Homo sapiens	19-31
31894286-14	2020	The present findings therefore strongly indicated that the anticancer activity of Evo may be partly mediated by BMP9 upregulation, which can activate p53 through upregulation of HIF-1alpha, at least in human colon cancer.	evodiamine	82-85	growth differentiation factor 2	Homo sapiens	112-116
31894286-14	2020	The present findings therefore strongly indicated that the anticancer activity of Evo may be partly mediated by BMP9 upregulation, which can activate p53 through upregulation of HIF-1alpha, at least in human colon cancer.	evodiamine	82-85	tumor protein p53	Homo sapiens	150-153
31894286-14	2020	The present findings therefore strongly indicated that the anticancer activity of Evo may be partly mediated by BMP9 upregulation, which can activate p53 through upregulation of HIF-1alpha, at least in human colon cancer.	evodiamine	82-85	hypoxia inducible factor 1 subunit alpha	Homo sapiens	178-188
31359090-0	2019	Growth inhibitor of human hepatic carcinoma HepG2 cells by evodiamine is associated with downregulation of PRAME.	evodiamine	59-69	PRAME nuclear receptor transcriptional regulator	Homo sapiens	107-112
31359090-2	2019	Preferentially expressed antigen of melanoma (PRAME) has a high expression in HCC patients, and the effects of evodiamine on HCC are less characterized, although evodiamine has anti-tumor activities in several tumor types.	evodiamine	162-172	PRAME nuclear receptor transcriptional regulator	Homo sapiens	0-44
31359090-3	2019	To investigate the effects of evodiamine on PRAME expression, the in vitro PRAME expression in HepG2 cells after incubated with evodiamine was determined by RT-PCR and western blot.	evodiamine	128-138	PRAME nuclear receptor transcriptional regulator	Homo sapiens	75-80
31359090-4	2019	Cell viability, migration, invasion, and apoptosis of evodiamine-incubated HepG2 cells were evaluated by Cell Counting Kit-8, wound healing, transwell assay, and Annexin V-FITC/PI double-staining assay, respectively.	evodiamine	54-64	annexin A5	Homo sapiens	162-171
31359090-5	2019	To evaluate the mechanism of the regulation of evodiamine on the PRAME expression, chromatin immunoprecipitation coupled with quantitative PCR was employed.	evodiamine	47-57	PRAME nuclear receptor transcriptional regulator	Homo sapiens	65-70
31359090-7	2019	The PRAME expression was inhibited in evodiamine-treated HepG2 cells in vitro and in vivo.	evodiamine	38-48	PRAME nuclear receptor transcriptional regulator	Homo sapiens	4-9
31359090-9	2019	The evodiamine inhibited the PRAME expression through trimethylation of H3K27.	evodiamine	4-14	PRAME nuclear receptor transcriptional regulator	Homo sapiens	29-34
31359090-11	2019	To achieve this inhibition, the PRAME expression may be repressed through trimethylation resulting from epigenetic regulation of evodiamine.	evodiamine	129-139	PRAME nuclear receptor transcriptional regulator	Homo sapiens	32-37
31437748-9	2019	Five natural products, including kaempferol, rutaecarpine, evodiamine, theophylline, lycobetaine showed potential inhibition for cathepsin B.	evodiamine	59-69	cathepsin B	Homo sapiens	129-140
31894007-0	2019	[Evodiamine inhibits injury of HUVECs induced by lipopolysaccharide through TLR4/NF-kappaB signaling pathway].	evodiamine	1-11	nuclear factor kappa B subunit 1	Homo sapiens	81-90
31894007-9	2019	Compared with LPS group, the pre-treatment of evodiamine obviously improved the cell survival rate, promoted the secretion of NO, inhibited the expression of TLR4 and NF-kappaBp65 and down-regulated the mRNA expression of NF-kappaBp65.	evodiamine	46-56	toll like receptor 4	Homo sapiens	158-162
31894007-9	2019	Compared with LPS group, the pre-treatment of evodiamine obviously improved the cell survival rate, promoted the secretion of NO, inhibited the expression of TLR4 and NF-kappaBp65 and down-regulated the mRNA expression of NF-kappaBp65.	evodiamine	46-56	RELA proto-oncogene, NF-kB subunit	Homo sapiens	167-179
31894007-9	2019	Compared with LPS group, the pre-treatment of evodiamine obviously improved the cell survival rate, promoted the secretion of NO, inhibited the expression of TLR4 and NF-kappaBp65 and down-regulated the mRNA expression of NF-kappaBp65.	evodiamine	46-56	RELA proto-oncogene, NF-kB subunit	Homo sapiens	222-234
31894007-10	2019	Conclusion Evodiamine can relieve the inflammatory injury of HUVECs induced by LPS and promote the synthesis of NO, which may be related to the regulation of TLR4/NF-kappaB signaling pathway.	evodiamine	11-21	toll like receptor 4	Homo sapiens	158-162
31894007-10	2019	Conclusion Evodiamine can relieve the inflammatory injury of HUVECs induced by LPS and promote the synthesis of NO, which may be related to the regulation of TLR4/NF-kappaB signaling pathway.	evodiamine	11-21	nuclear factor kappa B subunit 1	Homo sapiens	163-172
31099131-13	2019	Histopathologic examination revealed that caspase 3 and nuclear factor-kappaB levels decreased in the evodiamine group compared with the I/R group.	evodiamine	102-112	caspase 3	Rattus norvegicus	42-51
30488243-0	2019	A mediator of phosphorylated Smad2/3, evodiamine, in the reversion of TAF-induced EMT in normal colonic epithelial cells.	evodiamine	38-48	SMAD family member 2	Homo sapiens	29-36
30488243-0	2019	A mediator of phosphorylated Smad2/3, evodiamine, in the reversion of TAF-induced EMT in normal colonic epithelial cells.	evodiamine	38-48	insulin like growth factor binding protein 7	Homo sapiens	70-73
30488243-14	2019	Additionally, evodiamine down-regulated the expression of ZEB1/Snail and up-regulated the expression of phosphorylated Smad2/3 (pSmad2/3).	evodiamine	14-24	zinc finger E-box binding homeobox 1	Homo sapiens	58-62
30488243-14	2019	Additionally, evodiamine down-regulated the expression of ZEB1/Snail and up-regulated the expression of phosphorylated Smad2/3 (pSmad2/3).	evodiamine	14-24	snail family transcriptional repressor 1	Homo sapiens	63-68
30488243-14	2019	Additionally, evodiamine down-regulated the expression of ZEB1/Snail and up-regulated the expression of phosphorylated Smad2/3 (pSmad2/3).	evodiamine	14-24	SMAD family member 2	Homo sapiens	119-126
30488243-15	2019	Evodiamine also increased the ratios of pSmad2/Smad2 and pSmad3/Smad3.	evodiamine	0-10	SMAD family member 2	Homo sapiens	41-46
30488243-15	2019	Evodiamine also increased the ratios of pSmad2/Smad2 and pSmad3/Smad3.	evodiamine	0-10	SMAD family member 3	Homo sapiens	58-63
30488243-16	2019	Conclusion Based on our observations, evodiamine can reverse the TAF-induced EMT-like phenotype in colon epithelial cells, which may be associated with its mediation of phosphorylated Smad2 and Smad3 expression.	evodiamine	38-48	insulin like growth factor binding protein 7	Homo sapiens	65-68
30488243-16	2019	Conclusion Based on our observations, evodiamine can reverse the TAF-induced EMT-like phenotype in colon epithelial cells, which may be associated with its mediation of phosphorylated Smad2 and Smad3 expression.	evodiamine	38-48	SMAD family member 2	Homo sapiens	184-189
30488243-16	2019	Conclusion Based on our observations, evodiamine can reverse the TAF-induced EMT-like phenotype in colon epithelial cells, which may be associated with its mediation of phosphorylated Smad2 and Smad3 expression.	evodiamine	38-48	SMAD family member 3	Homo sapiens	194-199
30789361-10	2019	These findings provide evidences that EVO suppresses the migration and invasion of CRC cells by inhibiting the acetyl-NF-kappaB p65 by Sirt1, resulting in suppression of metalloproteinase-9 expression in vitro and in vivo.	evodiamine	38-41	RELA proto-oncogene, NF-kB subunit	Homo sapiens	128-131
31786843-11	2019	AO/EB staining showed that Evodiamine caused apoptosis of the SW480 cells and the percentage of the apoptotic SW480 cells increased with increase in the Evodiamine concentration as indicated by annexin V/PI staining.	evodiamine	153-163	annexin A5	Homo sapiens	194-203
31786843-12	2019	Evodiamine-induced apoptosis was also accompanied by upregulation of caspase-3 and Bax and suppression of Bcl-2.	evodiamine	0-10	caspase 3	Homo sapiens	69-78
31786843-12	2019	Evodiamine-induced apoptosis was also accompanied by upregulation of caspase-3 and Bax and suppression of Bcl-2.	evodiamine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	83-86
31786843-12	2019	Evodiamine-induced apoptosis was also accompanied by upregulation of caspase-3 and Bax and suppression of Bcl-2.	evodiamine	0-10	BCL2 apoptosis regulator	Homo sapiens	106-111
31786843-13	2019	TEM analysis showed that Evodiamine also activated autophagy in the SW480 cells by enhancing the expression of LC3 II and Beclin 1.	evodiamine	25-35	beclin 1	Homo sapiens	122-130
31328737-0	2019	Development of EGFR-targeted evodiamine nanoparticles for the treatment of colorectal cancer.	evodiamine	29-39	epidermal growth factor receptor	Homo sapiens	15-19
31328737-4	2019	In this study, we report the development of a new class of nanotherapeutics: EGFR-targeting Evo-encapsulated poly(amino acid) nanoparticles (GE11-Evo-NPs).	evodiamine	92-95	epidermal growth factor receptor	Homo sapiens	77-81
31328737-4	2019	In this study, we report the development of a new class of nanotherapeutics: EGFR-targeting Evo-encapsulated poly(amino acid) nanoparticles (GE11-Evo-NPs).	evodiamine	146-149	epidermal growth factor receptor	Homo sapiens	77-81
31328737-7	2019	Mechanisms of the GE11-Evo-NPs against EGFR mediated invasion and metastasis of CRC were also explored.	evodiamine	23-26	epidermal growth factor receptor	Homo sapiens	39-43
30789361-10	2019	These findings provide evidences that EVO suppresses the migration and invasion of CRC cells by inhibiting the acetyl-NF-kappaB p65 by Sirt1, resulting in suppression of metalloproteinase-9 expression in vitro and in vivo.	evodiamine	38-41	sirtuin 1	Homo sapiens	135-140
31102069-3	2019	RESULTS: After treatment with evodiamine and PXD101, cell viability, the percentage of viable cells and Bcl2 protein levels decreased, whereas cytotoxic activity, the percentage of apoptotic cells, the protein levels of gammaH2AX, acetyl.	evodiamine	30-40	BCL2 apoptosis regulator	Homo sapiens	104-108
31102069-5	2019	In cells treated with both evodiamine and PXD101, compared with PXD101 alone, decrement of cell viability, the percentage of viable cells, and Bcl2 protein levels as well as increment of cytotoxic activity, the percentage of apoptotic cells, the protein levels of gammaH2AX and cleaved PARP, and ROS production were significant, causing decrement of Bcl2/Bax ratio.	evodiamine	27-37	BCL2 apoptosis regulator	Homo sapiens	143-147
31102069-5	2019	In cells treated with both evodiamine and PXD101, compared with PXD101 alone, decrement of cell viability, the percentage of viable cells, and Bcl2 protein levels as well as increment of cytotoxic activity, the percentage of apoptotic cells, the protein levels of gammaH2AX and cleaved PARP, and ROS production were significant, causing decrement of Bcl2/Bax ratio.	evodiamine	27-37	collagen type XI alpha 2 chain	Homo sapiens	286-290
31102069-5	2019	In cells treated with both evodiamine and PXD101, compared with PXD101 alone, decrement of cell viability, the percentage of viable cells, and Bcl2 protein levels as well as increment of cytotoxic activity, the percentage of apoptotic cells, the protein levels of gammaH2AX and cleaved PARP, and ROS production were significant, causing decrement of Bcl2/Bax ratio.	evodiamine	27-37	BCL2 apoptosis regulator	Homo sapiens	350-354
31102069-5	2019	In cells treated with both evodiamine and PXD101, compared with PXD101 alone, decrement of cell viability, the percentage of viable cells, and Bcl2 protein levels as well as increment of cytotoxic activity, the percentage of apoptotic cells, the protein levels of gammaH2AX and cleaved PARP, and ROS production were significant, causing decrement of Bcl2/Bax ratio.	evodiamine	27-37	BCL2 associated X, apoptosis regulator	Homo sapiens	355-358
31102069-10	2019	Moreover, repression of PI3K/Akt signaling synergistically reinforces cytotoxicity of evodiamine combined with HDAC inhibitors in thyroid carcinoma cells.	evodiamine	86-96	AKT serine/threonine kinase 1	Homo sapiens	29-32
30701373-10	2019	The mitochondrial dysfunction evoked by paclitaxel was also remarkably improved in evodiamine-treated rats, evidenced by restoration of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), uncoupling protein 2 (UCP2), and superoxide dismutase 2 (SOD2) expression.	evodiamine	83-93	PPARG coactivator 1 alpha	Rattus norvegicus	136-204
30701373-10	2019	The mitochondrial dysfunction evoked by paclitaxel was also remarkably improved in evodiamine-treated rats, evidenced by restoration of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), uncoupling protein 2 (UCP2), and superoxide dismutase 2 (SOD2) expression.	evodiamine	83-93	PPARG coactivator 1 alpha	Rattus norvegicus	206-216
30701373-10	2019	The mitochondrial dysfunction evoked by paclitaxel was also remarkably improved in evodiamine-treated rats, evidenced by restoration of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), uncoupling protein 2 (UCP2), and superoxide dismutase 2 (SOD2) expression.	evodiamine	83-93	uncoupling protein 2	Rattus norvegicus	219-239
30701373-10	2019	The mitochondrial dysfunction evoked by paclitaxel was also remarkably improved in evodiamine-treated rats, evidenced by restoration of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), uncoupling protein 2 (UCP2), and superoxide dismutase 2 (SOD2) expression.	evodiamine	83-93	uncoupling protein 2	Rattus norvegicus	241-245
30701373-10	2019	The mitochondrial dysfunction evoked by paclitaxel was also remarkably improved in evodiamine-treated rats, evidenced by restoration of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), uncoupling protein 2 (UCP2), and superoxide dismutase 2 (SOD2) expression.	evodiamine	83-93	superoxide dismutase 2	Rattus norvegicus	252-274
30701373-10	2019	The mitochondrial dysfunction evoked by paclitaxel was also remarkably improved in evodiamine-treated rats, evidenced by restoration of peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), uncoupling protein 2 (UCP2), and superoxide dismutase 2 (SOD2) expression.	evodiamine	83-93	superoxide dismutase 2	Rattus norvegicus	276-280
30701373-11	2019	In in vitro studies, we found that evodiamine prevented paclitaxel-induced the loss of mitochondrial membrane potential and PGC-1alpha, UCP2 and SOD2 expression in DRG cells.	evodiamine	35-45	PPARG coactivator 1 alpha	Rattus norvegicus	124-134
30789361-0	2019	Evodiamine inhibits migration and invasion by Sirt1-mediated post-translational modulations in colorectal cancer.	evodiamine	0-10	sirtuin 1	Homo sapiens	46-51
30789361-6	2019	Western blot and RT-PCR showed that EVO reduced the expression of matrix metalloproteinase-9 in a dose-dependent manner.	evodiamine	36-39	matrix metallopeptidase 9	Homo sapiens	66-92
30789361-7	2019	In EVO-induced cells, the intracellular NAD+/NADH ratio was increased, the level of Sirt1 was increased, and acetyl-NF-kappaB P65 was decreased.	evodiamine	3-6	sirtuin 1	Homo sapiens	84-89
30789361-7	2019	In EVO-induced cells, the intracellular NAD+/NADH ratio was increased, the level of Sirt1 was increased, and acetyl-NF-kappaB P65 was decreased.	evodiamine	3-6	RELA proto-oncogene, NF-kB subunit	Homo sapiens	116-129
30701373-11	2019	In in vitro studies, we found that evodiamine prevented paclitaxel-induced the loss of mitochondrial membrane potential and PGC-1alpha, UCP2 and SOD2 expression in DRG cells.	evodiamine	35-45	uncoupling protein 2	Rattus norvegicus	136-140
30701373-11	2019	In in vitro studies, we found that evodiamine prevented paclitaxel-induced the loss of mitochondrial membrane potential and PGC-1alpha, UCP2 and SOD2 expression in DRG cells.	evodiamine	35-45	superoxide dismutase 2	Rattus norvegicus	145-149
30643424-0	2019	Evodiamine inactivates NF-kappaB and potentiates the antitumor effects of gemcitabine on tongue cancer both in vitro and in vivo.	evodiamine	0-10	nuclear factor kappa B subunit 1	Homo sapiens	23-32
30941189-7	2019	LPS-resulting increase of TNFalpha and IL-1beta in both serum and kidney of rats and NRK-52E cells was inhibited by EVO.	evodiamine	116-119	tumor necrosis factor	Rattus norvegicus	26-34
30554117-0	2019	Evodiamine prevents dextran sulfate sodium-induced murine experimental colitis via the regulation of NF-kappaB and NLRP3 inflammasome.	evodiamine	0-10	NLR family, pyrin domain containing 3	Mus musculus	115-120
30554117-4	2019	The results indicated that treatment with EVO ameliorated DSS-induced UC mice body weight loss, disease activity index (DAI), colon length shortening, colonic pathological damage, and myeloperoxidase (MPO) activity.	evodiamine	42-45	myeloperoxidase	Mus musculus	184-199
30554117-4	2019	The results indicated that treatment with EVO ameliorated DSS-induced UC mice body weight loss, disease activity index (DAI), colon length shortening, colonic pathological damage, and myeloperoxidase (MPO) activity.	evodiamine	42-45	myeloperoxidase	Mus musculus	201-204
30554117-5	2019	The production of TNF-alpha, IL-1beta and IL-6 was also significantly inhibited by EVO.	evodiamine	83-86	tumor necrosis factor	Mus musculus	18-27
30554117-5	2019	The production of TNF-alpha, IL-1beta and IL-6 was also significantly inhibited by EVO.	evodiamine	83-86	interleukin 1 beta	Mus musculus	29-37
30554117-5	2019	The production of TNF-alpha, IL-1beta and IL-6 was also significantly inhibited by EVO.	evodiamine	83-86	interleukin 6	Mus musculus	42-46
30971927-0	2019	Evodiamine Augments NLRP3 Inflammasome Activation and Anti-bacterial Responses Through Inducing alpha-Tubulin Acetylation.	evodiamine	0-10	NLR family, pyrin domain containing 3	Mus musculus	20-25
30971927-2	2019	Here we aimed to explore whether evodiamine influenced NLRP3 (NLR family, pyrin containing domain 3) inflammasome activation in macrophages, which is a critical mechanism for defending the host against pathogenic infections.	evodiamine	33-43	NLR family, pyrin domain containing 3	Mus musculus	55-60
30971927-3	2019	We uncovered that evodiamine dose-dependently enhanced NLRP3 inflammasome activation in lipopolysaccharide-primed macrophages, as indicated by increased interleukin (IL)-1beta production and caspase-1 cleavage, accompanied by increased ASC speck formation and pyroptosis.	evodiamine	18-28	NLR family, pyrin domain containing 3	Mus musculus	55-60
30971927-3	2019	We uncovered that evodiamine dose-dependently enhanced NLRP3 inflammasome activation in lipopolysaccharide-primed macrophages, as indicated by increased interleukin (IL)-1beta production and caspase-1 cleavage, accompanied by increased ASC speck formation and pyroptosis.	evodiamine	18-28	interleukin 1 beta	Mus musculus	153-175
30971927-3	2019	We uncovered that evodiamine dose-dependently enhanced NLRP3 inflammasome activation in lipopolysaccharide-primed macrophages, as indicated by increased interleukin (IL)-1beta production and caspase-1 cleavage, accompanied by increased ASC speck formation and pyroptosis.	evodiamine	18-28	caspase 1	Mus musculus	191-200
30971927-5	2019	Such evodiamine-mediated increases in NLRP3 activation and pyroptosis were attenuated by activators of alpha-tubulin deacetylase, resveratrol and NAD+, or dynein-specific inhibitor ciliobrevin A.	evodiamine	5-15	NLR family, pyrin domain containing 3	Mus musculus	38-43
30971927-6	2019	Small interfering RNA knockdown of alphaTAT1 (the gene encoding alpha-tubulin N-acetyltransferase) expression, which reduced alpha-tubulin acetylation, also diminished evodiamine-mediated augmentation of NLRP3 activation and pyroptosis.	evodiamine	168-178	alpha tubulin acetyltransferase 1	Mus musculus	35-44
30971927-6	2019	Small interfering RNA knockdown of alphaTAT1 (the gene encoding alpha-tubulin N-acetyltransferase) expression, which reduced alpha-tubulin acetylation, also diminished evodiamine-mediated augmentation of NLRP3 activation and pyroptosis.	evodiamine	168-178	NLR family, pyrin domain containing 3	Mus musculus	204-209
30971927-7	2019	Evodiamine also enhanced NLRP3-mediated production of IL-1beta and neutrophil recruitment in vivo.	evodiamine	0-10	NLR family, pyrin domain containing 3	Mus musculus	25-30
30971927-7	2019	Evodiamine also enhanced NLRP3-mediated production of IL-1beta and neutrophil recruitment in vivo.	evodiamine	0-10	interleukin 1 beta	Mus musculus	54-62
30971927-8	2019	Moreover, evodiamine administration evidently improved survival of mice with lethal bacterial infection, accompanied by increased production of IL-1beta and interferon-gamma, decreased bacterial load, and dampened liver inflammation.	evodiamine	10-20	interleukin 1 beta	Mus musculus	144-152
30971927-8	2019	Moreover, evodiamine administration evidently improved survival of mice with lethal bacterial infection, accompanied by increased production of IL-1beta and interferon-gamma, decreased bacterial load, and dampened liver inflammation.	evodiamine	10-20	interferon gamma	Mus musculus	157-173
30971927-9	2019	Resveratrol treatment reversed evodiamine-induced increases of IL-1beta and interferon-gamma, and decreased bacterial clearance in mice.	evodiamine	31-41	interleukin 1 beta	Mus musculus	63-71
30971927-9	2019	Resveratrol treatment reversed evodiamine-induced increases of IL-1beta and interferon-gamma, and decreased bacterial clearance in mice.	evodiamine	31-41	interferon gamma	Mus musculus	76-92
30971927-10	2019	Collectively, our results indicated that evodiamine augmented the NLRP3 inflammasome activation through inducing alpha-tubulin acetylation, thereby conferring intensified innate immunity against bacterial infection.	evodiamine	41-51	NLR family, pyrin domain containing 3	Mus musculus	66-71
30941189-7	2019	LPS-resulting increase of TNFalpha and IL-1beta in both serum and kidney of rats and NRK-52E cells was inhibited by EVO.	evodiamine	116-119	interleukin 1 beta	Rattus norvegicus	39-47
30941189-9	2019	EVO-induced reduction of TNFalpha and IL-1beta expression in LPS-treated cells was blocked by overexpression of P65 NF-kappaB.	evodiamine	0-3	tumor necrosis factor	Rattus norvegicus	25-33
30941189-9	2019	EVO-induced reduction of TNFalpha and IL-1beta expression in LPS-treated cells was blocked by overexpression of P65 NF-kappaB.	evodiamine	0-3	interleukin 1 beta	Rattus norvegicus	38-46
30682488-8	2019	Mechanistically, our studies demonstrated that evodiamine inhibited the activation of IL-6 -induced STAT3 signaling activation, and the inhibitory effect was likely due to the upregulation of phosphatase shatterproof 2 (SHP-2), a negative feedback regulator of IL-6/STAT3.	evodiamine	47-57	interleukin 6	Homo sapiens	86-90
30682488-8	2019	Mechanistically, our studies demonstrated that evodiamine inhibited the activation of IL-6 -induced STAT3 signaling activation, and the inhibitory effect was likely due to the upregulation of phosphatase shatterproof 2 (SHP-2), a negative feedback regulator of IL-6/STAT3.	evodiamine	47-57	signal transducer and activator of transcription 3	Homo sapiens	100-105
30682488-8	2019	Mechanistically, our studies demonstrated that evodiamine inhibited the activation of IL-6 -induced STAT3 signaling activation, and the inhibitory effect was likely due to the upregulation of phosphatase shatterproof 2 (SHP-2), a negative feedback regulator of IL-6/STAT3.	evodiamine	47-57	interleukin 6	Homo sapiens	261-265
30682488-8	2019	Mechanistically, our studies demonstrated that evodiamine inhibited the activation of IL-6 -induced STAT3 signaling activation, and the inhibitory effect was likely due to the upregulation of phosphatase shatterproof 2 (SHP-2), a negative feedback regulator of IL-6/STAT3.	evodiamine	47-57	signal transducer and activator of transcription 3	Homo sapiens	266-271
30682488-9	2019	Blockage of SHP-2 through small interference RNA (siRNA) abolished the evodiamine -induced IL-6/STAT3 signaling inhibition.	evodiamine	71-81	interleukin 6	Homo sapiens	91-95
30682488-9	2019	Blockage of SHP-2 through small interference RNA (siRNA) abolished the evodiamine -induced IL-6/STAT3 signaling inhibition.	evodiamine	71-81	signal transducer and activator of transcription 3	Homo sapiens	96-101
30682488-11	2019	In summary, our results implied evodiamine as a promising anti-cancer agent in the treatment of CCA, and the mechanism is likely due to the inhibition of IL-6/STAT3 signaling with upregulating the expression levels of SHP-2.	evodiamine	32-42	interleukin 6	Homo sapiens	154-158
30682488-11	2019	In summary, our results implied evodiamine as a promising anti-cancer agent in the treatment of CCA, and the mechanism is likely due to the inhibition of IL-6/STAT3 signaling with upregulating the expression levels of SHP-2.	evodiamine	32-42	signal transducer and activator of transcription 3	Homo sapiens	159-164
30554117-6	2019	Further mechanistic results showed that EVO restrained the inflammation by regulating NF-kappaB signal and NLRP3 inflammasome.	evodiamine	40-43	NLR family, pyrin domain containing 3	Mus musculus	107-112
30827999-10	2019	Finally, we identified a main alkaloid of the Evodia fruit, evodiamine, as a PPARgamma activator using this screening tool.	evodiamine	60-70	peroxisome proliferator activated receptor gamma	Homo sapiens	77-86
29714135-6	2019	RESULTS: In-vitro and in-vivo evidence supports the effect of berberine, trigonelline, piperine, oxymatrine, vindoneline, evodiamine and neferine on insulin-signaling and related cascades in beta-cells, myocytes, adipocytes, hepatocytes and other cells.	evodiamine	122-132	insulin	Homo sapiens	149-156
30451360-0	2019	Evodiamine inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in mice.	evodiamine	0-10	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	20-25
30451360-3	2019	By using an in vitro bone marrow macrophage (BMM)-derived osteoclast culture system, we found that EVO inhibited osteoclast formation, hydroxyapatite resorption and receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast marker gene and protein expression.	evodiamine	99-102	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	165-203
30451360-3	2019	By using an in vitro bone marrow macrophage (BMM)-derived osteoclast culture system, we found that EVO inhibited osteoclast formation, hydroxyapatite resorption and receptor activator of NF-kappaB ligand (RANKL)-induced osteoclast marker gene and protein expression.	evodiamine	99-102	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	205-210
30451360-4	2019	Mechanistically, we found that EVO inhibited the degradation and RANKL-induced transcriptional activity of IkappaBalpha.	evodiamine	31-34	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	65-70
30451360-4	2019	Mechanistically, we found that EVO inhibited the degradation and RANKL-induced transcriptional activity of IkappaBalpha.	evodiamine	31-34	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, alpha	Mus musculus	107-119
30451360-5	2019	RANKL-induced Ca2+ oscillations were also abrogated by EVO.	evodiamine	55-58	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	0-5
30451360-8	2019	Taken together, our findings suggest that EVO suppresses RANKL-induced osteoclastogenesis through NF-kappaB and calcium signalling pathways and has potential value as a therapeutic agent for PMO.	evodiamine	42-45	tumor necrosis factor (ligand) superfamily, member 11	Mus musculus	57-62
30643424-9	2019	In vivo, combination treatment of the xenograft model with EVO and GEM led to a significant reduction in tumor volume growth and inhibited the activation of NF-kappaB p65 with no obvious adverse reactions.	evodiamine	59-62	nuclear factor kappa B subunit 1	Homo sapiens	157-166
30643424-9	2019	In vivo, combination treatment of the xenograft model with EVO and GEM led to a significant reduction in tumor volume growth and inhibited the activation of NF-kappaB p65 with no obvious adverse reactions.	evodiamine	59-62	RELA proto-oncogene, NF-kB subunit	Homo sapiens	167-170
30643424-10	2019	Conclusion: The results of this study showed that EVO may inhibit cancer cells by suppressing NF-kappaB activity, and in combination with GEM, it may increase the chemosensitivity of tongue squamous cancer cells, thereby improving the treatment response.	evodiamine	50-53	nuclear factor kappa B subunit 1	Homo sapiens	94-103
30320369-7	2018	The results revealed that Evo dose-dependently reduced the protein and mRNA expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1beta, and inhibited the levels of phosphorylated (p-) inhibitor of NF-kappaBalpha, p-extracellular signal-regulated kinase, p-c-Jun N-terminal kinase and p-p38, and decreased the nuclear translocation of NF-kappaB/p65 in BEAS-2B cells infected with MSSA.	evodiamine	26-29	tumor necrosis factor	Homo sapiens	97-130
30320369-7	2018	The results revealed that Evo dose-dependently reduced the protein and mRNA expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1beta, and inhibited the levels of phosphorylated (p-) inhibitor of NF-kappaBalpha, p-extracellular signal-regulated kinase, p-c-Jun N-terminal kinase and p-p38, and decreased the nuclear translocation of NF-kappaB/p65 in BEAS-2B cells infected with MSSA.	evodiamine	26-29	interleukin 6	Homo sapiens	132-150
30320369-7	2018	The results revealed that Evo dose-dependently reduced the protein and mRNA expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1beta, and inhibited the levels of phosphorylated (p-) inhibitor of NF-kappaBalpha, p-extracellular signal-regulated kinase, p-c-Jun N-terminal kinase and p-p38, and decreased the nuclear translocation of NF-kappaB/p65 in BEAS-2B cells infected with MSSA.	evodiamine	26-29	interleukin 1 beta	Homo sapiens	155-163
30320369-7	2018	The results revealed that Evo dose-dependently reduced the protein and mRNA expression levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6 and IL-1beta, and inhibited the levels of phosphorylated (p-) inhibitor of NF-kappaBalpha, p-extracellular signal-regulated kinase, p-c-Jun N-terminal kinase and p-p38, and decreased the nuclear translocation of NF-kappaB/p65 in BEAS-2B cells infected with MSSA.	evodiamine	26-29	RELA proto-oncogene, NF-kB subunit	Homo sapiens	373-376
30114613-3	2018	To determine if evodiamine might be useful in the treatment of thyroid cancer and its cytotoxic mechanism, we analyzed the impact of evodiamine treatment on differential protein expression in human thyroid cancer cell line ARO using lysine-labeling two-dimensional difference gel electrophoresis (2D-DIGE) combined with mass spectrometry (MS).	evodiamine	133-143	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	223-226
30384473-0	2018	Evodiamine Induces Apoptosis in SMMC-7721 and HepG2 Cells by Suppressing NOD1 Signal Pathway.	evodiamine	0-10	nucleotide binding oligomerization domain containing 1	Homo sapiens	73-77
30384473-6	2018	Here we hypothesize that Evo exerts anti-hepatocellular carcinoma activity by inhibiting NOD1 to suppress NF-kappaB and MAPK activation.	evodiamine	25-28	nucleotide binding oligomerization domain containing 1	Homo sapiens	89-93
30384473-7	2018	Therefore, we proved the anti-hepatocellular carcinoma activity of Evo on HCC cells and detected the effect of Evo on the NOD1 pathway.	evodiamine	111-114	nucleotide binding oligomerization domain containing 1	Homo sapiens	122-126
30384473-8	2018	We found that Evo significantly induced cell cycle arrest at the G2/M phase, upregulated P53 and Bcl-2 associated X proteins (Bax) proteins, and downregulated B-cell lymphoma-2 (Bcl-2), cyclinB1, and cdc2 proteins in HCC cells.	evodiamine	14-17	tumor protein p53	Homo sapiens	89-92
30384473-8	2018	We found that Evo significantly induced cell cycle arrest at the G2/M phase, upregulated P53 and Bcl-2 associated X proteins (Bax) proteins, and downregulated B-cell lymphoma-2 (Bcl-2), cyclinB1, and cdc2 proteins in HCC cells.	evodiamine	14-17	BCL2 apoptosis regulator	Homo sapiens	97-102
30384473-8	2018	We found that Evo significantly induced cell cycle arrest at the G2/M phase, upregulated P53 and Bcl-2 associated X proteins (Bax) proteins, and downregulated B-cell lymphoma-2 (Bcl-2), cyclinB1, and cdc2 proteins in HCC cells.	evodiamine	14-17	BCL2 apoptosis regulator	Homo sapiens	159-176
30384473-8	2018	We found that Evo significantly induced cell cycle arrest at the G2/M phase, upregulated P53 and Bcl-2 associated X proteins (Bax) proteins, and downregulated B-cell lymphoma-2 (Bcl-2), cyclinB1, and cdc2 proteins in HCC cells.	evodiamine	14-17	BCL2 apoptosis regulator	Homo sapiens	178-183
30384473-8	2018	We found that Evo significantly induced cell cycle arrest at the G2/M phase, upregulated P53 and Bcl-2 associated X proteins (Bax) proteins, and downregulated B-cell lymphoma-2 (Bcl-2), cyclinB1, and cdc2 proteins in HCC cells.	evodiamine	14-17	cyclin B1	Homo sapiens	186-194
30384473-8	2018	We found that Evo significantly induced cell cycle arrest at the G2/M phase, upregulated P53 and Bcl-2 associated X proteins (Bax) proteins, and downregulated B-cell lymphoma-2 (Bcl-2), cyclinB1, and cdc2 proteins in HCC cells.	evodiamine	14-17	cyclin dependent kinase 1	Homo sapiens	200-204
30384473-9	2018	In addition, Evo reduced levels of NOD1, p-P65, p-ERK, p-p38, and p-JNK, where the level of IkappaBalpha of HCC cells increased.	evodiamine	13-16	nucleotide binding oligomerization domain containing 1	Homo sapiens	35-39
30384473-9	2018	In addition, Evo reduced levels of NOD1, p-P65, p-ERK, p-p38, and p-JNK, where the level of IkappaBalpha of HCC cells increased.	evodiamine	13-16	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	48-53
30384473-9	2018	In addition, Evo reduced levels of NOD1, p-P65, p-ERK, p-p38, and p-JNK, where the level of IkappaBalpha of HCC cells increased.	evodiamine	13-16	mitogen-activated protein kinase 14	Homo sapiens	57-60
30384473-9	2018	In addition, Evo reduced levels of NOD1, p-P65, p-ERK, p-p38, and p-JNK, where the level of IkappaBalpha of HCC cells increased.	evodiamine	13-16	NFKB inhibitor alpha	Homo sapiens	92-104
30384473-10	2018	Furthermore, NOD1 agonist gamma-D-Glu-mDAP (IE-DAP) treatment weakened the effect of Evo on suppression of NF-kappaB and MAPK activation and cellular proliferation of HCC.	evodiamine	85-88	nucleotide binding oligomerization domain containing 1	Homo sapiens	13-17
30384473-10	2018	Furthermore, NOD1 agonist gamma-D-Glu-mDAP (IE-DAP) treatment weakened the effect of Evo on suppression of NF-kappaB and MAPK activation and cellular proliferation of HCC.	evodiamine	85-88	death associated protein	Homo sapiens	39-42
30384473-11	2018	In an in vivo subcutaneous xenograft model, Evo also exhibited excellent tumor inhibitory effects via the NOD1 signal pathway.	evodiamine	44-47	nucleotide binding oligomerization domain containing 1	Homo sapiens	106-110
30384473-12	2018	Our results demonstrate that Evo could induce apoptosis remarkably and the inhibitory effect of Evo on HCC cells may be through suppressing the NOD1 signal pathway in vitro and in vivo.	evodiamine	29-32	nucleotide binding oligomerization domain containing 1	Homo sapiens	144-148
30384473-12	2018	Our results demonstrate that Evo could induce apoptosis remarkably and the inhibitory effect of Evo on HCC cells may be through suppressing the NOD1 signal pathway in vitro and in vivo.	evodiamine	96-99	nucleotide binding oligomerization domain containing 1	Homo sapiens	144-148
30396956-5	2018	RESULTS: Evodiamine treatment of cells decreased cell viability, and Bcl2 and phospho-AKT protein levels.	evodiamine	9-19	BCL2 apoptosis regulator	Homo sapiens	69-73
30396956-8	2018	In transforming growth factor-beta-treated cells, evodiamine attenuated variations in morphology, growth and migration, and increased p21 and p53 protein levels, and decreased beta-catenin, N-cadherin, vimentin, phospho-AKT, matrix metalloproteinase-2 and matrix metalloproteinase-9 protein levels.	evodiamine	50-60	H3 histone pseudogene 16	Homo sapiens	134-137
30396956-8	2018	In transforming growth factor-beta-treated cells, evodiamine attenuated variations in morphology, growth and migration, and increased p21 and p53 protein levels, and decreased beta-catenin, N-cadherin, vimentin, phospho-AKT, matrix metalloproteinase-2 and matrix metalloproteinase-9 protein levels.	evodiamine	50-60	tumor protein p53	Homo sapiens	142-145
30396956-8	2018	In transforming growth factor-beta-treated cells, evodiamine attenuated variations in morphology, growth and migration, and increased p21 and p53 protein levels, and decreased beta-catenin, N-cadherin, vimentin, phospho-AKT, matrix metalloproteinase-2 and matrix metalloproteinase-9 protein levels.	evodiamine	50-60	catenin beta 1	Homo sapiens	176-188
30396956-8	2018	In transforming growth factor-beta-treated cells, evodiamine attenuated variations in morphology, growth and migration, and increased p21 and p53 protein levels, and decreased beta-catenin, N-cadherin, vimentin, phospho-AKT, matrix metalloproteinase-2 and matrix metalloproteinase-9 protein levels.	evodiamine	50-60	cadherin 2	Homo sapiens	190-200
30396956-8	2018	In transforming growth factor-beta-treated cells, evodiamine attenuated variations in morphology, growth and migration, and increased p21 and p53 protein levels, and decreased beta-catenin, N-cadherin, vimentin, phospho-AKT, matrix metalloproteinase-2 and matrix metalloproteinase-9 protein levels.	evodiamine	50-60	vimentin	Homo sapiens	202-210
30396956-8	2018	In transforming growth factor-beta-treated cells, evodiamine attenuated variations in morphology, growth and migration, and increased p21 and p53 protein levels, and decreased beta-catenin, N-cadherin, vimentin, phospho-AKT, matrix metalloproteinase-2 and matrix metalloproteinase-9 protein levels.	evodiamine	50-60	AKT serine/threonine kinase 1	Homo sapiens	220-223
30396956-8	2018	In transforming growth factor-beta-treated cells, evodiamine attenuated variations in morphology, growth and migration, and increased p21 and p53 protein levels, and decreased beta-catenin, N-cadherin, vimentin, phospho-AKT, matrix metalloproteinase-2 and matrix metalloproteinase-9 protein levels.	evodiamine	50-60	matrix metallopeptidase 2	Homo sapiens	225-282
30396956-10	2018	CONCLUSION: Evodiamine was cytotoxic towards thyroid carcinoma cells, and repression of AKT reinforced evodiamine-induced cytotoxicity.	evodiamine	103-113	AKT serine/threonine kinase 1	Homo sapiens	88-91
29883380-3	2018	Evo significantly enhanced cell viability, inhibited the accumulation of reactive oxygen species, ameliorated mitochondrial function, increased the B-cell lymphoma-2 protein content, and inhibited the high expression levels of Bax, Bad, and cleaved-caspase-3 and -8 in l-Glu-induced HT22 cells.	evodiamine	0-3	BCL2-associated X protein	Mus musculus	227-230
29310424-9	2018	Taken together, our results demonstrate that ERAE and its major compound, evodiamine, provide an excellent candidate for the treatment or prevention of caffeine-induced sleep disturbances and excitatory states, and that the mechanism of these beneficial effects acts, at least in part, through the GABAA-ergic system.	evodiamine	74-84	gamma-aminobutyric acid (GABA) A receptor, subunit gamma 1	Mus musculus	298-303
30135419-0	2018	Evodiamine Induces Apoptosis, G2/M Cell Cycle Arrest, and Inhibition of Cell Migration and Invasion in Human Osteosarcoma Cells via Raf/MEK/ERK Signalling Pathway.	evodiamine	0-10	zinc fingers and homeoboxes 2	Homo sapiens	132-135
30135419-0	2018	Evodiamine Induces Apoptosis, G2/M Cell Cycle Arrest, and Inhibition of Cell Migration and Invasion in Human Osteosarcoma Cells via Raf/MEK/ERK Signalling Pathway.	evodiamine	0-10	mitogen-activated protein kinase kinase 7	Homo sapiens	136-139
30135419-0	2018	Evodiamine Induces Apoptosis, G2/M Cell Cycle Arrest, and Inhibition of Cell Migration and Invasion in Human Osteosarcoma Cells via Raf/MEK/ERK Signalling Pathway.	evodiamine	0-10	mitogen-activated protein kinase 1	Homo sapiens	140-143
30135419-11	2018	Moreover, Evodiamine downregulated the expression of important regulatory proteins such as p-MEK and p-ERK, leading to the inhibition of Raf/MEK/ERK signalling pathways.	evodiamine	10-20	mitogen-activated protein kinase kinase 7	Homo sapiens	93-96
30135419-11	2018	Moreover, Evodiamine downregulated the expression of important regulatory proteins such as p-MEK and p-ERK, leading to the inhibition of Raf/MEK/ERK signalling pathways.	evodiamine	10-20	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	101-106
30135419-11	2018	Moreover, Evodiamine downregulated the expression of important regulatory proteins such as p-MEK and p-ERK, leading to the inhibition of Raf/MEK/ERK signalling pathways.	evodiamine	10-20	zinc fingers and homeoboxes 2	Homo sapiens	137-140
30135419-11	2018	Moreover, Evodiamine downregulated the expression of important regulatory proteins such as p-MEK and p-ERK, leading to the inhibition of Raf/MEK/ERK signalling pathways.	evodiamine	10-20	mitogen-activated protein kinase kinase 7	Homo sapiens	141-144
30135419-11	2018	Moreover, Evodiamine downregulated the expression of important regulatory proteins such as p-MEK and p-ERK, leading to the inhibition of Raf/MEK/ERK signalling pathways.	evodiamine	10-20	mitogen-activated protein kinase 1	Homo sapiens	103-106
30038271-0	2018	Novel interactomics approach identifies ABCA1 as direct target of evodiamine, which increases macrophage cholesterol efflux.	evodiamine	66-76	ATP binding cassette subfamily A member 1	Homo sapiens	40-45
30038271-5	2018	Using a novel interactomics approach, the Nematic Protein Organisation Technique (NPOT), we report the identification of ATP-binding cassette transporter A1 (ABCA1), a key membrane transporter contributing to cholesterol efflux (ChE), as a direct binding target of evodiamine.	evodiamine	265-275	ATP binding cassette subfamily A member 1	Homo sapiens	121-156
30038271-5	2018	Using a novel interactomics approach, the Nematic Protein Organisation Technique (NPOT), we report the identification of ATP-binding cassette transporter A1 (ABCA1), a key membrane transporter contributing to cholesterol efflux (ChE), as a direct binding target of evodiamine.	evodiamine	265-275	ATP binding cassette subfamily A member 1	Homo sapiens	158-163
30038271-6	2018	The binding of evodiamine to ABCA1 is confirmed by surface plasmon resonance (SPR) experiments.	evodiamine	15-25	ATP binding cassette subfamily A member 1	Homo sapiens	29-34
30038271-7	2018	Examining the functional consequences of ABCA1 binding reveals that evodiamine treatment results in increased ABCA1 stability, elevated cellular ABCA1 protein levels, and ultimately increased ChE from THP-1-derived human macrophages.	evodiamine	68-78	ATP binding cassette subfamily A member 1	Homo sapiens	41-46
30038271-7	2018	Examining the functional consequences of ABCA1 binding reveals that evodiamine treatment results in increased ABCA1 stability, elevated cellular ABCA1 protein levels, and ultimately increased ChE from THP-1-derived human macrophages.	evodiamine	68-78	ATP binding cassette subfamily A member 1	Homo sapiens	110-115
30038271-7	2018	Examining the functional consequences of ABCA1 binding reveals that evodiamine treatment results in increased ABCA1 stability, elevated cellular ABCA1 protein levels, and ultimately increased ChE from THP-1-derived human macrophages.	evodiamine	68-78	ATP binding cassette subfamily A member 1	Homo sapiens	110-115
30038271-7	2018	Examining the functional consequences of ABCA1 binding reveals that evodiamine treatment results in increased ABCA1 stability, elevated cellular ABCA1 protein levels, and ultimately increased ChE from THP-1-derived human macrophages.	evodiamine	68-78	GLI family zinc finger 2	Homo sapiens	201-206
29765479-7	2018	Furthermore, evodiamine inhibited significantly glial cell activation and neuroinflammation (TNF-alpha, IL-1beta, and IL-6 levels) in the hippocampus.	evodiamine	13-23	tumor necrosis factor	Mus musculus	93-102
29765479-7	2018	Furthermore, evodiamine inhibited significantly glial cell activation and neuroinflammation (TNF-alpha, IL-1beta, and IL-6 levels) in the hippocampus.	evodiamine	13-23	interleukin 1 beta	Mus musculus	104-112
29765479-7	2018	Furthermore, evodiamine inhibited significantly glial cell activation and neuroinflammation (TNF-alpha, IL-1beta, and IL-6 levels) in the hippocampus.	evodiamine	13-23	interleukin 6	Mus musculus	118-122
29765479-8	2018	Moreover, evodiamine increased the activity of AKT/GSK-3beta signalling pathway and inhibited the activity of nuclear factor kappaB.	evodiamine	10-20	thymoma viral proto-oncogene 1	Mus musculus	47-50
29765479-8	2018	Moreover, evodiamine increased the activity of AKT/GSK-3beta signalling pathway and inhibited the activity of nuclear factor kappaB.	evodiamine	10-20	glycogen synthase kinase 3 beta	Mus musculus	51-60
30086275-0	2018	Evodiamine inhibits gastrointestinal motility via CCK and CCK1 receptor in water-avoidence stress rat model.	evodiamine	0-10	cholecystokinin	Rattus norvegicus	50-53
30086275-8	2018	Chronic WAS induced a slight but nonsignificant increase in the serum CCK-8 level, while EVO elevated the serum CCK-8 level in the WAS rats in a dose-dependent manner.	evodiamine	89-92	cholecystokinin	Rattus norvegicus	112-115
30210654-0	2018	Evodiamine Attenuates P2X7-Mediated Inflammatory Injury of Human Umbilical Vein Endothelial Cells Exposed to High Free Fatty Acids.	evodiamine	0-10	purinergic receptor P2X 7	Homo sapiens	22-26
30210654-5	2018	Evodiamine could effectively suppress the enhanced expression of P2X7 receptor caused by high FFAs at both mRNA and protein levels.	evodiamine	0-10	purinergic receptor P2X 7	Homo sapiens	65-78
30210654-8	2018	Moreover, evodiamine inhibited P2X7-dependent TNF-alpha expression and ERK 1/2 phosphorylation due to high FFAs.	evodiamine	10-20	purinergic receptor P2X 7	Homo sapiens	31-35
30210654-8	2018	Moreover, evodiamine inhibited P2X7-dependent TNF-alpha expression and ERK 1/2 phosphorylation due to high FFAs.	evodiamine	10-20	mitogen-activated protein kinase 3	Homo sapiens	71-78
30210654-9	2018	All these results indicated that evodiamine could correct the upregulated expression of P2X7 receptor induced under high FFA condition in HUVECs, and consequently suppressed oxidative stress and inflammatory responses.	evodiamine	33-43	purinergic receptor P2X 7	Homo sapiens	88-101
29883380-4	2018	Evo also enhanced the phosphorylation activities of protein kinase B and the mammalian target of rapamycin in the l-Glu-induced HT22 cells.	evodiamine	0-3	protein tyrosine kinase 2 beta	Homo sapiens	52-68
29883380-4	2018	Evo also enhanced the phosphorylation activities of protein kinase B and the mammalian target of rapamycin in the l-Glu-induced HT22 cells.	evodiamine	0-3	mechanistic target of rapamycin kinase	Homo sapiens	77-106
29883380-6	2018	Evo reduced the deposition of amyloid beta 42 (A&beta;42) in the brain, and increased the serum level of A&beta;42, but showed no significant effects on A&beta;40.	evodiamine	0-3	amyloid beta (A4) precursor protein	Mus musculus	47-53
29883380-8	2018	In the central cholinergic system of AD mice, Evo significantly increased the serum levels of acetylcholine and choline acetyltransferase and decreased the level of acetylcholinesterase in the serum, hypothalamus, and brain.	evodiamine	46-49	choline acetyltransferase	Mus musculus	112-137
29883380-8	2018	In the central cholinergic system of AD mice, Evo significantly increased the serum levels of acetylcholine and choline acetyltransferase and decreased the level of acetylcholinesterase in the serum, hypothalamus, and brain.	evodiamine	46-49	acetylcholinesterase	Mus musculus	165-185
29765324-0	2018	Evodiamine, a Novel NOTCH3 Methylation Stimulator, Significantly Suppresses Lung Carcinogenesis in Vitro and in Vivo.	evodiamine	0-10	notch 3	Mus musculus	20-26
28875323-0	2018	Evodiamine Inhibits Angiotensin II-Induced Rat Cardiomyocyte Hypertrophy.	evodiamine	0-10	angiotensinogen	Rattus norvegicus	20-34
28875323-8	2018	Compared with Ang II, Evo (0.3, 3 mumol/L) significantly attenuated Ang II-induced cardiomyocyte hypertrophy, decreased the [Ca2+]i concentration and expressions of CaN mRNA, CnA protein, and ERK-2 mRNA, but increased MKP-1 protein expression (P&lt;0.05 or P&lt;0.01).	evodiamine	22-25	angiogenin	Rattus norvegicus	14-17
28875323-8	2018	Compared with Ang II, Evo (0.3, 3 mumol/L) significantly attenuated Ang II-induced cardiomyocyte hypertrophy, decreased the [Ca2+]i concentration and expressions of CaN mRNA, CnA protein, and ERK-2 mRNA, but increased MKP-1 protein expression (P&lt;0.05 or P&lt;0.01).	evodiamine	22-25	mitogen activated protein kinase 1	Rattus norvegicus	192-197
28875323-8	2018	Compared with Ang II, Evo (0.3, 3 mumol/L) significantly attenuated Ang II-induced cardiomyocyte hypertrophy, decreased the [Ca2+]i concentration and expressions of CaN mRNA, CnA protein, and ERK-2 mRNA, but increased MKP-1 protein expression (P&lt;0.05 or P&lt;0.01).	evodiamine	22-25	dual specificity phosphatase 1	Rattus norvegicus	218-223
29765324-6	2018	In this study, we explored the involvement of NOTCH3 signaling in the anti-lung cancer effects of EVO.	evodiamine	98-101	notch 3	Mus musculus	46-52
29765324-8	2018	A DNA methyltransferase inhibitor was employed to investigate the role of NOTCH3 signaling in the anti-lung cancer effects of EVO.	evodiamine	126-129	notch 3	Mus musculus	74-80
29765324-9	2018	Results showed that EVO potently reduced tumor size and tumor numbers in mice, and inhibited NOTCH3 in the tumors.	evodiamine	20-23	notch 3	Mus musculus	93-99
29765324-11	2018	Mechanistic studies showed that EVO potently inhibited NOTCH3 signaling by activation of DNMTs-induced NOTCH3 methylation.	evodiamine	32-35	notch 3	Mus musculus	55-61
29765324-11	2018	Mechanistic studies showed that EVO potently inhibited NOTCH3 signaling by activation of DNMTs-induced NOTCH3 methylation.	evodiamine	32-35	notch 3	Mus musculus	103-109
29765324-12	2018	Importantly, inhibition of NOTCH3 methylation in NSCLC cells diminished EVO"s anti-NSCLC effects.	evodiamine	72-75	notch 3	Mus musculus	27-33
29765324-13	2018	Collectively, EVO, a novel NOTCH3 methylation stimulator, exerted potent anti-lung cancer effects partially by inhibiting NOTCH3 signaling.	evodiamine	14-17	notch 3	Mus musculus	27-33
29765324-13	2018	Collectively, EVO, a novel NOTCH3 methylation stimulator, exerted potent anti-lung cancer effects partially by inhibiting NOTCH3 signaling.	evodiamine	14-17	notch 3	Mus musculus	122-128
29535541-0	2018	Evodiamine activates cellular apoptosis through suppressing PI3K/AKT and activating MAPK in glioma.	evodiamine	0-10	AKT serine/threonine kinase 1	Homo sapiens	65-68
28875323-10	2018	CONCLUSION: Evo signifificantly attenuated Ang II-induced cardiomyocyte hypertrophy, and this effect was partly due to promotion of NO production, reduction of [Ca2+]i concentration, and inhibition of CaN and ERK-2 signal transduction pathways.	evodiamine	12-15	angiotensinogen	Rattus norvegicus	43-49
28875323-10	2018	CONCLUSION: Evo signifificantly attenuated Ang II-induced cardiomyocyte hypertrophy, and this effect was partly due to promotion of NO production, reduction of [Ca2+]i concentration, and inhibition of CaN and ERK-2 signal transduction pathways.	evodiamine	12-15	mitogen activated protein kinase 1	Rattus norvegicus	209-214
29505792-0	2018	Evodiamine induces apoptosis and promotes hepatocellular carcinoma cell death induced by vorinostat via downregulating HIF-1alpha under hypoxia.	evodiamine	0-10	hypoxia inducible factor 1 subunit alpha	Homo sapiens	119-129
29505792-3	2018	In this study, we showed that evodiamine might be a potential therapeutic medicine for HCC by suppressing HIF-1alpha.	evodiamine	30-40	hypoxia inducible factor 1 subunit alpha	Homo sapiens	106-116
29505792-5	2018	Furthermore, evodiamine plus vorinostat accelerated the degradation of HIF-1alpha in HCC cells under hypoxia.	evodiamine	13-23	hypoxia inducible factor 1 subunit alpha	Homo sapiens	71-81
29535541-8	2018	Finally, Evo induced apoptosis in cancer cells by suppressing PI3K/AKT signaling and inducing MAPK phosphorylation (p38 and JNK, but not ERK) to regulate apoptotic proteins (Bax, Bcl-2, Cytochrome c, Caspase-3, and PARP).	evodiamine	9-12	AKT serine/threonine kinase 1	Homo sapiens	67-70
29535541-8	2018	Finally, Evo induced apoptosis in cancer cells by suppressing PI3K/AKT signaling and inducing MAPK phosphorylation (p38 and JNK, but not ERK) to regulate apoptotic proteins (Bax, Bcl-2, Cytochrome c, Caspase-3, and PARP).	evodiamine	9-12	mitogen-activated protein kinase 8	Homo sapiens	124-127
29535541-8	2018	Finally, Evo induced apoptosis in cancer cells by suppressing PI3K/AKT signaling and inducing MAPK phosphorylation (p38 and JNK, but not ERK) to regulate apoptotic proteins (Bax, Bcl-2, Cytochrome c, Caspase-3, and PARP).	evodiamine	9-12	mitogen-activated protein kinase 1	Homo sapiens	137-140
29535541-8	2018	Finally, Evo induced apoptosis in cancer cells by suppressing PI3K/AKT signaling and inducing MAPK phosphorylation (p38 and JNK, but not ERK) to regulate apoptotic proteins (Bax, Bcl-2, Cytochrome c, Caspase-3, and PARP).	evodiamine	9-12	BCL2 associated X, apoptosis regulator	Homo sapiens	174-177
29535541-8	2018	Finally, Evo induced apoptosis in cancer cells by suppressing PI3K/AKT signaling and inducing MAPK phosphorylation (p38 and JNK, but not ERK) to regulate apoptotic proteins (Bax, Bcl-2, Cytochrome c, Caspase-3, and PARP).	evodiamine	9-12	BCL2 apoptosis regulator	Homo sapiens	179-184
29535541-8	2018	Finally, Evo induced apoptosis in cancer cells by suppressing PI3K/AKT signaling and inducing MAPK phosphorylation (p38 and JNK, but not ERK) to regulate apoptotic proteins (Bax, Bcl-2, Cytochrome c, Caspase-3, and PARP).	evodiamine	9-12	cytochrome c, somatic	Homo sapiens	186-198
29535541-8	2018	Finally, Evo induced apoptosis in cancer cells by suppressing PI3K/AKT signaling and inducing MAPK phosphorylation (p38 and JNK, but not ERK) to regulate apoptotic proteins (Bax, Bcl-2, Cytochrome c, Caspase-3, and PARP).	evodiamine	9-12	caspase 3	Homo sapiens	200-209
29535541-8	2018	Finally, Evo induced apoptosis in cancer cells by suppressing PI3K/AKT signaling and inducing MAPK phosphorylation (p38 and JNK, but not ERK) to regulate apoptotic proteins (Bax, Bcl-2, Cytochrome c, Caspase-3, and PARP).	evodiamine	9-12	collagen type XI alpha 2 chain	Homo sapiens	215-219
29535541-9	2018	Conclusion: In summary, Evo inhibits cell proliferation by inducing cellular apoptosis via suppressing PI3K/AKT and activating MAPK in GBM; these results indicate that Evo may be regarded as a new approach for GBM treatment.	evodiamine	24-27	AKT serine/threonine kinase 1	Homo sapiens	108-111
29535541-9	2018	Conclusion: In summary, Evo inhibits cell proliferation by inducing cellular apoptosis via suppressing PI3K/AKT and activating MAPK in GBM; these results indicate that Evo may be regarded as a new approach for GBM treatment.	evodiamine	168-171	AKT serine/threonine kinase 1	Homo sapiens	108-111
29286060-6	2018	The results demonstrated that Evo promoted the expression of myogenic marker genes (Myogenin and muscle myosin heavy chain) and increased myoblast differentiation, potentially via activation of the Wnt/beta-catenin pathway.	evodiamine	30-33	myogenin	Mus musculus	84-92
29286060-6	2018	The results demonstrated that Evo promoted the expression of myogenic marker genes (Myogenin and muscle myosin heavy chain) and increased myoblast differentiation, potentially via activation of the Wnt/beta-catenin pathway.	evodiamine	30-33	catenin (cadherin associated protein), beta 1	Mus musculus	202-214
29286060-7	2018	Furthermore, Evo increased mRNA expression of p21, reduced mRNA expression of Cyclin B, Cyclin D and Cyclin E and reduced the percentage of proliferating cells.	evodiamine	13-16	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	46-49
29286060-8	2018	Also, phosphorylation of ERK1/2 was decreased by Evo treatment during cell proliferation.	evodiamine	49-52	mitogen-activated protein kinase 3	Mus musculus	25-31
28936800-0	2018	Evodiamine ameliorates liver fibrosis in rats via TGF-beta1/Smad signaling pathway.	evodiamine	0-10	transforming growth factor, beta 1	Rattus norvegicus	50-59
28936800-3	2018	This study focused on the effects of evodiamine on carbon tetrachloride (CCl4)-induced liver fibrosis in rats and HSCs in vitro via the TGF-beta1/Smad signaling pathway.	evodiamine	37-47	C-C motif chemokine ligand 4	Rattus norvegicus	73-77
28936800-3	2018	This study focused on the effects of evodiamine on carbon tetrachloride (CCl4)-induced liver fibrosis in rats and HSCs in vitro via the TGF-beta1/Smad signaling pathway.	evodiamine	37-47	transforming growth factor, beta 1	Rattus norvegicus	136-145
28936800-7	2018	The results indicated that evodiamine could improve the histopathological abnormalities in liver tissues and decrease the level of aspartate aminotransferase (AST), alanine aminotransferase (ALT), hydroxyproline, and total bilirubin (TBIL).	evodiamine	27-37	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	131-157
28936800-7	2018	The results indicated that evodiamine could improve the histopathological abnormalities in liver tissues and decrease the level of aspartate aminotransferase (AST), alanine aminotransferase (ALT), hydroxyproline, and total bilirubin (TBIL).	evodiamine	27-37	glutamic-oxaloacetic transaminase 2	Rattus norvegicus	159-162
28936800-8	2018	Concentrations of IL-6, tumor necrosis factor-alpha (TNF-alpha), collagen-I (COL-I), and collagen-III (COL-III) were reduced by evodiamine.	evodiamine	128-138	interleukin 6	Rattus norvegicus	18-22
28936800-8	2018	Concentrations of IL-6, tumor necrosis factor-alpha (TNF-alpha), collagen-I (COL-I), and collagen-III (COL-III) were reduced by evodiamine.	evodiamine	128-138	tumor necrosis factor	Rattus norvegicus	24-51
28936800-8	2018	Concentrations of IL-6, tumor necrosis factor-alpha (TNF-alpha), collagen-I (COL-I), and collagen-III (COL-III) were reduced by evodiamine.	evodiamine	128-138	tumor necrosis factor	Rattus norvegicus	53-62
28936800-10	2018	The cell proliferation, production of hydroxyproline, and the protein expression of TGF-beta1, p-Smad 2/3, and alpha-SMA in HSCs were dose-dependently reduced by evodiamine.	evodiamine	162-172	transforming growth factor, beta 1	Rattus norvegicus	84-93
28936800-10	2018	The cell proliferation, production of hydroxyproline, and the protein expression of TGF-beta1, p-Smad 2/3, and alpha-SMA in HSCs were dose-dependently reduced by evodiamine.	evodiamine	162-172	SMAD family member 3	Rattus norvegicus	97-105
28936800-11	2018	Collectively, evodiamine had an antifibrosis effect in CCl4-induced liver fibrosis, and reduced HSCs proliferation and collagen metabolism in vitro.	evodiamine	14-24	C-C motif chemokine ligand 4	Rattus norvegicus	55-59
28571904-5	2017	Notably, evodiamine and rutaecarpine administered using ME-Gel effectively down-regulated serum levels of prostaglandin E2, interleukin 6, and tumor necrosis factor alpha in formaldehyde-induced mouse pain models, possibly reflecting the improved transdermal permeability of ME-Gel co-delivered evodiamine and rutaecarpine, particularly with hyaluronic acid as the hydrogel matrix.	evodiamine	9-19	interleukin 6	Mus musculus	124-137
29228954-11	2017	In addition, immunohistochemical analysis revealed that BB + EV treatment down-regulated the expressions of intestinal NPC1L1 and ACAT2, and ApoB48 in HFD induced rats.	evodiamine	61-63	NPC1 like intracellular cholesterol transporter 1	Rattus norvegicus	119-125
29228954-11	2017	In addition, immunohistochemical analysis revealed that BB + EV treatment down-regulated the expressions of intestinal NPC1L1 and ACAT2, and ApoB48 in HFD induced rats.	evodiamine	61-63	acetyl-CoA acetyltransferase 2	Rattus norvegicus	130-135
29228954-11	2017	In addition, immunohistochemical analysis revealed that BB + EV treatment down-regulated the expressions of intestinal NPC1L1 and ACAT2, and ApoB48 in HFD induced rats.	evodiamine	61-63	apolipoprotein B	Rattus norvegicus	141-147
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	evodiamine	115-125	latexin	Homo sapiens	130-133
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	evodiamine	115-125	cyclin dependent kinase 4	Homo sapiens	325-328
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	evodiamine	115-125	H3 histone pseudogene 16	Homo sapiens	340-343
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	evodiamine	115-125	dynactin subunit 6	Homo sapiens	348-351
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	evodiamine	115-125	cyclin D1	Homo sapiens	440-449
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	evodiamine	115-125	cyclin dependent kinase 4	Homo sapiens	461-465
29061795-7	2017	RESULTS: Compared to berberine or evodiamine treatments alone, the combination treatment of berberine (25 muM) and evodiamine (15 muM) synergistically inhibited the proliferation of MCF-7 cells in a time-dependent manner and resulted in the G0/G1 phase accumulation of cells that exhibited increased expression levels of the CDK inhibitors p21 and p27 with a concomitant reduction in the expression levels of cell-cycle checkpoint proteins cyclin D1, cyclin E, CDK4, and CDK6.	evodiamine	115-125	cyclin dependent kinase 6	Homo sapiens	471-475
28571904-5	2017	Notably, evodiamine and rutaecarpine administered using ME-Gel effectively down-regulated serum levels of prostaglandin E2, interleukin 6, and tumor necrosis factor alpha in formaldehyde-induced mouse pain models, possibly reflecting the improved transdermal permeability of ME-Gel co-delivered evodiamine and rutaecarpine, particularly with hyaluronic acid as the hydrogel matrix.	evodiamine	9-19	tumor necrosis factor	Mus musculus	143-170
28708106-0	2017	Evodiamine Exerts an Anti-Hepatocellular Carcinoma Activity through a WWOX-Dependent Pathway.	evodiamine	0-10	WW domain-containing oxidoreductase	Mus musculus	70-74
28708106-3	2017	While previous studies indicated that evodiamine exerts anti-tumor effects through inhibiting beta-catenin activity, and WW domain-containing oxidoreductase (WWOX) regulates beta-catenin accumulation in cytoplasm, the effects of evodiamine on the expression of WWOX are still unknown.	evodiamine	38-48	catenin (cadherin associated protein), beta 1	Mus musculus	94-106
28708106-3	2017	While previous studies indicated that evodiamine exerts anti-tumor effects through inhibiting beta-catenin activity, and WW domain-containing oxidoreductase (WWOX) regulates beta-catenin accumulation in cytoplasm, the effects of evodiamine on the expression of WWOX are still unknown.	evodiamine	229-239	WW domain-containing oxidoreductase	Mus musculus	121-156
28708106-3	2017	While previous studies indicated that evodiamine exerts anti-tumor effects through inhibiting beta-catenin activity, and WW domain-containing oxidoreductase (WWOX) regulates beta-catenin accumulation in cytoplasm, the effects of evodiamine on the expression of WWOX are still unknown.	evodiamine	229-239	WW domain-containing oxidoreductase	Mus musculus	158-162
28708106-6	2017	Moreover, the expressions of WWOX were dose-dependently increased in HCC cell lines as well as in Hepa1-6 hepatoma-bearing mice after the treatment with evodiamine.	evodiamine	153-163	WW domain-containing oxidoreductase	Mus musculus	29-33
28708106-7	2017	Knockdown of WWOX in HepG2 and Hepa1-6 cells diminished the effects of evodiamine on the inhibitory effect of cancer cell growth, indicating that evodiamine induced anti-cancer activity through a WWOX-dependent pathway.	evodiamine	71-81	WW domain containing oxidoreductase	Homo sapiens	13-17
28708106-7	2017	Knockdown of WWOX in HepG2 and Hepa1-6 cells diminished the effects of evodiamine on the inhibitory effect of cancer cell growth, indicating that evodiamine induced anti-cancer activity through a WWOX-dependent pathway.	evodiamine	146-156	WW domain containing oxidoreductase	Homo sapiens	13-17
28708106-7	2017	Knockdown of WWOX in HepG2 and Hepa1-6 cells diminished the effects of evodiamine on the inhibitory effect of cancer cell growth, indicating that evodiamine induced anti-cancer activity through a WWOX-dependent pathway.	evodiamine	146-156	WW domain-containing oxidoreductase	Mus musculus	196-200
28708106-8	2017	As such, evodiamine activated WWOX to exert an anti-HCC activity, and might be a potential therapeutic or preventive candidate for HCC treatment.	evodiamine	9-19	WW domain-containing oxidoreductase	Mus musculus	30-34
28337636-0	2017	Evodiamine Inhibits Zymosan-Induced Inflammation In Vitro and In Vivo: Inactivation of NF-kappaB by Inhibiting IkappaBalpha Phosphorylation.	evodiamine	0-10	nuclear factor kappa B subunit 1	Homo sapiens	87-96
28337636-0	2017	Evodiamine Inhibits Zymosan-Induced Inflammation In Vitro and In Vivo: Inactivation of NF-kappaB by Inhibiting IkappaBalpha Phosphorylation.	evodiamine	0-10	NFKB inhibitor alpha	Homo sapiens	111-123
28337636-3	2017	Our results showed that EVO effectively suppressed both protein and mRNA expression of interleukin-1beta, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in vitro.	evodiamine	24-27	interleukin 1 beta	Homo sapiens	87-104
28337636-3	2017	Our results showed that EVO effectively suppressed both protein and mRNA expression of interleukin-1beta, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in vitro.	evodiamine	24-27	interleukin 6	Homo sapiens	106-119
28337636-3	2017	Our results showed that EVO effectively suppressed both protein and mRNA expression of interleukin-1beta, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in vitro.	evodiamine	24-27	interleukin 6	Homo sapiens	121-125
28010025-12	2017	Furthermore, isoproterenol-induced activation of transforming growth factor-beta1/Smad signal was also blunted by evodiamine.	evodiamine	114-124	transforming growth factor, beta 1	Mus musculus	49-81
28010025-13	2017	Therefore, evodiamine may prevent isoproterenol-induced cardiac fibrosis by regulating endothelial-to-mesenchymal transition, which is probably mediated by the blockage of the transforming growth factor-beta1/Smad pathway.	evodiamine	11-21	transforming growth factor, beta 1	Mus musculus	176-208
28303407-0	2017	Evodiamine attenuates TGF-beta1-induced fibroblast activation and endothelial to mesenchymal transition.	evodiamine	0-10	transforming growth factor, beta 1	Rattus norvegicus	22-31
28303407-6	2017	As a result, Evodiamine-blunted TGF-beta1 induced activation of cardiac fibroblast into myofibroblast as assessed by the decreased expressions of alpha-SMA.	evodiamine	13-23	transforming growth factor, beta 1	Rattus norvegicus	32-41
28303407-7	2017	Furthermore, evodiamine reduced the increased protein expression of fibrosis markers in neonatal and adult rat cardiac fibroblasts induced by TGF-beta1.	evodiamine	13-23	transforming growth factor, beta 1	Rattus norvegicus	142-151
28303407-10	2017	Evodiamine significantly reduced the increase in migration ability that occurred in response to TGF-beta1 in HUVECs.	evodiamine	0-10	transforming growth factor, beta 1	Rattus norvegicus	96-105
28303407-11	2017	In addition, the activation of Smad2, Smad3, ERK1/2, and Akt, and the nuclear translocation of Smad4 in both cardiac fibroblasts and HUVEC were blocked by evodiamine treatment.	evodiamine	155-165	SMAD family member 2	Rattus norvegicus	31-36
28303407-11	2017	In addition, the activation of Smad2, Smad3, ERK1/2, and Akt, and the nuclear translocation of Smad4 in both cardiac fibroblasts and HUVEC were blocked by evodiamine treatment.	evodiamine	155-165	SMAD family member 3	Rattus norvegicus	38-43
28303407-11	2017	In addition, the activation of Smad2, Smad3, ERK1/2, and Akt, and the nuclear translocation of Smad4 in both cardiac fibroblasts and HUVEC were blocked by evodiamine treatment.	evodiamine	155-165	mitogen activated protein kinase 3	Rattus norvegicus	45-51
28303407-11	2017	In addition, the activation of Smad2, Smad3, ERK1/2, and Akt, and the nuclear translocation of Smad4 in both cardiac fibroblasts and HUVEC were blocked by evodiamine treatment.	evodiamine	155-165	AKT serine/threonine kinase 1	Rattus norvegicus	57-60
28303407-11	2017	In addition, the activation of Smad2, Smad3, ERK1/2, and Akt, and the nuclear translocation of Smad4 in both cardiac fibroblasts and HUVEC were blocked by evodiamine treatment.	evodiamine	155-165	SMAD family member 4	Rattus norvegicus	95-100
28337636-3	2017	Our results showed that EVO effectively suppressed both protein and mRNA expression of interleukin-1beta, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in vitro.	evodiamine	24-27	tumor necrosis factor	Homo sapiens	132-159
28337636-3	2017	Our results showed that EVO effectively suppressed both protein and mRNA expression of interleukin-1beta, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-alpha) in vitro.	evodiamine	24-27	tumor necrosis factor	Homo sapiens	161-170
28337636-4	2017	Zymosan-induced DNA-binding activity of nuclear factor-kappa B (NF-kappaB) was attenuated by EVO, which was achieved through inhibitory effects on the phosphorylation of inhibitory kappaB alpha and p65 nuclear translocation, but there was very little association with mitogen-activated protein kinase activation.	evodiamine	93-96	nuclear factor kappa B subunit 1	Homo sapiens	40-62
28337636-4	2017	Zymosan-induced DNA-binding activity of nuclear factor-kappa B (NF-kappaB) was attenuated by EVO, which was achieved through inhibitory effects on the phosphorylation of inhibitory kappaB alpha and p65 nuclear translocation, but there was very little association with mitogen-activated protein kinase activation.	evodiamine	93-96	nuclear factor kappa B subunit 1	Homo sapiens	64-73
28337636-4	2017	Zymosan-induced DNA-binding activity of nuclear factor-kappa B (NF-kappaB) was attenuated by EVO, which was achieved through inhibitory effects on the phosphorylation of inhibitory kappaB alpha and p65 nuclear translocation, but there was very little association with mitogen-activated protein kinase activation.	evodiamine	93-96	RELA proto-oncogene, NF-kB subunit	Homo sapiens	198-201
28337636-5	2017	In vivo, treatment with EVO markedly decreased TNF-alpha and IL-6 levels in plasma.	evodiamine	24-27	tumor necrosis factor	Homo sapiens	47-56
28337636-5	2017	In vivo, treatment with EVO markedly decreased TNF-alpha and IL-6 levels in plasma.	evodiamine	24-27	interleukin 6	Homo sapiens	61-65
28337636-6	2017	EVO also repressed inflammatory cytokine expression and ameliorated the abnormal state in both lung and intestine tissues by inactivation of NF-kappaB.	evodiamine	0-3	nuclear factor kappa B subunit 1	Homo sapiens	141-150
28098901-0	2017	Effect of evodiamine and berberine on the interaction between DNMTs and target microRNAs during malignant transformation of the colon by TGF-beta1.	evodiamine	10-20	transforming growth factor, beta 1	Rattus norvegicus	137-146
28190539-0	2017	Corrigendum to "Evodiamine, a plant alkaloid, induces calcium/JNK-mediated autophagy and calcium/mitochondria-mediated apoptosis in human glioblastoma cells" [Chem.	evodiamine	16-26	mitogen-activated protein kinase 8	Homo sapiens	62-65
28189683-0	2017	Anti-tumor effect of evodiamine by inducing Akt-mediated apoptosis in hepatocellular carcinoma.	evodiamine	21-31	AKT serine/threonine kinase 1	Homo sapiens	44-47
28189683-7	2017	RESULTS: Evodiamine suppressed tumor growth, improved the expression of cleaved-caspase3 and decreased tumor specific growth factor (TSGF) and alpha fetoprotein (AFP) activities.	evodiamine	9-19	alpha fetoprotein	Homo sapiens	143-160
28189683-7	2017	RESULTS: Evodiamine suppressed tumor growth, improved the expression of cleaved-caspase3 and decreased tumor specific growth factor (TSGF) and alpha fetoprotein (AFP) activities.	evodiamine	9-19	alpha fetoprotein	Homo sapiens	162-165
28189683-11	2017	Furthermore, evodiamine suppressed Akt and regulated apoptotic proteins in HepG2 cells.	evodiamine	13-23	AKT serine/threonine kinase 1	Homo sapiens	35-38
28189683-12	2017	Evodiamine decreased p-Akt levels activated by SC79, which led to the increase of bax/bcl-2 and cleaved-caspase3.	evodiamine	0-10	AKT serine/threonine kinase 1	Homo sapiens	23-26
28189683-12	2017	Evodiamine decreased p-Akt levels activated by SC79, which led to the increase of bax/bcl-2 and cleaved-caspase3.	evodiamine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	82-85
28189683-12	2017	Evodiamine decreased p-Akt levels activated by SC79, which led to the increase of bax/bcl-2 and cleaved-caspase3.	evodiamine	0-10	BCL2 apoptosis regulator	Homo sapiens	86-91
28189683-13	2017	CONCLUSIONS: Our findings suggested that evodiamine could exert anti-HCC effect through inducing Akt-mediated apoptosis.	evodiamine	41-51	AKT serine/threonine kinase 1	Homo sapiens	97-100
28098901-6	2017	After treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted.	evodiamine	35-45	DNA methyltransferase 1	Rattus norvegicus	94-99
28098901-6	2017	After treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted.	evodiamine	35-45	DNA methyltransferase 3 alpha	Rattus norvegicus	101-107
28098901-6	2017	After treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted.	evodiamine	35-45	DNA methyltransferase 3 beta	Rattus norvegicus	109-115
28098901-6	2017	After treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted.	evodiamine	35-45	microRNA 152	Rattus norvegicus	120-127
28098901-6	2017	After treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted.	evodiamine	35-45	microRNA 429	Rattus norvegicus	129-136
28098901-6	2017	After treatment with berberine and evodiamine for 24 h, respectively, increased expression of DNMT1, DNMT3A, DNMT3B and miR-152, miR-429, miR-29a was noted.	evodiamine	35-45	microRNA 29a	Rattus norvegicus	138-145
27878250-4	2017	Of the other agents, evodiamine was found to inhibit both IL-8 secretion and cell proliferation, and jatrorrhizine was found to increase IL-8 secretion without any obvious inhibitory effect on cell proliferation.	evodiamine	21-31	C-X-C motif chemokine ligand 8	Homo sapiens	58-62
26455953-3	2016	In this study, we investigated the effects of two evodia alkaloids, rutaecarpine (Rut) and evodiamine (Evo), on gluconeogenesis and lipogenesis through their activation of the human CAR (hCAR).	evodiamine	91-101	nuclear receptor subfamily 1 group I member 3	Homo sapiens	182-185
27402273-0	2016	A novel alkaloid, evodiamine causes nuclear localization of cytochrome-c and induces apoptosis independent of p53 in human lung cancer cells.	evodiamine	18-28	cytochrome c, somatic	Homo sapiens	60-72
27402273-0	2016	A novel alkaloid, evodiamine causes nuclear localization of cytochrome-c and induces apoptosis independent of p53 in human lung cancer cells.	evodiamine	18-28	tumor protein p53	Homo sapiens	110-113
27402273-4	2016	Our data showed that 20-40 muM evodiamine treatment for 24-48 h strongly (up to 73%, P &lt; 0.001) reduced the growth and survival of these cancer cells.	evodiamine	31-41	latexin	Homo sapiens	27-30
27402273-7	2016	Further, evodiamine increased (4-fold) mitochondrial membrane depolarization with 6-fold increase in apoptosis and a slight increase in Bax/Bcl-2 ratio.	evodiamine	9-19	BCL2 associated X, apoptosis regulator	Homo sapiens	136-139
27402273-7	2016	Further, evodiamine increased (4-fold) mitochondrial membrane depolarization with 6-fold increase in apoptosis and a slight increase in Bax/Bcl-2 ratio.	evodiamine	9-19	BCL2 apoptosis regulator	Homo sapiens	140-145
27402273-12	2016	Pifithrin-alpha, a p53 inhibitor, slightly inhibited growth of A549 cells and under p53 inhibitory condition evodiamine-induced apoptosis could not be reversed.	evodiamine	109-119	tumor protein p53	Homo sapiens	84-87
27402273-13	2016	Together these findings suggest that evodiamine is a strong inducer of apoptosis in lung epithelial cancer cells independent of their p53 status and that could involve both intrinsic as well as extrinsic pathway of apoptosis.	evodiamine	37-47	tumor protein p53	Homo sapiens	134-137
26455953-3	2016	In this study, we investigated the effects of two evodia alkaloids, rutaecarpine (Rut) and evodiamine (Evo), on gluconeogenesis and lipogenesis through their activation of the human CAR (hCAR).	evodiamine	91-101	CXADR Ig-like cell adhesion molecule	Homo sapiens	187-191
26455953-3	2016	In this study, we investigated the effects of two evodia alkaloids, rutaecarpine (Rut) and evodiamine (Evo), on gluconeogenesis and lipogenesis through their activation of the human CAR (hCAR).	evodiamine	103-106	nuclear receptor subfamily 1 group I member 3	Homo sapiens	182-185
26455953-3	2016	In this study, we investigated the effects of two evodia alkaloids, rutaecarpine (Rut) and evodiamine (Evo), on gluconeogenesis and lipogenesis through their activation of the human CAR (hCAR).	evodiamine	103-106	CXADR Ig-like cell adhesion molecule	Homo sapiens	187-191
26455953-5	2016	Both compounds can potently activate hCAR, and treatment of cells with hCAR antagonists reversed the anti-lipogenic and anti-gluconeogenic effects of Rut and Evo.	evodiamine	158-161	CXADR Ig-like cell adhesion molecule	Homo sapiens	71-75
26455953-6	2016	The anti-gluconeogenic effect of Rut and Evo was due to the CAR-mediated inhibition of the recruitment of forkhead box O1 (FoxO1) and hepatocyte nuclear factor 4alpha (HNF4alpha) onto the phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) gene promoters.	evodiamine	41-44	nuclear receptor subfamily 1 group I member 3	Homo sapiens	60-63
26455953-6	2016	The anti-gluconeogenic effect of Rut and Evo was due to the CAR-mediated inhibition of the recruitment of forkhead box O1 (FoxO1) and hepatocyte nuclear factor 4alpha (HNF4alpha) onto the phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) gene promoters.	evodiamine	41-44	forkhead box O1	Homo sapiens	106-121
26455953-6	2016	The anti-gluconeogenic effect of Rut and Evo was due to the CAR-mediated inhibition of the recruitment of forkhead box O1 (FoxO1) and hepatocyte nuclear factor 4alpha (HNF4alpha) onto the phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) gene promoters.	evodiamine	41-44	forkhead box O1	Homo sapiens	123-128
26455953-6	2016	The anti-gluconeogenic effect of Rut and Evo was due to the CAR-mediated inhibition of the recruitment of forkhead box O1 (FoxO1) and hepatocyte nuclear factor 4alpha (HNF4alpha) onto the phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) gene promoters.	evodiamine	41-44	hepatocyte nuclear factor 4 alpha	Homo sapiens	134-166
26455953-6	2016	The anti-gluconeogenic effect of Rut and Evo was due to the CAR-mediated inhibition of the recruitment of forkhead box O1 (FoxO1) and hepatocyte nuclear factor 4alpha (HNF4alpha) onto the phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) gene promoters.	evodiamine	41-44	hepatocyte nuclear factor 4 alpha	Homo sapiens	168-177
26455953-6	2016	The anti-gluconeogenic effect of Rut and Evo was due to the CAR-mediated inhibition of the recruitment of forkhead box O1 (FoxO1) and hepatocyte nuclear factor 4alpha (HNF4alpha) onto the phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) gene promoters.	evodiamine	41-44	phosphoenolpyruvate carboxykinase 2, mitochondrial	Homo sapiens	188-221
26455953-6	2016	The anti-gluconeogenic effect of Rut and Evo was due to the CAR-mediated inhibition of the recruitment of forkhead box O1 (FoxO1) and hepatocyte nuclear factor 4alpha (HNF4alpha) onto the phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) gene promoters.	evodiamine	41-44	phosphoenolpyruvate carboxykinase 2, mitochondrial	Homo sapiens	223-228
26455953-6	2016	The anti-gluconeogenic effect of Rut and Evo was due to the CAR-mediated inhibition of the recruitment of forkhead box O1 (FoxO1) and hepatocyte nuclear factor 4alpha (HNF4alpha) onto the phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) gene promoters.	evodiamine	41-44	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	234-255
26455953-6	2016	The anti-gluconeogenic effect of Rut and Evo was due to the CAR-mediated inhibition of the recruitment of forkhead box O1 (FoxO1) and hepatocyte nuclear factor 4alpha (HNF4alpha) onto the phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) gene promoters.	evodiamine	41-44	glucose-6-phosphatase catalytic subunit 1	Homo sapiens	257-263
27485202-4	2016	The results indicated that evodiamine significantly inhibited proliferation, induced apoptosis and the expression of reactive oxygen species, arrested the cell cycle, regulated the expression of Survivin, Bcl-2 and Cyclin B1, regulated the activity of caspase-3/8 and glutathione in tumor cells, and decreased the activity of AKT/nuclear factor-kappaB (NF-kappaB) and Sonic hedgehog/GLI family zinc finger 1 (SHH/GLI1) signaling pathways in A549 cells.	evodiamine	27-37	BCL2 apoptosis regulator	Homo sapiens	205-210
27485202-4	2016	The results indicated that evodiamine significantly inhibited proliferation, induced apoptosis and the expression of reactive oxygen species, arrested the cell cycle, regulated the expression of Survivin, Bcl-2 and Cyclin B1, regulated the activity of caspase-3/8 and glutathione in tumor cells, and decreased the activity of AKT/nuclear factor-kappaB (NF-kappaB) and Sonic hedgehog/GLI family zinc finger 1 (SHH/GLI1) signaling pathways in A549 cells.	evodiamine	27-37	cyclin B1	Homo sapiens	215-224
27485202-4	2016	The results indicated that evodiamine significantly inhibited proliferation, induced apoptosis and the expression of reactive oxygen species, arrested the cell cycle, regulated the expression of Survivin, Bcl-2 and Cyclin B1, regulated the activity of caspase-3/8 and glutathione in tumor cells, and decreased the activity of AKT/nuclear factor-kappaB (NF-kappaB) and Sonic hedgehog/GLI family zinc finger 1 (SHH/GLI1) signaling pathways in A549 cells.	evodiamine	27-37	caspase 3	Homo sapiens	252-263
27485202-4	2016	The results indicated that evodiamine significantly inhibited proliferation, induced apoptosis and the expression of reactive oxygen species, arrested the cell cycle, regulated the expression of Survivin, Bcl-2 and Cyclin B1, regulated the activity of caspase-3/8 and glutathione in tumor cells, and decreased the activity of AKT/nuclear factor-kappaB (NF-kappaB) and Sonic hedgehog/GLI family zinc finger 1 (SHH/GLI1) signaling pathways in A549 cells.	evodiamine	27-37	AKT serine/threonine kinase 1	Homo sapiens	326-329
27485202-4	2016	The results indicated that evodiamine significantly inhibited proliferation, induced apoptosis and the expression of reactive oxygen species, arrested the cell cycle, regulated the expression of Survivin, Bcl-2 and Cyclin B1, regulated the activity of caspase-3/8 and glutathione in tumor cells, and decreased the activity of AKT/nuclear factor-kappaB (NF-kappaB) and Sonic hedgehog/GLI family zinc finger 1 (SHH/GLI1) signaling pathways in A549 cells.	evodiamine	27-37	sonic hedgehog signaling molecule	Homo sapiens	409-412
27485202-4	2016	The results indicated that evodiamine significantly inhibited proliferation, induced apoptosis and the expression of reactive oxygen species, arrested the cell cycle, regulated the expression of Survivin, Bcl-2 and Cyclin B1, regulated the activity of caspase-3/8 and glutathione in tumor cells, and decreased the activity of AKT/nuclear factor-kappaB (NF-kappaB) and Sonic hedgehog/GLI family zinc finger 1 (SHH/GLI1) signaling pathways in A549 cells.	evodiamine	27-37	GLI family zinc finger 1	Homo sapiens	413-417
27485202-5	2016	In conclusion, the evodiamine-induced inhibition of the proliferation of A549 lung cancer cells may be attributable to its ability to promote oxidative injury in the cells, induce apoptosis, arrest the cell cycle and regulate the AKT/NF-kappaB and SHH/GLI1 signaling pathways, subsequently controlling the expression of tumor-associated genes.	evodiamine	19-29	AKT serine/threonine kinase 1	Homo sapiens	230-233
27485202-5	2016	In conclusion, the evodiamine-induced inhibition of the proliferation of A549 lung cancer cells may be attributable to its ability to promote oxidative injury in the cells, induce apoptosis, arrest the cell cycle and regulate the AKT/NF-kappaB and SHH/GLI1 signaling pathways, subsequently controlling the expression of tumor-associated genes.	evodiamine	19-29	sonic hedgehog signaling molecule	Homo sapiens	248-251
27485202-5	2016	In conclusion, the evodiamine-induced inhibition of the proliferation of A549 lung cancer cells may be attributable to its ability to promote oxidative injury in the cells, induce apoptosis, arrest the cell cycle and regulate the AKT/NF-kappaB and SHH/GLI1 signaling pathways, subsequently controlling the expression of tumor-associated genes.	evodiamine	19-29	GLI family zinc finger 1	Homo sapiens	252-256
27449032-0	2016	Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting beta-catenin-mediated angiogenesis.	evodiamine	0-10	catenin (cadherin associated protein), beta 1	Mus musculus	89-101
27449032-8	2016	In a subcutaneous H22 xenograft model, evodiamine inhibited tumor growth and reduced serum tumor markers and the levels of beta-catenin and VEGFa.	evodiamine	39-49	catenin (cadherin associated protein), beta 1	Mus musculus	123-135
27449032-8	2016	In a subcutaneous H22 xenograft model, evodiamine inhibited tumor growth and reduced serum tumor markers and the levels of beta-catenin and VEGFa.	evodiamine	39-49	vascular endothelial growth factor A	Mus musculus	140-145
27449032-12	2016	Also, evodiamine suppressed various biomarkers of angiogenesis and the expression of beta-catenin.	evodiamine	6-16	catenin (cadherin associated protein), beta 1	Mus musculus	85-97
27449032-13	2016	Evodiamine decreased beta-catenin levels activated by LiCl, which led to reduced expression of VEGFa.	evodiamine	0-10	catenin (cadherin associated protein), beta 1	Mus musculus	21-33
27449032-13	2016	Evodiamine decreased beta-catenin levels activated by LiCl, which led to reduced expression of VEGFa.	evodiamine	0-10	vascular endothelial growth factor A	Mus musculus	95-100
27449032-14	2016	In addition, beta-catenin interacted with VEGFa and transcriptionally regulated VEGFa, an effect inhibited by evodiamine in HCCs.	evodiamine	110-120	catenin (cadherin associated protein), beta 1	Mus musculus	13-25
27449032-14	2016	In addition, beta-catenin interacted with VEGFa and transcriptionally regulated VEGFa, an effect inhibited by evodiamine in HCCs.	evodiamine	110-120	vascular endothelial growth factor A	Mus musculus	42-47
27449032-14	2016	In addition, beta-catenin interacted with VEGFa and transcriptionally regulated VEGFa, an effect inhibited by evodiamine in HCCs.	evodiamine	110-120	vascular endothelial growth factor A	Mus musculus	80-85
27449032-15	2016	Moreover, in an SMMC-7721 xenograft model, evodiamine suppressed tumor growth, various biomarkers of angiogenesis, and the levels of beta-catenin and VEGFa.	evodiamine	43-53	catenin (cadherin associated protein), beta 1	Mus musculus	133-145
27449032-15	2016	Moreover, in an SMMC-7721 xenograft model, evodiamine suppressed tumor growth, various biomarkers of angiogenesis, and the levels of beta-catenin and VEGFa.	evodiamine	43-53	vascular endothelial growth factor A	Mus musculus	150-155
27449032-16	2016	Evodiamine has anti-tumor effects on HCCs through inhibiting beta-catenin, which interacts with and reduces VEGFa expression, thus inhibiting angiogenesis.	evodiamine	0-10	catenin (cadherin associated protein), beta 1	Mus musculus	61-73
27449032-16	2016	Evodiamine has anti-tumor effects on HCCs through inhibiting beta-catenin, which interacts with and reduces VEGFa expression, thus inhibiting angiogenesis.	evodiamine	0-10	vascular endothelial growth factor A	Mus musculus	108-113
26671528-0	2016	Evodiamine inhibits the proliferation of leukemia cell line K562 by regulating peroxisome proliferators-activated receptor gamma (PPARgamma) pathway.	evodiamine	0-10	peroxisome proliferator activated receptor gamma	Homo sapiens	79-128
27483435-0	2016	Protein Kinase RNA-Like Endoplasmic Reticulum Kinase-Mediated Bcl-2 Protein Phosphorylation Contributes to Evodiamine-Induced Apoptosis of Human Renal Cell Carcinoma Cells.	evodiamine	107-117	BCL2 apoptosis regulator	Homo sapiens	62-67
27483435-2	2016	The in vitro study showed that EVO decreased the viability of A498 cells with the occurrence of apoptotic characteristics such as hypodiploid cells, DNA ladders, chromatin-condensed cells, and cleaved caspase (Casp)-3/poly(ADP ribose) polymerase (PARP) proteins.	evodiamine	31-34	poly(ADP-ribose) polymerase 1	Homo sapiens	247-251
27483435-3	2016	Pharmacological studies using chemical inhibitors of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) indicated that phosphorylation of the c-Jun N-terminal kinase (JNK) protein participated in EVO-induced cell death of A498 cells, and application of the JNK inhibitor, SP600125 (SP), inhibited EVO-induced cleavage of the Casp-3/PARP proteins and chromatin condensation according to Giemsa staining.	evodiamine	222-225	mitogen-activated protein kinase 8	Homo sapiens	168-191
27483435-3	2016	Pharmacological studies using chemical inhibitors of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) indicated that phosphorylation of the c-Jun N-terminal kinase (JNK) protein participated in EVO-induced cell death of A498 cells, and application of the JNK inhibitor, SP600125 (SP), inhibited EVO-induced cleavage of the Casp-3/PARP proteins and chromatin condensation according to Giemsa staining.	evodiamine	222-225	mitogen-activated protein kinase 8	Homo sapiens	193-196
27483435-3	2016	Pharmacological studies using chemical inhibitors of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) indicated that phosphorylation of the c-Jun N-terminal kinase (JNK) protein participated in EVO-induced cell death of A498 cells, and application of the JNK inhibitor, SP600125 (SP), inhibited EVO-induced cleavage of the Casp-3/PARP proteins and chromatin condensation according to Giemsa staining.	evodiamine	222-225	mitogen-activated protein kinase 8	Homo sapiens	283-286
27483435-3	2016	Pharmacological studies using chemical inhibitors of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) indicated that phosphorylation of the c-Jun N-terminal kinase (JNK) protein participated in EVO-induced cell death of A498 cells, and application of the JNK inhibitor, SP600125 (SP), inhibited EVO-induced cleavage of the Casp-3/PARP proteins and chromatin condensation according to Giemsa staining.	evodiamine	222-225	caspase 3	Homo sapiens	351-357
27483435-3	2016	Pharmacological studies using chemical inhibitors of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) indicated that phosphorylation of the c-Jun N-terminal kinase (JNK) protein participated in EVO-induced cell death of A498 cells, and application of the JNK inhibitor, SP600125 (SP), inhibited EVO-induced cleavage of the Casp-3/PARP proteins and chromatin condensation according to Giemsa staining.	evodiamine	222-225	poly(ADP-ribose) polymerase 1	Homo sapiens	358-362
27483435-3	2016	Pharmacological studies using chemical inhibitors of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) indicated that phosphorylation of the c-Jun N-terminal kinase (JNK) protein participated in EVO-induced cell death of A498 cells, and application of the JNK inhibitor, SP600125 (SP), inhibited EVO-induced cleavage of the Casp-3/PARP proteins and chromatin condensation according to Giemsa staining.	evodiamine	323-326	mitogen-activated protein kinase 8	Homo sapiens	168-191
27483435-3	2016	Pharmacological studies using chemical inhibitors of mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) indicated that phosphorylation of the c-Jun N-terminal kinase (JNK) protein participated in EVO-induced cell death of A498 cells, and application of the JNK inhibitor, SP600125 (SP), inhibited EVO-induced cleavage of the Casp-3/PARP proteins and chromatin condensation according to Giemsa staining.	evodiamine	323-326	mitogen-activated protein kinase 8	Homo sapiens	193-196
27483435-4	2016	EVO disruption of the mitochondrial membrane potential (MMP) with increased protein levels of the phosphorylated Bcl-2 protein (p-Bcl-2) was prevented by JNK inhibitors in A498 cells.	evodiamine	0-3	BCL2 apoptosis regulator	Homo sapiens	113-118
27483435-4	2016	EVO disruption of the mitochondrial membrane potential (MMP) with increased protein levels of the phosphorylated Bcl-2 protein (p-Bcl-2) was prevented by JNK inhibitors in A498 cells.	evodiamine	0-3	BCL2 apoptosis regulator	Homo sapiens	130-135
27483435-4	2016	EVO disruption of the mitochondrial membrane potential (MMP) with increased protein levels of the phosphorylated Bcl-2 protein (p-Bcl-2) was prevented by JNK inhibitors in A498 cells.	evodiamine	0-3	mitogen-activated protein kinase 8	Homo sapiens	154-157
27483435-5	2016	A structure-activity relationship study showed that a methyl group at position 14 in EVO was important for its apoptotic effects and increased p-Bcl-2 protein in A498 cells.	evodiamine	85-88	BCL2 apoptosis regulator	Homo sapiens	145-150
27483435-6	2016	Furthermore, significant increases in the phosphorylated endoplasmic reticular stress protein, protein kinase RNA-like endoplasmic reticulum kinase (p-PERK at Thr980), by EVO were detected in A498 cells, and the PERK inhibitor, GSK2606414, significantly suppressed EVO-induced apoptosis, p-JNK, p-PERK, and cleaved PARP proteins.	evodiamine	171-174	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	151-155
27483435-6	2016	Furthermore, significant increases in the phosphorylated endoplasmic reticular stress protein, protein kinase RNA-like endoplasmic reticulum kinase (p-PERK at Thr980), by EVO were detected in A498 cells, and the PERK inhibitor, GSK2606414, significantly suppressed EVO-induced apoptosis, p-JNK, p-PERK, and cleaved PARP proteins.	evodiamine	171-174	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	212-216
27483435-6	2016	Furthermore, significant increases in the phosphorylated endoplasmic reticular stress protein, protein kinase RNA-like endoplasmic reticulum kinase (p-PERK at Thr980), by EVO were detected in A498 cells, and the PERK inhibitor, GSK2606414, significantly suppressed EVO-induced apoptosis, p-JNK, p-PERK, and cleaved PARP proteins.	evodiamine	171-174	mitogen-activated protein kinase 8	Homo sapiens	290-293
27483435-6	2016	Furthermore, significant increases in the phosphorylated endoplasmic reticular stress protein, protein kinase RNA-like endoplasmic reticulum kinase (p-PERK at Thr980), by EVO were detected in A498 cells, and the PERK inhibitor, GSK2606414, significantly suppressed EVO-induced apoptosis, p-JNK, p-PERK, and cleaved PARP proteins.	evodiamine	171-174	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	212-216
27483435-6	2016	Furthermore, significant increases in the phosphorylated endoplasmic reticular stress protein, protein kinase RNA-like endoplasmic reticulum kinase (p-PERK at Thr980), by EVO were detected in A498 cells, and the PERK inhibitor, GSK2606414, significantly suppressed EVO-induced apoptosis, p-JNK, p-PERK, and cleaved PARP proteins.	evodiamine	171-174	poly(ADP-ribose) polymerase 1	Homo sapiens	315-319
27748810-8	2016	In addition, evodiamine attenuated the PDGF-BB-induced phosphorylation of mitogen-activated protein kinases p38 and extracellular signal-regulated kinases 1/2, however, it had no effect on the phosphorylation of Akt.	evodiamine	13-23	mitogen activated protein kinase 14	Rattus norvegicus	108-111
27748810-8	2016	In addition, evodiamine attenuated the PDGF-BB-induced phosphorylation of mitogen-activated protein kinases p38 and extracellular signal-regulated kinases 1/2, however, it had no effect on the phosphorylation of Akt.	evodiamine	13-23	mitogen activated protein kinase 3	Rattus norvegicus	116-158
27483435-7	2016	The in vivo study showed that EVO significantly reduced RCC growth elicited by a subcutaneous injection of A498 cells, and an increased protein level of p-PERK was observed according to an immunohistochemical analysis.	evodiamine	30-33	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	155-159
26671528-0	2016	Evodiamine inhibits the proliferation of leukemia cell line K562 by regulating peroxisome proliferators-activated receptor gamma (PPARgamma) pathway.	evodiamine	0-10	peroxisome proliferator activated receptor gamma	Homo sapiens	130-139
26671528-7	2016	2-Chloro-5-nitro-N-phenylbenzamide (GW9662) and/or PPARgamma-siRNA pretreatment alleviated the cell growth suppression triggered by evodiamine.	evodiamine	132-142	peroxisome proliferator activated receptor gamma	Homo sapiens	51-60
26671528-8	2016	Meanwhile, evodiamine intervention elevated the expression of PPARgamma in K562 cells, while pretreatment with GW9662 attenuated the enhanced upregulation of PPARgamma expression induced by evodiamine.	evodiamine	11-21	peroxisome proliferator activated receptor gamma	Homo sapiens	62-71
26671528-8	2016	Meanwhile, evodiamine intervention elevated the expression of PPARgamma in K562 cells, while pretreatment with GW9662 attenuated the enhanced upregulation of PPARgamma expression induced by evodiamine.	evodiamine	190-200	peroxisome proliferator activated receptor gamma	Homo sapiens	158-167
26671528-9	2016	In addition, GW9662 and PPARgamma-siRNA pretreatment also significantly attenuated the downregulation of the cell cycle control protein cyclin D1 and the upregulation of cyclin-dependent kinase inhibitor p21 induced by evodiamine.	evodiamine	219-229	peroxisome proliferator activated receptor gamma	Homo sapiens	24-33
26671528-10	2016	In conclusion, PPARgamma signaling pathway may involve in the proliferation inhibition of evodiamine on K562 cells via inhibiting cylcin D1 and stimulating of p21.	evodiamine	90-100	peroxisome proliferator activated receptor gamma	Homo sapiens	15-24
26671528-10	2016	In conclusion, PPARgamma signaling pathway may involve in the proliferation inhibition of evodiamine on K562 cells via inhibiting cylcin D1 and stimulating of p21.	evodiamine	90-100	cyclin dependent kinase inhibitor 1A	Homo sapiens	159-162
27462166-0	2016	Effect of evodiamine and berberine on miR-429 as an oncogene in human colorectal cancer.	evodiamine	10-20	microRNA 429	Homo sapiens	38-45
27278862-7	2016	However, there was no significant synergistic inhibitory effect of combined BER and evodiamine (EVO) treatment on tumorigenesis, and BER reduced the upregulation of IL-8 induced by EVO in vivo.	evodiamine	181-184	C-X-C motif chemokine ligand 8	Homo sapiens	165-169
27462166-4	2016	An in vitro culture of colorectal tissue was established to analyze the effect of berberine (BER) and evodiamine (EVO) on the level of miR-429.	evodiamine	102-112	microRNA 429	Homo sapiens	135-142
27462166-4	2016	An in vitro culture of colorectal tissue was established to analyze the effect of berberine (BER) and evodiamine (EVO) on the level of miR-429.	evodiamine	114-117	microRNA 429	Homo sapiens	135-142
27462166-6	2016	After treatment of BER and EVO, the level of miR-429 was lower in tumor tissues than in normal tissues.	evodiamine	27-30	microRNA 429	Homo sapiens	45-52
27462166-8	2016	The data suggested that BER and EVO can be potential therapeutic agents for CRC, as they downregulated the expression level of miR-429.	evodiamine	32-35	microRNA 429	Homo sapiens	127-134
27363277-11	2016	Additionally, evodiamine treatment also significantly inhibited radiotherapy-induced increase in Ku70, Ku80, DNA-PKcs and Rad51 expressions.	evodiamine	14-24	X-ray repair cross complementing 6	Homo sapiens	97-101
27363277-11	2016	Additionally, evodiamine treatment also significantly inhibited radiotherapy-induced increase in Ku70, Ku80, DNA-PKcs and Rad51 expressions.	evodiamine	14-24	X-ray repair cross complementing 5	Homo sapiens	103-107
27363277-11	2016	Additionally, evodiamine treatment also significantly inhibited radiotherapy-induced increase in Ku70, Ku80, DNA-PKcs and Rad51 expressions.	evodiamine	14-24	protein kinase, DNA-activated, catalytic subunit	Homo sapiens	109-117
27363277-11	2016	Additionally, evodiamine treatment also significantly inhibited radiotherapy-induced increase in Ku70, Ku80, DNA-PKcs and Rad51 expressions.	evodiamine	14-24	RAD51 recombinase	Homo sapiens	122-127
27468551-0	2016	[Evodiamine induces extrinsic and intrinsic apoptosis of ovarian cancer cells via the mitogen-activated protein kinase/phosphatidylinositol-3-kinase/protein kinase B signaling pathways].	evodiamine	1-11	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	119-148
26590365-0	2016	Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-kappaB Pathway in Colorectal Cancer.	evodiamine	0-10	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	22-27
26590365-0	2016	Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-kappaB Pathway in Colorectal Cancer.	evodiamine	0-10	nuclear factor kappa B subunit 1	Homo sapiens	67-70
26590365-0	2016	Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-kappaB Pathway in Colorectal Cancer.	evodiamine	0-10	RELA proto-oncogene, NF-kB subunit	Homo sapiens	71-74
26590365-0	2016	Evodiamine Suppresses ABCG2 Mediated Drug Resistance by Inhibiting p50/p65 NF-kappaB Pathway in Colorectal Cancer.	evodiamine	0-10	nuclear factor kappa B subunit 1	Homo sapiens	75-84
26590365-5	2016	Interestingly, phosphorylation of NF-kappaB pathway, particularly p50/p65, was also inhibited by Evo treatment.	evodiamine	97-100	nuclear factor kappa B subunit 1	Homo sapiens	34-43
26590365-5	2016	Interestingly, phosphorylation of NF-kappaB pathway, particularly p50/p65, was also inhibited by Evo treatment.	evodiamine	97-100	nuclear factor kappa B subunit 1	Homo sapiens	66-69
26590365-5	2016	Interestingly, phosphorylation of NF-kappaB pathway, particularly p50/p65, was also inhibited by Evo treatment.	evodiamine	97-100	RELA proto-oncogene, NF-kB subunit	Homo sapiens	70-73
26590365-6	2016	Furthermore the effect of Evo in reversing drug resistance and suppressing phosphorylation of NF-kappaB pathway were attenuated after treatment with the NF-kappaB activator (LPS).	evodiamine	26-29	nuclear factor kappa B subunit 1	Homo sapiens	94-103
26590365-6	2016	Furthermore the effect of Evo in reversing drug resistance and suppressing phosphorylation of NF-kappaB pathway were attenuated after treatment with the NF-kappaB activator (LPS).	evodiamine	26-29	nuclear factor kappa B subunit 1	Homo sapiens	153-162
26590365-7	2016	Additionally, Evo inhibited the tumor growth in a colorectal MDR cancer xenograft model and down regulated p-NF-kappaB level in vivo.	evodiamine	14-17	nuclear factor kappa B subunit 1	Homo sapiens	109-118
26590365-8	2016	Our study provided the first direct evidence that Evo can attenuate multidrug resistance by blocking p-NF-kappaB signaling pathway in human colorectal cancer.	evodiamine	50-53	nuclear factor kappa B subunit 1	Homo sapiens	103-112
27468551-9	2016	Evodiamine induced G2/M arrest with an increase of cyclin B1 level, and promoted cell apoptosis with a decrease of B cell lymphoma/lewkmia-2 (Bcl-2) and an increase of Bcl-2-associated X protein (Bax) level.	evodiamine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	196-199
27468551-10	2016	In addition, evodiamine treatment led to the activation of caspase-8, caspase-9, and caspase-3 and the cleavage of poly (ADP-ribose)-polymerase (PARP).	evodiamine	13-23	caspase 8	Homo sapiens	59-68
27468551-10	2016	In addition, evodiamine treatment led to the activation of caspase-8, caspase-9, and caspase-3 and the cleavage of poly (ADP-ribose)-polymerase (PARP).	evodiamine	13-23	caspase 9	Homo sapiens	70-79
27468551-10	2016	In addition, evodiamine treatment led to the activation of caspase-8, caspase-9, and caspase-3 and the cleavage of poly (ADP-ribose)-polymerase (PARP).	evodiamine	13-23	caspase 3	Homo sapiens	85-94
27468551-10	2016	In addition, evodiamine treatment led to the activation of caspase-8, caspase-9, and caspase-3 and the cleavage of poly (ADP-ribose)-polymerase (PARP).	evodiamine	13-23	poly(ADP-ribose) polymerase 1	Homo sapiens	115-143
27468551-10	2016	In addition, evodiamine treatment led to the activation of caspase-8, caspase-9, and caspase-3 and the cleavage of poly (ADP-ribose)-polymerase (PARP).	evodiamine	13-23	poly(ADP-ribose) polymerase 1	Homo sapiens	145-149
27468551-11	2016	Evodiamine targeted the MAPK and/or PI3K/Akt pathways by reducing the expression and activity of PI3K, Akt, and extracellular signal-regulated kinase mitogen-activated protein kinase (ERK1/2 MAPK) and the activity of p38 MAPK.	evodiamine	0-10	AKT serine/threonine kinase 1	Homo sapiens	41-44
27468551-11	2016	Evodiamine targeted the MAPK and/or PI3K/Akt pathways by reducing the expression and activity of PI3K, Akt, and extracellular signal-regulated kinase mitogen-activated protein kinase (ERK1/2 MAPK) and the activity of p38 MAPK.	evodiamine	0-10	AKT serine/threonine kinase 1	Homo sapiens	103-106
27468551-11	2016	Evodiamine targeted the MAPK and/or PI3K/Akt pathways by reducing the expression and activity of PI3K, Akt, and extracellular signal-regulated kinase mitogen-activated protein kinase (ERK1/2 MAPK) and the activity of p38 MAPK.	evodiamine	0-10	mitogen-activated protein kinase 3	Homo sapiens	184-190
27468551-11	2016	Evodiamine targeted the MAPK and/or PI3K/Akt pathways by reducing the expression and activity of PI3K, Akt, and extracellular signal-regulated kinase mitogen-activated protein kinase (ERK1/2 MAPK) and the activity of p38 MAPK.	evodiamine	0-10	mitogen-activated protein kinase 1	Homo sapiens	217-220
27468551-13	2016	In addition, evodiamine-induced PI3K/Akt, ERK1/2 MAPK, and p38 MAPK signaling may be involved in cell death.	evodiamine	13-23	AKT serine/threonine kinase 1	Homo sapiens	37-40
27468551-13	2016	In addition, evodiamine-induced PI3K/Akt, ERK1/2 MAPK, and p38 MAPK signaling may be involved in cell death.	evodiamine	13-23	mitogen-activated protein kinase 3	Homo sapiens	42-48
27468551-13	2016	In addition, evodiamine-induced PI3K/Akt, ERK1/2 MAPK, and p38 MAPK signaling may be involved in cell death.	evodiamine	13-23	mitogen-activated protein kinase 1	Homo sapiens	59-62
27159637-0	2016	Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa.	evodiamine	55-65	transient receptor potential cation channel subfamily V member 1	Homo sapiens	37-42
27159637-8	2016	Evodiamine (1), but not rutaecarpine (2), can desensitize or competitively inhibit the activity of TRPV1.	evodiamine	0-10	transient receptor potential cation channel subfamily V member 1	Homo sapiens	99-104
27468551-9	2016	Evodiamine induced G2/M arrest with an increase of cyclin B1 level, and promoted cell apoptosis with a decrease of B cell lymphoma/lewkmia-2 (Bcl-2) and an increase of Bcl-2-associated X protein (Bax) level.	evodiamine	0-10	cyclin B1	Homo sapiens	51-60
27468551-9	2016	Evodiamine induced G2/M arrest with an increase of cyclin B1 level, and promoted cell apoptosis with a decrease of B cell lymphoma/lewkmia-2 (Bcl-2) and an increase of Bcl-2-associated X protein (Bax) level.	evodiamine	0-10	BCL2 apoptosis regulator	Homo sapiens	115-140
27468551-9	2016	Evodiamine induced G2/M arrest with an increase of cyclin B1 level, and promoted cell apoptosis with a decrease of B cell lymphoma/lewkmia-2 (Bcl-2) and an increase of Bcl-2-associated X protein (Bax) level.	evodiamine	0-10	BCL2 apoptosis regulator	Homo sapiens	142-147
27468551-9	2016	Evodiamine induced G2/M arrest with an increase of cyclin B1 level, and promoted cell apoptosis with a decrease of B cell lymphoma/lewkmia-2 (Bcl-2) and an increase of Bcl-2-associated X protein (Bax) level.	evodiamine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	168-194
26713361-0	2016	Evodiamine selectively targets cancer stem-like cells through the p53-p21-Rb pathway.	evodiamine	0-10	tumor protein p53	Homo sapiens	66-69
26757927-0	2016	Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition.	evodiamine	0-10	epidermal growth factor receptor	Homo sapiens	86-90
26757927-0	2016	Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition.	evodiamine	0-10	ribosomal protein S6 kinase B1	Homo sapiens	107-111
26757927-0	2016	Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition.	evodiamine	0-10	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	121-126
26757927-3	2016	Benth, we showed that evodiamine could induce anti-proliferation and apoptosis in four wild-type EGFR NSCLC cell lines, and combining evodiamine with erlotinib might successfully inhibit cell proliferation and survival in wild-type EGFR NSCLC cells, characterized as erlotinib-resistant.	evodiamine	22-32	epidermal growth factor receptor	Homo sapiens	97-101
26757927-3	2016	Benth, we showed that evodiamine could induce anti-proliferation and apoptosis in four wild-type EGFR NSCLC cell lines, and combining evodiamine with erlotinib might successfully inhibit cell proliferation and survival in wild-type EGFR NSCLC cells, characterized as erlotinib-resistant.	evodiamine	134-144	epidermal growth factor receptor	Homo sapiens	232-236
26757927-5	2016	Further investigation of the mechanism underlying these effects revealed that evodiamine plus erlotinib might downregulate Mcl-1 expression through the mTOR/S6K1 control of its translation.	evodiamine	78-88	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	123-128
26757927-5	2016	Further investigation of the mechanism underlying these effects revealed that evodiamine plus erlotinib might downregulate Mcl-1 expression through the mTOR/S6K1 control of its translation.	evodiamine	78-88	mechanistic target of rapamycin kinase	Homo sapiens	152-156
26757927-5	2016	Further investigation of the mechanism underlying these effects revealed that evodiamine plus erlotinib might downregulate Mcl-1 expression through the mTOR/S6K1 control of its translation.	evodiamine	78-88	ribosomal protein S6 kinase B1	Homo sapiens	157-161
26713361-0	2016	Evodiamine selectively targets cancer stem-like cells through the p53-p21-Rb pathway.	evodiamine	0-10	H3 histone pseudogene 16	Homo sapiens	70-73
26713361-7	2016	Surprisingly, evodiamine selectively activated p53 and p21 and decreased inactive Rb, the master molecules in G1/S checkpoint.	evodiamine	14-24	tumor protein p53	Homo sapiens	47-50
26713361-7	2016	Surprisingly, evodiamine selectively activated p53 and p21 and decreased inactive Rb, the master molecules in G1/S checkpoint.	evodiamine	14-24	H3 histone pseudogene 16	Homo sapiens	55-58
26902409-0	2016	Evodiamine from Evodia rutaecarpa induces apoptosis via activation of JNK and PERK in human ovarian cancer cells.	evodiamine	0-10	mitogen-activated protein kinase 8	Homo sapiens	70-73
26902409-0	2016	Evodiamine from Evodia rutaecarpa induces apoptosis via activation of JNK and PERK in human ovarian cancer cells.	evodiamine	0-10	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	78-82
26872133-0	2016	Effect of Evodiamine on CYP Enzymes in Rats by a Cocktail Method.	evodiamine	10-20	cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1	Rattus norvegicus	24-27
24904975-7	2016	Meanwhile, EVO-PLGA NPs could increase the expression of cyclin B1 and decrease the expression of beta-actin.	evodiamine	11-14	cyclin B1	Homo sapiens	57-66
24904975-7	2016	Meanwhile, EVO-PLGA NPs could increase the expression of cyclin B1 and decrease the expression of beta-actin.	evodiamine	11-14	POTE ankyrin domain family member F	Homo sapiens	98-108
26188960-7	2016	The effect of evodiamine was completely blocked by capsazepine, a competitive antagonist of TRPV1.	evodiamine	14-24	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	92-97
26188960-8	2016	Evodiamine induced significant inward currents in TRPV1-, but not TRPA1-transfected HEK293 cells.	evodiamine	0-10	transient receptor potential cation channel subfamily V member 1	Homo sapiens	50-55
26188960-11	2016	These results identify that the analgesic effect of EF and evodiamine may be due to the activation and subsequent desensitization of TRPV1 in sensory neurons.	evodiamine	59-69	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	133-138
26872133-1	2016	The aim of this study was to assess the influence of evodiamine on the activities of the drug-metabolizing enzymes cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 in rats.	evodiamine	53-63	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	115-140
26872133-5	2016	The data showed that evodiamine exhibits an inhibitory effect on CYP1A2, CYP2C9 and CYP2D6 by increasing t(1/2), Cmax and AUC(0- ), and decreasing CL/F compared with those of the control group.	evodiamine	21-31	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	65-71
26872133-5	2016	The data showed that evodiamine exhibits an inhibitory effect on CYP1A2, CYP2C9 and CYP2D6 by increasing t(1/2), Cmax and AUC(0- ), and decreasing CL/F compared with those of the control group.	evodiamine	21-31	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	84-90
26872133-7	2016	In conclusion, the results indicated that evodiamine could inhibit CYP1A2, CYP2C9 and CYP2D6, which may affect the disposition of medicines primarily dependent on these pathways.	evodiamine	42-52	cytochrome P450, family 1, subfamily a, polypeptide 2	Rattus norvegicus	67-73
26872133-7	2016	In conclusion, the results indicated that evodiamine could inhibit CYP1A2, CYP2C9 and CYP2D6, which may affect the disposition of medicines primarily dependent on these pathways.	evodiamine	42-52	cytochrome P450, family 2, subfamily d, polypeptide 4	Rattus norvegicus	86-92
26344431-0	2015	Beneficial effects of evodiamine on P2X(4)-mediated inflammatory injury of human umbilical vein endothelial cells due to high glucose.	evodiamine	22-32	purinergic receptor P2X 4	Homo sapiens	36-42
26546460-0	2015	Evodiamine inhibits the migration and invasion of nasopharyngeal carcinoma cells in vitro via repressing MMP-2 expression.	evodiamine	0-10	matrix metallopeptidase 2	Homo sapiens	105-110
26546460-8	2015	Additionally, evodiamine treatment significantly decreased mRNA and protein levels of MMP-2 and its activity in the NPC cells, but had little effects on MMP-9 mRNA and protein levels and its activity.	evodiamine	14-24	matrix metallopeptidase 2	Homo sapiens	86-91
26546460-9	2015	Further investigation revealed that evodiamine inhibited the translocation of NF-kappaB p65, which involves the regulation of MMP-2 expression in cancer invasion.	evodiamine	36-46	RELA proto-oncogene, NF-kB subunit	Homo sapiens	78-91
26546460-9	2015	Further investigation revealed that evodiamine inhibited the translocation of NF-kappaB p65, which involves the regulation of MMP-2 expression in cancer invasion.	evodiamine	36-46	matrix metallopeptidase 2	Homo sapiens	126-131
26546460-10	2015	Additionally, evodiamine treatment did not significantly affect the protein levels of JNK, p38, Akt, and their phosphorylated forms and ERK1/2, but strongly attenuated ERK1/2 phosphorylation level, which at least partly accounts for the signal pathway of evodiamine-inhibited migration and invasion of NPC cells.	evodiamine	14-24	mitogen-activated protein kinase 3	Homo sapiens	168-174
26503233-0	2015	Antiproliferation effect of evodiamine in human colon cancer cells  is associated with IGF-1/HIF-1alpha downregulation.	evodiamine	28-38	insulin like growth factor 1	Homo sapiens	87-92
26503233-0	2015	Antiproliferation effect of evodiamine in human colon cancer cells  is associated with IGF-1/HIF-1alpha downregulation.	evodiamine	28-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	93-103
26503233-8	2015	Evo leads to apparent downregulation of HIF-1alpha either in vitro or in vivo; exogenous expression of HIF-1alpha can attenuate the antiproliferation effect of Evo in LoVo cells, while HIF-1alpha knockdown potentiates this effect greatly.	evodiamine	0-3	hypoxia inducible factor 1 subunit alpha	Homo sapiens	40-50
26503233-8	2015	Evo leads to apparent downregulation of HIF-1alpha either in vitro or in vivo; exogenous expression of HIF-1alpha can attenuate the antiproliferation effect of Evo in LoVo cells, while HIF-1alpha knockdown potentiates this effect greatly.	evodiamine	160-163	hypoxia inducible factor 1 subunit alpha	Homo sapiens	103-113
26503233-8	2015	Evo leads to apparent downregulation of HIF-1alpha either in vitro or in vivo; exogenous expression of HIF-1alpha can attenuate the antiproliferation effect of Evo in LoVo cells, while HIF-1alpha knockdown potentiates this effect greatly.	evodiamine	160-163	hypoxia inducible factor 1 subunit alpha	Homo sapiens	103-113
26503233-9	2015	Further analysis indicated that Evo can also inhibit the phosphorylation of Akt1/2/3 and decrease greatly the expression of IGF-1.	evodiamine	32-35	AKT serine/threonine kinase 1	Homo sapiens	76-84
26503233-9	2015	Further analysis indicated that Evo can also inhibit the phosphorylation of Akt1/2/3 and decrease greatly the expression of IGF-1.	evodiamine	32-35	insulin like growth factor 1	Homo sapiens	124-129
26503233-10	2015	Thus, our findings strongly suggested that the anticancer effect of Evo in human colon cancer may be partly mediated by downregulating HIF-1alpha expression, which is initiated by inactivating PI3K/Akt signaling transduction though decreasing the expression of IGF-1 in colon cancer cells.	evodiamine	68-71	hypoxia inducible factor 1 subunit alpha	Homo sapiens	135-145
26503233-10	2015	Thus, our findings strongly suggested that the anticancer effect of Evo in human colon cancer may be partly mediated by downregulating HIF-1alpha expression, which is initiated by inactivating PI3K/Akt signaling transduction though decreasing the expression of IGF-1 in colon cancer cells.	evodiamine	68-71	AKT serine/threonine kinase 1	Homo sapiens	198-201
26503233-10	2015	Thus, our findings strongly suggested that the anticancer effect of Evo in human colon cancer may be partly mediated by downregulating HIF-1alpha expression, which is initiated by inactivating PI3K/Akt signaling transduction though decreasing the expression of IGF-1 in colon cancer cells.	evodiamine	68-71	insulin like growth factor 1	Homo sapiens	261-266
26703570-0	2015	Evodiamine Attenuates PDGF-BB-Induced Migration of Rat Vascular Smooth Muscle Cells through Activating PPARgamma.	evodiamine	0-10	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	103-112
26703570-4	2015	More importantly, we found that evodiamine activated the expression and nuclear translocation of peroxisome proliferator-activated receptor gamma (PPARgamma).	evodiamine	32-42	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	97-145
26703570-4	2015	More importantly, we found that evodiamine activated the expression and nuclear translocation of peroxisome proliferator-activated receptor gamma (PPARgamma).	evodiamine	32-42	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	147-156
26703570-5	2015	Inhibition of PPARgamma activity by using its antagonist T0070907 and its specific siRNA oligonucleotides significantly attenuated the inhibitory effects of evodiamine on VSMC migration.	evodiamine	157-167	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	14-23
26703570-6	2015	Taken together, our results indicate a promising anti-atherogenic effect of evodiamine through attenuation of VSMC migration by activating PPARgamma.	evodiamine	76-86	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	139-148
26580615-9	2015	Taken together, our results suggest that EVO modulates the activity of the p53 signaling pathway to induce apoptosis and downregulate MMP3 expression by inactivating the JAK2/STAT3 pathway through the downregulation of PGI to inhibit migration of HCT-116 human colorectal cancer cells.	evodiamine	41-44	tumor protein p53	Homo sapiens	75-78
26580615-9	2015	Taken together, our results suggest that EVO modulates the activity of the p53 signaling pathway to induce apoptosis and downregulate MMP3 expression by inactivating the JAK2/STAT3 pathway through the downregulation of PGI to inhibit migration of HCT-116 human colorectal cancer cells.	evodiamine	41-44	matrix metallopeptidase 3	Homo sapiens	134-138
26580615-9	2015	Taken together, our results suggest that EVO modulates the activity of the p53 signaling pathway to induce apoptosis and downregulate MMP3 expression by inactivating the JAK2/STAT3 pathway through the downregulation of PGI to inhibit migration of HCT-116 human colorectal cancer cells.	evodiamine	41-44	Janus kinase 2	Homo sapiens	170-174
26580615-9	2015	Taken together, our results suggest that EVO modulates the activity of the p53 signaling pathway to induce apoptosis and downregulate MMP3 expression by inactivating the JAK2/STAT3 pathway through the downregulation of PGI to inhibit migration of HCT-116 human colorectal cancer cells.	evodiamine	41-44	signal transducer and activator of transcription 3	Homo sapiens	175-180
26580615-9	2015	Taken together, our results suggest that EVO modulates the activity of the p53 signaling pathway to induce apoptosis and downregulate MMP3 expression by inactivating the JAK2/STAT3 pathway through the downregulation of PGI to inhibit migration of HCT-116 human colorectal cancer cells.	evodiamine	41-44	glucose-6-phosphate isomerase	Homo sapiens	219-222
26344431-4	2015	We found that culturing human umbilical vein endothelial cells (HUVECs) with high glucose significantly increased the expression of P2X4 receptor in HUVECs, cytosolic Ca(2+) concentrations and intracellular reactive oxygen species (ROS) while decreasing nitric oxide (NO); these effects could be reversed by evodiamine.	evodiamine	308-318	purinergic receptor P2X 4	Homo sapiens	132-145
26344431-6	2015	Evodiamine was able to down-regulate the elevated NF-kappaB, TNFR-alpha, P2X4R and ROS, and up-regulate the decreased NO.	evodiamine	0-10	purinergic receptor P2X 4	Homo sapiens	73-78
26344431-7	2015	Thus the evodiamine may exert the anti-inflammation activity on high-glucose challenge HUVEC via suppressing the P2X4R signaling pathway, exhibiting beneficial ability to protect HUVECs from glucotoxicity.	evodiamine	9-19	purinergic receptor P2X 4	Homo sapiens	113-118
26171032-9	2015	Messenger (m)RNA levels of survivin decreased and those of caspase-3 increase in a dose-dependent manner in SGC7901 cells treated with various concentrations of evodiamine for 24 h. In conclusion, the results of the present study demonstrated that evodiamine inhibited proliferation and induced apoptosis in gastric cancer cells via the downregulation of survivin and upregulation of caspase-3 mRNA.	evodiamine	161-171	caspase 3	Homo sapiens	59-68
26225926-5	2015	Pre-treatment with EVD prevented the oxidative damage and decreased the levels of prostaglandin E2 (PGE2) content, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	evodiamine	19-22	interleukin 6	Mus musculus	115-128
26225926-5	2015	Pre-treatment with EVD prevented the oxidative damage and decreased the levels of prostaglandin E2 (PGE2) content, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	evodiamine	19-22	interleukin 6	Mus musculus	130-134
26225926-5	2015	Pre-treatment with EVD prevented the oxidative damage and decreased the levels of prostaglandin E2 (PGE2) content, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	evodiamine	19-22	tumor necrosis factor	Mus musculus	140-167
26225926-5	2015	Pre-treatment with EVD prevented the oxidative damage and decreased the levels of prostaglandin E2 (PGE2) content, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha).	evodiamine	19-22	tumor necrosis factor	Mus musculus	169-178
26135006-0	2015	Evodiamine inhibits the proliferation of human osteosarcoma cells by blocking PI3K/Akt signaling.	evodiamine	0-10	AKT serine/threonine kinase 1	Homo sapiens	83-86
26135006-6	2015	According to our findings of polymerase chain reaction (PCR), western blot analysis and recombinant adenoviral transfection, we confirmed that EVO upregulates both the protein and gene levels of phosphatase and tensin homolog (PTEN) in a concentration-dependent manner in 143B cells.	evodiamine	143-146	phosphatase and tensin homolog	Homo sapiens	227-231
26135006-7	2015	Overexpression of PTEN reinforced the anti-proliferative effect of EVO in the 143B cells, while knockdown of PTEN upregulated PI3K/Akt signaling transduction and reversed the inhibitory effect of EVO on 143B cell proliferation.	evodiamine	67-70	phosphatase and tensin homolog	Homo sapiens	18-22
26135006-7	2015	Overexpression of PTEN reinforced the anti-proliferative effect of EVO in the 143B cells, while knockdown of PTEN upregulated PI3K/Akt signaling transduction and reversed the inhibitory effect of EVO on 143B cell proliferation.	evodiamine	196-199	phosphatase and tensin homolog	Homo sapiens	109-113
26135006-7	2015	Overexpression of PTEN reinforced the anti-proliferative effect of EVO in the 143B cells, while knockdown of PTEN upregulated PI3K/Akt signaling transduction and reversed the inhibitory effect of EVO on 143B cell proliferation.	evodiamine	196-199	AKT serine/threonine kinase 1	Homo sapiens	131-134
26135006-8	2015	Further analysis indicated that EVO upregulated the expression of PTEN by inactivating PI3K/Akt signaling by decreasing phosphorylated Akt1/2.	evodiamine	32-35	phosphatase and tensin homolog	Homo sapiens	66-70
26135006-8	2015	Further analysis indicated that EVO upregulated the expression of PTEN by inactivating PI3K/Akt signaling by decreasing phosphorylated Akt1/2.	evodiamine	32-35	AKT serine/threonine kinase 1	Homo sapiens	92-95
26135006-8	2015	Further analysis indicated that EVO upregulated the expression of PTEN by inactivating PI3K/Akt signaling by decreasing phosphorylated Akt1/2.	evodiamine	32-35	AKT serine/threonine kinase 1	Homo sapiens	135-141
26135006-9	2015	Based on the above results, we conclude that PTEN/PI3K/Akt signaling is involved in the inhibitory effect on human OS 143B cell proliferation by EVO.	evodiamine	145-148	phosphatase and tensin homolog	Homo sapiens	45-49
26135006-9	2015	Based on the above results, we conclude that PTEN/PI3K/Akt signaling is involved in the inhibitory effect on human OS 143B cell proliferation by EVO.	evodiamine	145-148	AKT serine/threonine kinase 1	Homo sapiens	55-58
26580615-7	2015	Our results showed that EVO inhibited the proliferation of HCT-116 cells, caused accumulation of cells in S and G2/M phases, and reduced the levels of the secreted form of AMF.	evodiamine	24-27	glucose-6-phosphate isomerase	Homo sapiens	172-175
26354012-0	2015	[Effects of evodiamine, a major alkaloid of Goshuyu (Evodia Fruits), on TRPV1].	evodiamine	12-22	transient receptor potential cation channel subfamily V member 1	Homo sapiens	72-77
25903972-3	2015	Our data revealed that evodiamine significantly inhibited the proliferation of human oral cancer cells and resulted in the cleavages of PARP (poly (ADP-ribose) polymerase) and caspase-3, in addition to causing the typical characteristics of apoptosis.	evodiamine	23-33	poly(ADP-ribose) polymerase 1	Homo sapiens	136-140
25903972-3	2015	Our data revealed that evodiamine significantly inhibited the proliferation of human oral cancer cells and resulted in the cleavages of PARP (poly (ADP-ribose) polymerase) and caspase-3, in addition to causing the typical characteristics of apoptosis.	evodiamine	23-33	caspase 3	Homo sapiens	176-185
25903972-4	2015	Evodiamine also increased Bax protein levels and caused translocation of Bax into mitochondria and Bax oligomerization.	evodiamine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	26-29
25903972-4	2015	Evodiamine also increased Bax protein levels and caused translocation of Bax into mitochondria and Bax oligomerization.	evodiamine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	73-76
25903972-4	2015	Evodiamine also increased Bax protein levels and caused translocation of Bax into mitochondria and Bax oligomerization.	evodiamine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	73-76
25903972-5	2015	In addition, evodiamine decreased expression of myeloid cell leukemia (Mcl-1) at the transcriptional modification, and knockdown of Mcl-1 clearly resulted in an increase in expression of Bax and active Bax, resulting in induction of apoptosis.	evodiamine	13-23	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	71-76
25903972-6	2015	Evodiamine reduced expression of phosphorylated AKT, and LY294002 potentiated evodiamine-induced apoptosis by regulating Mcl-1 protein.	evodiamine	0-10	AKT serine/threonine kinase 1	Homo sapiens	48-51
26790304-0	2015	[Effect of evodiamine in inducing apoptosis of gastric cancer SGC-7901 cells through mTOR signal pathway].	evodiamine	11-21	mechanistic target of rapamycin kinase	Homo sapiens	85-89
26790304-2	2015	This study focused on the mechanism of evodiamine in inducing apoptosis of gastric cancer SGC-7901 cells through mammalian target of rapamycin (mTOR) signal pathway, in order to explore its antitumor mechanism and lay a foundation for clinical treatment of gastric cancer.	evodiamine	39-49	mechanistic target of rapamycin kinase	Homo sapiens	113-142
26790304-2	2015	This study focused on the mechanism of evodiamine in inducing apoptosis of gastric cancer SGC-7901 cells through mammalian target of rapamycin (mTOR) signal pathway, in order to explore its antitumor mechanism and lay a foundation for clinical treatment of gastric cancer.	evodiamine	39-49	mechanistic target of rapamycin kinase	Homo sapiens	144-148
26790304-9	2015	According to the Western Blot result, evodiamine can inhibit the protein expressions of mTOR and p-mTOR regardless of the combination with z-VAD-fmk, with a higher inhibitory rate after z-VAD-fmk blocked caspase.	evodiamine	38-48	mechanistic target of rapamycin kinase	Homo sapiens	88-92
26790304-9	2015	According to the Western Blot result, evodiamine can inhibit the protein expressions of mTOR and p-mTOR regardless of the combination with z-VAD-fmk, with a higher inhibitory rate after z-VAD-fmk blocked caspase.	evodiamine	38-48	mechanistic target of rapamycin kinase	Homo sapiens	99-103
26790304-10	2015	In conclusion, evodiamine may promote the apoptosis of SGC-7901 cells through mTOR signal pathway.	evodiamine	15-25	mechanistic target of rapamycin kinase	Homo sapiens	78-82
26171032-9	2015	Messenger (m)RNA levels of survivin decreased and those of caspase-3 increase in a dose-dependent manner in SGC7901 cells treated with various concentrations of evodiamine for 24 h. In conclusion, the results of the present study demonstrated that evodiamine inhibited proliferation and induced apoptosis in gastric cancer cells via the downregulation of survivin and upregulation of caspase-3 mRNA.	evodiamine	161-171	caspase 3	Homo sapiens	384-393
26171032-9	2015	Messenger (m)RNA levels of survivin decreased and those of caspase-3 increase in a dose-dependent manner in SGC7901 cells treated with various concentrations of evodiamine for 24 h. In conclusion, the results of the present study demonstrated that evodiamine inhibited proliferation and induced apoptosis in gastric cancer cells via the downregulation of survivin and upregulation of caspase-3 mRNA.	evodiamine	248-258	caspase 3	Homo sapiens	59-68
26171032-9	2015	Messenger (m)RNA levels of survivin decreased and those of caspase-3 increase in a dose-dependent manner in SGC7901 cells treated with various concentrations of evodiamine for 24 h. In conclusion, the results of the present study demonstrated that evodiamine inhibited proliferation and induced apoptosis in gastric cancer cells via the downregulation of survivin and upregulation of caspase-3 mRNA.	evodiamine	248-258	caspase 3	Homo sapiens	384-393
25986990-3	2015	The results revealed that sinomenine, stachydrine and chuanxionggzine inhibited production of NO; stachydrine and evodiamine inhibited secretion of IL-10; sinomenine and chuanxionggzine down-regulated ICAM-1 expression; oxymartrine and evodiamine decreased production of IL-2 by the LPS-stimulated endothelial cells.	evodiamine	114-124	interleukin 10	Homo sapiens	148-153
25652471-0	2015	Apoptosis of human non-small-cell lung cancer A549 cells triggered by evodiamine through MTDH-dependent signaling pathway.	evodiamine	70-80	metadherin	Homo sapiens	89-93
25652471-4	2015	In this study, we investigated the antitumor effect of evodiamine in human non-small-cell lung carcinoma (NSCLC) A549 cell line and the inhibitory effect of evodiamine on MTDH pathway.	evodiamine	157-167	metadherin	Homo sapiens	171-175
25652471-6	2015	Besides, evodiamine or MTDH shRNA-induced activation of the caspase-3 in A549 cells under same conditions.	evodiamine	9-19	caspase 3	Homo sapiens	60-69
25652471-7	2015	In addition, Western blotting analysis showed that treatment of A549 cells with evodiamine or MTDH shRNA resulted in an increase of proapoptotic protein Bax expression but decreased the expression levels of antiapoptotic protein Bcl-2 and MTDH, which altogether account for apoptotic cell death.	evodiamine	80-90	BCL2 associated X, apoptosis regulator	Homo sapiens	153-156
25652471-7	2015	In addition, Western blotting analysis showed that treatment of A549 cells with evodiamine or MTDH shRNA resulted in an increase of proapoptotic protein Bax expression but decreased the expression levels of antiapoptotic protein Bcl-2 and MTDH, which altogether account for apoptotic cell death.	evodiamine	80-90	BCL2 apoptosis regulator	Homo sapiens	229-234
25652471-7	2015	In addition, Western blotting analysis showed that treatment of A549 cells with evodiamine or MTDH shRNA resulted in an increase of proapoptotic protein Bax expression but decreased the expression levels of antiapoptotic protein Bcl-2 and MTDH, which altogether account for apoptotic cell death.	evodiamine	80-90	metadherin	Homo sapiens	239-243
25652471-8	2015	Taken together, our results suggest that the evodiamine suppress the proliferation of lung cancer cells, at least, in part, via inhibition of MTDH expression and activation of apoptosis.	evodiamine	45-55	metadherin	Homo sapiens	142-146
24959718-0	2014	Activation of JNK contributes to evodiamine-induced apoptosis and G2/M arrest in human colorectal carcinoma cells: a structure-activity study of evodiamine.	evodiamine	33-43	mitogen-activated protein kinase 8	Homo sapiens	14-17
25542684-3	2015	In this research, we provide evidence that evodia fruit extract activates peroxisome proliferator-activated receptor gamma (PPARgamma) and, as identified through HPLC fractionation and mass spectroscopy, the activating phytochemical is evodiamine.	evodiamine	236-246	peroxisome proliferator activated receptor gamma	Homo sapiens	74-122
25542684-4	2015	Evodiamine was shown to bind to and activate PPARgamma.	evodiamine	0-10	peroxisome proliferator activated receptor gamma	Homo sapiens	45-54
25545553-5	2015	Furthermore, we found that evodiamine was able to up-regulate the expression of brain-derived neurotrophic factor (BDNF) and phosphorylated tropomyosin-related kinase B (pTrkB) without altering TrkB.	evodiamine	27-37	brain-derived neurotrophic factor	Rattus norvegicus	80-113
25545553-5	2015	Furthermore, we found that evodiamine was able to up-regulate the expression of brain-derived neurotrophic factor (BDNF) and phosphorylated tropomyosin-related kinase B (pTrkB) without altering TrkB.	evodiamine	27-37	brain-derived neurotrophic factor	Rattus norvegicus	115-119
25545553-5	2015	Furthermore, we found that evodiamine was able to up-regulate the expression of brain-derived neurotrophic factor (BDNF) and phosphorylated tropomyosin-related kinase B (pTrkB) without altering TrkB.	evodiamine	27-37	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	171-175
25545553-6	2015	This study suggests potential antidepressant-like effect of evodiamine on CUMS rats, and its underlying mechanisms can be potentially linked to their modulating effects on the monoamine transmitters and BDNF-TrkB signaling in the hippocampus.	evodiamine	60-70	brain-derived neurotrophic factor	Rattus norvegicus	203-207
25545553-6	2015	This study suggests potential antidepressant-like effect of evodiamine on CUMS rats, and its underlying mechanisms can be potentially linked to their modulating effects on the monoamine transmitters and BDNF-TrkB signaling in the hippocampus.	evodiamine	60-70	neurotrophic receptor tyrosine kinase 2	Rattus norvegicus	208-212
25621054-6	2015	The effect of evodiamine on the protein expression levels of B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-3 and survivin were detected by performing western blot analysis.	evodiamine	14-24	BCL2 apoptosis regulator	Homo sapiens	61-78
25621054-6	2015	The effect of evodiamine on the protein expression levels of B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-3 and survivin were detected by performing western blot analysis.	evodiamine	14-24	BCL2 apoptosis regulator	Homo sapiens	80-85
25621054-6	2015	The effect of evodiamine on the protein expression levels of B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-3 and survivin were detected by performing western blot analysis.	evodiamine	14-24	BCL2 associated X, apoptosis regulator	Homo sapiens	88-114
25621054-6	2015	The effect of evodiamine on the protein expression levels of B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-3 and survivin were detected by performing western blot analysis.	evodiamine	14-24	BCL2 associated X, apoptosis regulator	Homo sapiens	116-119
25621054-6	2015	The effect of evodiamine on the protein expression levels of B-cell lymphoma-2 (Bcl-2), Bcl-2-associated X protein (Bax), caspase-3 and survivin were detected by performing western blot analysis.	evodiamine	14-24	caspase 3	Homo sapiens	122-131
25621054-8	2015	Western blotting demonstrated that evodiamine downregulated the expression of Bcl-2, caspase-3 and survivin, and upregulated the expression of Bax in human osteosarcoma cells.	evodiamine	35-45	BCL2 apoptosis regulator	Homo sapiens	78-83
25621054-8	2015	Western blotting demonstrated that evodiamine downregulated the expression of Bcl-2, caspase-3 and survivin, and upregulated the expression of Bax in human osteosarcoma cells.	evodiamine	35-45	caspase 3	Homo sapiens	85-94
25621054-8	2015	Western blotting demonstrated that evodiamine downregulated the expression of Bcl-2, caspase-3 and survivin, and upregulated the expression of Bax in human osteosarcoma cells.	evodiamine	35-45	BCL2 associated X, apoptosis regulator	Homo sapiens	143-146
25621054-9	2015	Evodiamine effectively inhibited proliferation and induced apoptosis of osteosarcoma cells in a dose-dependent manner via downregulation of Bcl-2, caspase-3 and survivin protein expression levels and upregulation of Bax protein expression levels.	evodiamine	0-10	BCL2 apoptosis regulator	Homo sapiens	140-145
25621054-9	2015	Evodiamine effectively inhibited proliferation and induced apoptosis of osteosarcoma cells in a dose-dependent manner via downregulation of Bcl-2, caspase-3 and survivin protein expression levels and upregulation of Bax protein expression levels.	evodiamine	0-10	caspase 3	Homo sapiens	147-156
25621054-9	2015	Evodiamine effectively inhibited proliferation and induced apoptosis of osteosarcoma cells in a dose-dependent manner via downregulation of Bcl-2, caspase-3 and survivin protein expression levels and upregulation of Bax protein expression levels.	evodiamine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	216-219
24919817-8	2014	Compared with Vehicle group, Evo significantly ameliorated neurological deficit, brain water content and infarct size, upregulated the expression of pAkt, pGSK3beta and claudin-5, and downregulated the nuclear accumulation of NF-kappaB (P &lt; 0.05).	evodiamine	29-32	claudin 5	Mus musculus	169-178
24919817-9	2014	Evo protected the brain from ischemic damage caused by pMCAO; this effect may be through upregulation of pAkt, pGSK3beta and claudin-5, and downregulation of NF-kappaB expression.	evodiamine	0-3	claudin 5	Mus musculus	125-134
24604887-0	2014	Evodiamine might inhibit TGF-beta1-induced epithelial-mesenchymal transition in NRK52E cells via Smad and PPAR-gamma pathway.	evodiamine	0-10	transforming growth factor, beta 1	Rattus norvegicus	25-34
24604887-0	2014	Evodiamine might inhibit TGF-beta1-induced epithelial-mesenchymal transition in NRK52E cells via Smad and PPAR-gamma pathway.	evodiamine	0-10	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	106-116
24604887-10	2014	These observations suggest that evodiamine and rosiglitazone inhibit TGF-beta1-induced EMT in NRK52E cells.	evodiamine	32-42	transforming growth factor, beta 1	Rattus norvegicus	69-78
24604887-11	2014	Smad 2 and PPAR-gamma signal pathway might participate in the effects of evodiamine and rosiglitazone in EMT induced by TGF-beta1.	evodiamine	73-83	SMAD family member 2	Rattus norvegicus	0-6
24604887-11	2014	Smad 2 and PPAR-gamma signal pathway might participate in the effects of evodiamine and rosiglitazone in EMT induced by TGF-beta1.	evodiamine	73-83	peroxisome proliferator-activated receptor gamma	Rattus norvegicus	11-21
24604887-11	2014	Smad 2 and PPAR-gamma signal pathway might participate in the effects of evodiamine and rosiglitazone in EMT induced by TGF-beta1.	evodiamine	73-83	transforming growth factor, beta 1	Rattus norvegicus	120-129
25903972-6	2015	Evodiamine reduced expression of phosphorylated AKT, and LY294002 potentiated evodiamine-induced apoptosis by regulating Mcl-1 protein.	evodiamine	78-88	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	121-126
25903972-7	2015	Our results suggest that evodiamine induces apoptosis in human oral cancer cells through the AKT pathway.	evodiamine	25-35	AKT serine/threonine kinase 1	Homo sapiens	93-96
25333675-0	2015	Evodiamine sensitizes U87 glioblastoma cells to TRAIL via the death receptor pathway.	evodiamine	0-10	TNF superfamily member 10	Homo sapiens	48-53
25333675-5	2015	Evodiamine, a major bioactive compound of the Chinese herb Evodiae fructus, has been reported to sensitize U87 glioblastoma cells to TRAIL.	evodiamine	0-10	TNF superfamily member 10	Homo sapiens	133-138
25333675-8	2015	Combining TRAIL with evodiamine significantly increased the apoptotic rate of U87 glioblastoma cells, as compared to evodiamine treatment alone.	evodiamine	117-127	TNF superfamily member 10	Homo sapiens	10-15
25333675-9	2015	Further investigation of the mechanism underlying these effects revealed that the evodiamine + TRAIL effect is associated with the increased expression of death receptor (DR)4, DR5, caspase-8 and cleaved caspase-3.	evodiamine	82-92	TNF superfamily member 10	Homo sapiens	95-100
25333675-9	2015	Further investigation of the mechanism underlying these effects revealed that the evodiamine + TRAIL effect is associated with the increased expression of death receptor (DR)4, DR5, caspase-8 and cleaved caspase-3.	evodiamine	82-92	TNF receptor superfamily member 10a	Homo sapiens	155-175
25333675-9	2015	Further investigation of the mechanism underlying these effects revealed that the evodiamine + TRAIL effect is associated with the increased expression of death receptor (DR)4, DR5, caspase-8 and cleaved caspase-3.	evodiamine	82-92	TNF receptor superfamily member 10b	Homo sapiens	177-180
25333675-9	2015	Further investigation of the mechanism underlying these effects revealed that the evodiamine + TRAIL effect is associated with the increased expression of death receptor (DR)4, DR5, caspase-8 and cleaved caspase-3.	evodiamine	82-92	caspase 8	Homo sapiens	182-191
25333675-10	2015	The present study demonstrated, for the first time to the best of our knowledge, that evodiamine can sensitize U87 glioblastoma cells to TRAIL via the death receptor pathway.	evodiamine	86-96	TNF superfamily member 10	Homo sapiens	137-142
25112370-5	2015	Evodiamine-exerted stimulatory effects were blocked by c-kit receptor tyrosine kinase inhibitor imatinib.	evodiamine	0-10	KIT proto-oncogene receptor tyrosine kinase	Rattus norvegicus	55-85
25506932-7	2014	EVO induced cell cycle arrest at G2/M phase, induced apoptosis by up-regulating the expression of caspase-12 and cytochrome C protein, and induced the expression of Bax mRNA and by down-regulating of the expression of Bcl-2 mRNA in both H446 and H1688 cells.	evodiamine	0-3	cytochrome c, somatic	Homo sapiens	113-125
25506932-7	2014	EVO induced cell cycle arrest at G2/M phase, induced apoptosis by up-regulating the expression of caspase-12 and cytochrome C protein, and induced the expression of Bax mRNA and by down-regulating of the expression of Bcl-2 mRNA in both H446 and H1688 cells.	evodiamine	0-3	BCL2 associated X, apoptosis regulator	Homo sapiens	165-168
25506932-7	2014	EVO induced cell cycle arrest at G2/M phase, induced apoptosis by up-regulating the expression of caspase-12 and cytochrome C protein, and induced the expression of Bax mRNA and by down-regulating of the expression of Bcl-2 mRNA in both H446 and H1688 cells.	evodiamine	0-3	BCL2 apoptosis regulator	Homo sapiens	218-223
24819955-0	2014	Identification of a neuroprotective and selective butyrylcholinesterase inhibitor derived from the natural alkaloid evodiamine.	evodiamine	116-126	butyrylcholinesterase	Homo sapiens	50-71
24819955-1	2014	Two sets of carbamates based on the natural alkaloid evodiamine were designed, synthesized and evaluated as potential butyrylcholinesterase inhibitors.	evodiamine	53-63	butyrylcholinesterase	Homo sapiens	118-139
24959718-0	2014	Activation of JNK contributes to evodiamine-induced apoptosis and G2/M arrest in human colorectal carcinoma cells: a structure-activity study of evodiamine.	evodiamine	145-155	mitogen-activated protein kinase 8	Homo sapiens	14-17
24696463-0	2014	Metabolic activation of the indoloquinazoline alkaloids evodiamine and rutaecarpine by human liver microsomes: dehydrogenation and inactivation of cytochrome P450 3A4.	evodiamine	56-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	147-166
24696463-8	2014	Formation of the evodiamine and rutaecarpine GSH conjugates was primarily catalyzed by heterologously expressed recombinant CYP3A4 and, to a lesser extent, CYP1A2 and CYP2D6, respectively.	evodiamine	17-27	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	124-130
24696463-8	2014	Formation of the evodiamine and rutaecarpine GSH conjugates was primarily catalyzed by heterologously expressed recombinant CYP3A4 and, to a lesser extent, CYP1A2 and CYP2D6, respectively.	evodiamine	17-27	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	156-162
24696463-8	2014	Formation of the evodiamine and rutaecarpine GSH conjugates was primarily catalyzed by heterologously expressed recombinant CYP3A4 and, to a lesser extent, CYP1A2 and CYP2D6, respectively.	evodiamine	17-27	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	167-173
24696463-10	2014	In summary, these findings are of significance in understanding the bioactivation mechanisms of indoloquinazoline alkaloids, and dehydrogenation of evodiamine and rutaecarpine may cause toxicities through formation of electrophilic intermediates and lead to drug-drug interactions mainly via CYP3A4 inactivation.	evodiamine	148-158	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	292-298
23902373-0	2014	Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1 channels.	evodiamine	68-78	transient receptor potential cation channel subfamily V member 1	Homo sapiens	100-105
24830744-3	2014	In this study, we determined that evodiamine (EVO), a major constituent of the Chinese herbal medicine Evodiae Fructus, could induce apoptosis of doxorubicin (DOX)-sensitive MCF-7 and DOX-resistant MCF-7/ADR cells in a caspase-dependent manner, as confirmed by significant increases of cleaved poly(ADP-ribose) polymerase (PARP), caspase-7/9, and caspase activities.	evodiamine	34-44	poly(ADP-ribose) polymerase 1	Homo sapiens	294-321
24830744-3	2014	In this study, we determined that evodiamine (EVO), a major constituent of the Chinese herbal medicine Evodiae Fructus, could induce apoptosis of doxorubicin (DOX)-sensitive MCF-7 and DOX-resistant MCF-7/ADR cells in a caspase-dependent manner, as confirmed by significant increases of cleaved poly(ADP-ribose) polymerase (PARP), caspase-7/9, and caspase activities.	evodiamine	34-44	poly(ADP-ribose) polymerase 1	Homo sapiens	323-327
24830744-3	2014	In this study, we determined that evodiamine (EVO), a major constituent of the Chinese herbal medicine Evodiae Fructus, could induce apoptosis of doxorubicin (DOX)-sensitive MCF-7 and DOX-resistant MCF-7/ADR cells in a caspase-dependent manner, as confirmed by significant increases of cleaved poly(ADP-ribose) polymerase (PARP), caspase-7/9, and caspase activities.	evodiamine	34-44	caspase 7	Homo sapiens	330-341
24830744-3	2014	In this study, we determined that evodiamine (EVO), a major constituent of the Chinese herbal medicine Evodiae Fructus, could induce apoptosis of doxorubicin (DOX)-sensitive MCF-7 and DOX-resistant MCF-7/ADR cells in a caspase-dependent manner, as confirmed by significant increases of cleaved poly(ADP-ribose) polymerase (PARP), caspase-7/9, and caspase activities.	evodiamine	46-49	poly(ADP-ribose) polymerase 1	Homo sapiens	294-321
24830744-3	2014	In this study, we determined that evodiamine (EVO), a major constituent of the Chinese herbal medicine Evodiae Fructus, could induce apoptosis of doxorubicin (DOX)-sensitive MCF-7 and DOX-resistant MCF-7/ADR cells in a caspase-dependent manner, as confirmed by significant increases of cleaved poly(ADP-ribose) polymerase (PARP), caspase-7/9, and caspase activities.	evodiamine	46-49	poly(ADP-ribose) polymerase 1	Homo sapiens	323-327
24830744-3	2014	In this study, we determined that evodiamine (EVO), a major constituent of the Chinese herbal medicine Evodiae Fructus, could induce apoptosis of doxorubicin (DOX)-sensitive MCF-7 and DOX-resistant MCF-7/ADR cells in a caspase-dependent manner, as confirmed by significant increases of cleaved poly(ADP-ribose) polymerase (PARP), caspase-7/9, and caspase activities.	evodiamine	46-49	caspase 7	Homo sapiens	330-341
24830744-4	2014	Notably, the reversed phenomenon of apoptosis resistance by EVO might be attributed to its ability to inhibit the Ras/MEK/ERK pathway and the expression of inhibitors of apoptosis (IAPs).	evodiamine	60-63	mitogen-activated protein kinase kinase 7	Homo sapiens	118-121
24830744-4	2014	Notably, the reversed phenomenon of apoptosis resistance by EVO might be attributed to its ability to inhibit the Ras/MEK/ERK pathway and the expression of inhibitors of apoptosis (IAPs).	evodiamine	60-63	mitogen-activated protein kinase 1	Homo sapiens	122-125
24830744-5	2014	Furthermore, our results indicated that EVO enhanced the apoptotic action of DOX by inhibiting the Ras/MEK/ERK cascade and the expression of IAPs without inhibiting the expression and activity of P-glycoprotein (P-gp).	evodiamine	40-43	mitogen-activated protein kinase kinase 7	Homo sapiens	103-106
24830744-5	2014	Furthermore, our results indicated that EVO enhanced the apoptotic action of DOX by inhibiting the Ras/MEK/ERK cascade and the expression of IAPs without inhibiting the expression and activity of P-glycoprotein (P-gp).	evodiamine	40-43	mitogen-activated protein kinase 1	Homo sapiens	107-110
24830744-5	2014	Furthermore, our results indicated that EVO enhanced the apoptotic action of DOX by inhibiting the Ras/MEK/ERK cascade and the expression of IAPs without inhibiting the expression and activity of P-glycoprotein (P-gp).	evodiamine	40-43	ATP binding cassette subfamily B member 1	Homo sapiens	212-216
23902373-1	2014	BACKGROUND AND PURPOSE: Evodiamine, a racemic quinazolinocarboline alkaloid isolated from the traditional Chinese medicine Evodiae fructus, has been reported to act as an agonist of the transient receptor potential vanilloid type-1 (TRPV1) cation channel both in vitro and in vivo.	evodiamine	24-34	transient receptor potential cation channel subfamily V member 1	Homo sapiens	186-231
23902373-1	2014	BACKGROUND AND PURPOSE: Evodiamine, a racemic quinazolinocarboline alkaloid isolated from the traditional Chinese medicine Evodiae fructus, has been reported to act as an agonist of the transient receptor potential vanilloid type-1 (TRPV1) cation channel both in vitro and in vivo.	evodiamine	24-34	transient receptor potential cation channel subfamily V member 1	Homo sapiens	233-238
23902373-2	2014	Evodiamine is structurally different from all known TRPV1 activators, and has significant clinical potential as a thermogenic agent.	evodiamine	0-10	transient receptor potential cation channel subfamily V member 1	Homo sapiens	52-57
23902373-8	2014	CONCLUSIONS AND IMPLICATIONS: Evodiamine qualifies as structurally unique lead structure to develop new potent TRPV1 agonists/desensitizers.	evodiamine	30-40	transient receptor potential cation channel subfamily V member 1	Homo sapiens	111-116
24773265-3	2014	These reviews are complemented by original research reports focusing, among others, on the emerging roles of TRPV1 in osteoporosis and cystitis and on evodiamine as a lead structure for the development of potent TRPV1 agonists/desensitizers.	evodiamine	151-161	transient receptor potential cation channel subfamily V member 1	Homo sapiens	212-217
24481835-6	2014	Cell cycle analysis indicated that evodiamine induced G2/M phase arrest in SGC-7901 cells and flow cytometry revealed that evodiamine induced apoptosis.	evodiamine	35-45	sarcoglycan beta	Homo sapiens	75-78
24481835-0	2014	Growth inhibition and induction of apoptosis in SGC-7901 human gastric cancer cells by evodiamine.	evodiamine	87-97	sarcoglycan beta	Homo sapiens	48-51
24481835-3	2014	In the present study, the effect of evodiamine on the proliferation and apoptosis of SGC-7901 human gastric cancer cells and the correlative mechanisms were investigated.	evodiamine	36-46	sarcoglycan beta	Homo sapiens	85-88
24481835-5	2014	Following treatment with evodiamine, the typical morphological changes of apoptosis were observed in human SGC-7901 cells.	evodiamine	25-35	sarcoglycan beta	Homo sapiens	107-110
25337567-9	2014	Evodiamine also significantly increased the ratio of Bax/Bcl-2 and decreased procaspase-3, suggesting evodiamine-induced apoptosis via the intrinsic apoptotic pathway.	evodiamine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	53-56
25337567-9	2014	Evodiamine also significantly increased the ratio of Bax/Bcl-2 and decreased procaspase-3, suggesting evodiamine-induced apoptosis via the intrinsic apoptotic pathway.	evodiamine	0-10	BCL2 apoptosis regulator	Homo sapiens	57-62
25337567-9	2014	Evodiamine also significantly increased the ratio of Bax/Bcl-2 and decreased procaspase-3, suggesting evodiamine-induced apoptosis via the intrinsic apoptotic pathway.	evodiamine	0-10	caspase 3	Homo sapiens	77-89
25337567-9	2014	Evodiamine also significantly increased the ratio of Bax/Bcl-2 and decreased procaspase-3, suggesting evodiamine-induced apoptosis via the intrinsic apoptotic pathway.	evodiamine	102-112	BCL2 apoptosis regulator	Homo sapiens	57-62
25337567-9	2014	Evodiamine also significantly increased the ratio of Bax/Bcl-2 and decreased procaspase-3, suggesting evodiamine-induced apoptosis via the intrinsic apoptotic pathway.	evodiamine	102-112	caspase 3	Homo sapiens	77-89
25337567-10	2014	In addition, evodiamine inhibited the expression of p-ERK and ERK.	evodiamine	13-23	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	52-57
25337567-10	2014	In addition, evodiamine inhibited the expression of p-ERK and ERK.	evodiamine	13-23	mitogen-activated protein kinase 1	Homo sapiens	54-57
25337567-11	2014	CONCLUSIONS: These findings suggest that the anti-proliferative effect of evodiamine was associated in part with the induction of G2/M phase cell cycle arrest and apoptosis, and down-regulation of ERK in human lung cancer cells.	evodiamine	74-84	mitogen-activated protein kinase 1	Homo sapiens	197-200
24634125-5	2014	Evodiamine changed expressions of the peroxisome proliferator-activated receptor-g (PPARg) in mouse adipose and liver tissues in time- and dose-dependent manners.	evodiamine	0-10	peroxisome proliferator activated receptor gamma	Mus musculus	38-82
24634125-5	2014	Evodiamine changed expressions of the peroxisome proliferator-activated receptor-g (PPARg) in mouse adipose and liver tissues in time- and dose-dependent manners.	evodiamine	0-10	peroxisome proliferator activated receptor gamma	Mus musculus	84-89
24634125-6	2014	We found that evodiamine decreased mRNA expression of the sterol-regulatory element binding protein (SREBP-1c) and fatty acid synthase in adipose tissue.	evodiamine	14-24	sterol regulatory element binding transcription factor 1	Mus musculus	101-109
24634125-8	2014	Interestingly, evodiamine increased the expression of triglyceride hydrolase only in adipose tissue.	evodiamine	15-25	patatin-like phospholipase domain containing 2	Mus musculus	54-76
24566141-0	2014	Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1.	evodiamine	0-10	TNF superfamily member 10	Homo sapiens	42-47
24566141-0	2014	Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1.	evodiamine	0-10	mechanistic target of rapamycin kinase	Homo sapiens	104-108
24566141-0	2014	Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1.	evodiamine	0-10	ribosomal protein S6 kinase B1	Homo sapiens	109-113
24566141-0	2014	Evodiamine induces apoptosis and enhances TRAIL-induced apoptosis in human bladder cancer cells through mTOR/S6K1-mediated downregulation of Mcl-1.	evodiamine	0-10	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	141-146
24566141-2	2014	In this study, we demonstrated that evodiamine, a quinolone alkaloid isolated from the fruit of Evodia fructus, induced apoptosis and enhanced TRAIL-induced apoptosis in human bladder cancer cells.	evodiamine	36-46	TNF superfamily member 10	Homo sapiens	143-148
24566141-3	2014	To elucidate the underlying mechanism, we found that evodiamine significantly reduced the protein levels of Mcl-1 in 253J and T24 bladder cancer cells, and overexpression of this molecule attenuated the apoptosis induced by evodiamine alone, or in combination with TRAIL.	evodiamine	53-63	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	108-113
24566141-3	2014	To elucidate the underlying mechanism, we found that evodiamine significantly reduced the protein levels of Mcl-1 in 253J and T24 bladder cancer cells, and overexpression of this molecule attenuated the apoptosis induced by evodiamine alone, or in combination with TRAIL.	evodiamine	53-63	TNF superfamily member 10	Homo sapiens	265-270
24566141-5	2014	On the other hand, evodiamine inhibited the mTOR/S6K1 pathway, which usually regulates protein translation; moreover, knockdown of S6K1 with small interfering RNA (siRNA) effectively reduced Mcl-1 levels, indicating evodiamine downregulates c-FLIP through inhibition of mTOR/S6K1 pathway.	evodiamine	19-29	mechanistic target of rapamycin kinase	Homo sapiens	44-48
24566141-5	2014	On the other hand, evodiamine inhibited the mTOR/S6K1 pathway, which usually regulates protein translation; moreover, knockdown of S6K1 with small interfering RNA (siRNA) effectively reduced Mcl-1 levels, indicating evodiamine downregulates c-FLIP through inhibition of mTOR/S6K1 pathway.	evodiamine	19-29	ribosomal protein S6 kinase B1	Homo sapiens	49-53
24566141-5	2014	On the other hand, evodiamine inhibited the mTOR/S6K1 pathway, which usually regulates protein translation; moreover, knockdown of S6K1 with small interfering RNA (siRNA) effectively reduced Mcl-1 levels, indicating evodiamine downregulates c-FLIP through inhibition of mTOR/S6K1 pathway.	evodiamine	19-29	ribosomal protein S6 kinase B1	Homo sapiens	131-135
24566141-5	2014	On the other hand, evodiamine inhibited the mTOR/S6K1 pathway, which usually regulates protein translation; moreover, knockdown of S6K1 with small interfering RNA (siRNA) effectively reduced Mcl-1 levels, indicating evodiamine downregulates c-FLIP through inhibition of mTOR/S6K1 pathway.	evodiamine	19-29	ribosomal protein S6 kinase B1	Homo sapiens	131-135
24566141-5	2014	On the other hand, evodiamine inhibited the mTOR/S6K1 pathway, which usually regulates protein translation; moreover, knockdown of S6K1 with small interfering RNA (siRNA) effectively reduced Mcl-1 levels, indicating evodiamine downregulates c-FLIP through inhibition of mTOR/S6K1 pathway.	evodiamine	216-226	ribosomal protein S6 kinase B1	Homo sapiens	131-135
24566141-5	2014	On the other hand, evodiamine inhibited the mTOR/S6K1 pathway, which usually regulates protein translation; moreover, knockdown of S6K1 with small interfering RNA (siRNA) effectively reduced Mcl-1 levels, indicating evodiamine downregulates c-FLIP through inhibition of mTOR/S6K1 pathway.	evodiamine	216-226	ribosomal protein S6 kinase B1	Homo sapiens	131-135
24566141-6	2014	Taken together, our results indicate that evodiamine induces apoptosis and enhances TRAIL-induced apoptosis possibly through mTOR/S6K1-mediated downregulation of Mcl-1; furthermore, these findings provide a rationale for the combined application of evodiamine with TRAIL in the treatment of bladder cancer.	evodiamine	42-52	TNF superfamily member 10	Homo sapiens	84-89
24566141-6	2014	Taken together, our results indicate that evodiamine induces apoptosis and enhances TRAIL-induced apoptosis possibly through mTOR/S6K1-mediated downregulation of Mcl-1; furthermore, these findings provide a rationale for the combined application of evodiamine with TRAIL in the treatment of bladder cancer.	evodiamine	42-52	mechanistic target of rapamycin kinase	Homo sapiens	125-129
24566141-6	2014	Taken together, our results indicate that evodiamine induces apoptosis and enhances TRAIL-induced apoptosis possibly through mTOR/S6K1-mediated downregulation of Mcl-1; furthermore, these findings provide a rationale for the combined application of evodiamine with TRAIL in the treatment of bladder cancer.	evodiamine	42-52	ribosomal protein S6 kinase B1	Homo sapiens	130-134
24566141-6	2014	Taken together, our results indicate that evodiamine induces apoptosis and enhances TRAIL-induced apoptosis possibly through mTOR/S6K1-mediated downregulation of Mcl-1; furthermore, these findings provide a rationale for the combined application of evodiamine with TRAIL in the treatment of bladder cancer.	evodiamine	42-52	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	162-167
24566141-6	2014	Taken together, our results indicate that evodiamine induces apoptosis and enhances TRAIL-induced apoptosis possibly through mTOR/S6K1-mediated downregulation of Mcl-1; furthermore, these findings provide a rationale for the combined application of evodiamine with TRAIL in the treatment of bladder cancer.	evodiamine	42-52	TNF superfamily member 10	Homo sapiens	265-270
24566141-6	2014	Taken together, our results indicate that evodiamine induces apoptosis and enhances TRAIL-induced apoptosis possibly through mTOR/S6K1-mediated downregulation of Mcl-1; furthermore, these findings provide a rationale for the combined application of evodiamine with TRAIL in the treatment of bladder cancer.	evodiamine	249-259	TNF superfamily member 10	Homo sapiens	84-89
24566141-6	2014	Taken together, our results indicate that evodiamine induces apoptosis and enhances TRAIL-induced apoptosis possibly through mTOR/S6K1-mediated downregulation of Mcl-1; furthermore, these findings provide a rationale for the combined application of evodiamine with TRAIL in the treatment of bladder cancer.	evodiamine	249-259	mechanistic target of rapamycin kinase	Homo sapiens	125-129
24481835-7	2014	Analysis of the enzymatic activity demonstrated that evodiamine increased the activity of caspase-3, -8 and -9 in SGC-7901 cells.	evodiamine	53-63	caspase 3	Homo sapiens	90-110
24481835-7	2014	Analysis of the enzymatic activity demonstrated that evodiamine increased the activity of caspase-3, -8 and -9 in SGC-7901 cells.	evodiamine	53-63	sarcoglycan beta	Homo sapiens	114-117
24481835-8	2014	The protein expression of caspase-3, -8 and -9 and Bax increased, and the expression of Bcl-2 decreased following treatment with evodiamine.	evodiamine	129-139	caspase 3	Homo sapiens	26-46
24481835-8	2014	The protein expression of caspase-3, -8 and -9 and Bax increased, and the expression of Bcl-2 decreased following treatment with evodiamine.	evodiamine	129-139	BCL2 associated X, apoptosis regulator	Homo sapiens	51-54
24481835-8	2014	The protein expression of caspase-3, -8 and -9 and Bax increased, and the expression of Bcl-2 decreased following treatment with evodiamine.	evodiamine	129-139	BCL2 apoptosis regulator	Homo sapiens	88-93
24481835-9	2014	These results suggest that evodiamine is able to inhibit the proliferation of SGC-7901 cells by inhibiting the cell cycle at G2/M phase and inducing apoptosis in SGC-7901 cells by activating caspase-3, -8 and -9, and altering the expression of caspase-3, Bax and Bcl-2.	evodiamine	27-37	sarcoglycan beta	Homo sapiens	78-81
24481835-9	2014	These results suggest that evodiamine is able to inhibit the proliferation of SGC-7901 cells by inhibiting the cell cycle at G2/M phase and inducing apoptosis in SGC-7901 cells by activating caspase-3, -8 and -9, and altering the expression of caspase-3, Bax and Bcl-2.	evodiamine	27-37	sarcoglycan beta	Homo sapiens	162-165
24481835-9	2014	These results suggest that evodiamine is able to inhibit the proliferation of SGC-7901 cells by inhibiting the cell cycle at G2/M phase and inducing apoptosis in SGC-7901 cells by activating caspase-3, -8 and -9, and altering the expression of caspase-3, Bax and Bcl-2.	evodiamine	27-37	caspase 3	Homo sapiens	191-211
24481835-9	2014	These results suggest that evodiamine is able to inhibit the proliferation of SGC-7901 cells by inhibiting the cell cycle at G2/M phase and inducing apoptosis in SGC-7901 cells by activating caspase-3, -8 and -9, and altering the expression of caspase-3, Bax and Bcl-2.	evodiamine	27-37	caspase 3	Homo sapiens	191-200
24481835-9	2014	These results suggest that evodiamine is able to inhibit the proliferation of SGC-7901 cells by inhibiting the cell cycle at G2/M phase and inducing apoptosis in SGC-7901 cells by activating caspase-3, -8 and -9, and altering the expression of caspase-3, Bax and Bcl-2.	evodiamine	27-37	BCL2 associated X, apoptosis regulator	Homo sapiens	255-258
24481835-9	2014	These results suggest that evodiamine is able to inhibit the proliferation of SGC-7901 cells by inhibiting the cell cycle at G2/M phase and inducing apoptosis in SGC-7901 cells by activating caspase-3, -8 and -9, and altering the expression of caspase-3, Bax and Bcl-2.	evodiamine	27-37	BCL2 apoptosis regulator	Homo sapiens	263-268
25082563-0	2014	Evodiamine activates AMPK and promotes adiponectin multimerization in 3T3-L1 adipocytes.	evodiamine	0-10	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	21-25
25082563-5	2014	Activation of AMPK by evodiamine promoted the assembly of HMW adiponectin and increased the HMW/total ratio of adiponectin in 3T3-L1 adipocytes.	evodiamine	22-32	cilia and flagella associated protein 97	Homo sapiens	92-95
25082563-0	2014	Evodiamine activates AMPK and promotes adiponectin multimerization in 3T3-L1 adipocytes.	evodiamine	0-10	adiponectin, C1Q and collagen domain containing	Homo sapiens	39-50
25082563-4	2014	In this study, evodiamine was found to activate AMP-activated protein kinase (AMPK) in both 3T3-L1 adipocytes and 293T cells.	evodiamine	15-25	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	78-82
25082563-5	2014	Activation of AMPK by evodiamine promoted the assembly of HMW adiponectin and increased the HMW/total ratio of adiponectin in 3T3-L1 adipocytes.	evodiamine	22-32	adiponectin, C1Q and collagen domain containing	Homo sapiens	111-122
25082563-5	2014	Activation of AMPK by evodiamine promoted the assembly of HMW adiponectin and increased the HMW/total ratio of adiponectin in 3T3-L1 adipocytes.	evodiamine	22-32	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	14-18
25082563-6	2014	The Ca(2+)-dependent PI3K/Akt/CaMKII-signaling pathway was demonstrated to be involved in evodiamine-induced AMPK activation.	evodiamine	90-100	AKT serine/threonine kinase 1	Homo sapiens	26-29
25082563-6	2014	The Ca(2+)-dependent PI3K/Akt/CaMKII-signaling pathway was demonstrated to be involved in evodiamine-induced AMPK activation.	evodiamine	90-100	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	30-36
25082563-6	2014	The Ca(2+)-dependent PI3K/Akt/CaMKII-signaling pathway was demonstrated to be involved in evodiamine-induced AMPK activation.	evodiamine	90-100	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	109-113
25082563-5	2014	Activation of AMPK by evodiamine promoted the assembly of HMW adiponectin and increased the HMW/total ratio of adiponectin in 3T3-L1 adipocytes.	evodiamine	22-32	cilia and flagella associated protein 97	Homo sapiens	58-61
25082563-5	2014	Activation of AMPK by evodiamine promoted the assembly of HMW adiponectin and increased the HMW/total ratio of adiponectin in 3T3-L1 adipocytes.	evodiamine	22-32	adiponectin, C1Q and collagen domain containing	Homo sapiens	62-73
24391749-0	2013	Evodiamine inhibits insulin-stimulated mTOR-S6K activation and IRS1 serine phosphorylation in adipocytes and improves glucose tolerance in obese/diabetic mice.	evodiamine	0-10	mechanistic target of rapamycin kinase	Mus musculus	39-43
24391749-5	2013	As well as the stimulation of IRS1 and Akt serine phosphorylation, insulin-stimulated phosphorylation of mTOR and S6K is time-dependent in 3T3-L1 adipocytes, whereas evodiamine does not affect their phosphorylation except for an inhibitory effect on mTOR phosphorylation.	evodiamine	166-176	thymoma viral proto-oncogene 1	Mus musculus	39-42
24391749-5	2013	As well as the stimulation of IRS1 and Akt serine phosphorylation, insulin-stimulated phosphorylation of mTOR and S6K is time-dependent in 3T3-L1 adipocytes, whereas evodiamine does not affect their phosphorylation except for an inhibitory effect on mTOR phosphorylation.	evodiamine	166-176	mechanistic target of rapamycin kinase	Mus musculus	105-109
24391749-6	2013	Moreover, evodiamine inhibits the insulin-stimulated phosphorylation of mTOR and S6K, leading to down-regulation of IRS1 serine phosphorylation in the adipocytes.	evodiamine	10-20	mechanistic target of rapamycin kinase	Mus musculus	72-76
24391749-6	2013	Moreover, evodiamine inhibits the insulin-stimulated phosphorylation of mTOR and S6K, leading to down-regulation of IRS1 serine phosphorylation in the adipocytes.	evodiamine	10-20	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	81-84
24391749-6	2013	Moreover, evodiamine inhibits the insulin-stimulated phosphorylation of mTOR and S6K, leading to down-regulation of IRS1 serine phosphorylation in the adipocytes.	evodiamine	10-20	insulin receptor substrate 1	Mus musculus	116-120
24391749-7	2013	Evodiamine also stimulates phosphorylation of AMP-activated protein kinase (AMPK), an important regulator of energy metabolism, which may cause down-regulation of mTOR signaling in adipocytes.	evodiamine	0-10	mechanistic target of rapamycin kinase	Mus musculus	163-167
24391749-9	2013	These results suggest evodiamine improves glucose tolerance and prevents the progress of insulin resistance associated with obese/diabetic states, at least in part, through inhibition of mTOR-S6K signaling and IRS1 serine phosphorylation in adipocytes.	evodiamine	22-32	mechanistic target of rapamycin kinase	Mus musculus	187-191
24391749-9	2013	These results suggest evodiamine improves glucose tolerance and prevents the progress of insulin resistance associated with obese/diabetic states, at least in part, through inhibition of mTOR-S6K signaling and IRS1 serine phosphorylation in adipocytes.	evodiamine	22-32	ribosomal protein S6 kinase B1	Homo sapiens	192-195
24391749-9	2013	These results suggest evodiamine improves glucose tolerance and prevents the progress of insulin resistance associated with obese/diabetic states, at least in part, through inhibition of mTOR-S6K signaling and IRS1 serine phosphorylation in adipocytes.	evodiamine	22-32	insulin receptor substrate 1	Mus musculus	210-214
24391749-0	2013	Evodiamine inhibits insulin-stimulated mTOR-S6K activation and IRS1 serine phosphorylation in adipocytes and improves glucose tolerance in obese/diabetic mice.	evodiamine	0-10	ribosomal protein S6 kinase B1	Homo sapiens	44-47
24063987-13	2013	Evodiamine provoked IL-8 secretion via ERK1/2, SAPK/JNK, JAK2 and AP-1 pathways which could be counteracted by berberine.	evodiamine	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	20-24
24063987-13	2013	Evodiamine provoked IL-8 secretion via ERK1/2, SAPK/JNK, JAK2 and AP-1 pathways which could be counteracted by berberine.	evodiamine	0-10	mitogen-activated protein kinase 3	Homo sapiens	39-45
24391749-0	2013	Evodiamine inhibits insulin-stimulated mTOR-S6K activation and IRS1 serine phosphorylation in adipocytes and improves glucose tolerance in obese/diabetic mice.	evodiamine	0-10	insulin receptor substrate 1	Mus musculus	63-67
24391749-3	2013	There is a significant decrease in the mammalian target of rapamycin (mTOR) and ribosomal S6 protein kinase (S6K) signaling in white adipose tissue (WAT) in KK-Ay mice treated with evodiamine, in which glucose tolerance is improved.	evodiamine	181-191	mechanistic target of rapamycin kinase	Homo sapiens	39-68
24063987-13	2013	Evodiamine provoked IL-8 secretion via ERK1/2, SAPK/JNK, JAK2 and AP-1 pathways which could be counteracted by berberine.	evodiamine	0-10	mitogen-activated protein kinase 9	Homo sapiens	47-51
24391749-3	2013	There is a significant decrease in the mammalian target of rapamycin (mTOR) and ribosomal S6 protein kinase (S6K) signaling in white adipose tissue (WAT) in KK-Ay mice treated with evodiamine, in which glucose tolerance is improved.	evodiamine	181-191	mechanistic target of rapamycin kinase	Homo sapiens	70-74
24063987-13	2013	Evodiamine provoked IL-8 secretion via ERK1/2, SAPK/JNK, JAK2 and AP-1 pathways which could be counteracted by berberine.	evodiamine	0-10	mitogen-activated protein kinase 8	Homo sapiens	52-55
24063987-13	2013	Evodiamine provoked IL-8 secretion via ERK1/2, SAPK/JNK, JAK2 and AP-1 pathways which could be counteracted by berberine.	evodiamine	0-10	Janus kinase 2	Homo sapiens	57-61
24391749-3	2013	There is a significant decrease in the mammalian target of rapamycin (mTOR) and ribosomal S6 protein kinase (S6K) signaling in white adipose tissue (WAT) in KK-Ay mice treated with evodiamine, in which glucose tolerance is improved.	evodiamine	181-191	ribosomal protein S6 kinase B1	Homo sapiens	109-112
24063987-14	2013	SIGNIFICANCE: Although showing anti-proliferative and anti-migratory activities in AGS cells, evodiamine displayed a potential tendency to promote metastasis of gastric cancer cells by increasing IL-8 secretion and adhesion molecules.	evodiamine	94-104	C-X-C motif chemokine ligand 8	Homo sapiens	196-200
24028645-6	2013	Moreover, evodiamine decreased the phosphorylation of eNOS at Thr497, PKCalpha at Ser657 and PKCbeta2 at Ser660 in apolipoprotein E (ApoE)-deficient mouse aortas but not TRPV1-deficient or ApoE/TRPV1 double-knockout mice.	evodiamine	10-20	apolipoprotein E	Mus musculus	133-137
24063987-0	2013	Berberine counteracts enhanced IL-8 expression of AGS cells induced by evodiamine.	evodiamine	71-81	C-X-C motif chemokine ligand 8	Homo sapiens	31-35
24063987-1	2013	AIMS: Although showing an anti-tumor activity, evodiamine also up-regulated IL-8 production of human gastric cancer AGS cells.	evodiamine	47-57	C-X-C motif chemokine ligand 8	Homo sapiens	76-80
24028645-6	2013	Moreover, evodiamine decreased the phosphorylation of eNOS at Thr497, PKCalpha at Ser657 and PKCbeta2 at Ser660 in apolipoprotein E (ApoE)-deficient mouse aortas but not TRPV1-deficient or ApoE/TRPV1 double-knockout mice.	evodiamine	10-20	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	170-175
24063987-10	2013	IL-8 expression and the adhesive ability of AGS cells to HUVECs were significantly increased by evodiamine, but were inhibited after being co-treated with berberine in AGS cells.	evodiamine	96-106	C-X-C motif chemokine ligand 8	Homo sapiens	0-4
24063987-11	2013	As IL-8 was neutralized, increased adhesion of AGS cells to HUVECs induced by evodiamine was abolished.	evodiamine	78-88	C-X-C motif chemokine ligand 8	Homo sapiens	3-7
24063987-12	2013	Berberine significantly suppressed the up-regulation of VCAM-1 and the down-regulation of ICAM-1 induced by evodiamine.	evodiamine	108-118	intercellular adhesion molecule 1	Homo sapiens	90-96
24028645-6	2013	Moreover, evodiamine decreased the phosphorylation of eNOS at Thr497, PKCalpha at Ser657 and PKCbeta2 at Ser660 in apolipoprotein E (ApoE)-deficient mouse aortas but not TRPV1-deficient or ApoE/TRPV1 double-knockout mice.	evodiamine	10-20	apolipoprotein E	Mus musculus	189-193
24028645-6	2013	Moreover, evodiamine decreased the phosphorylation of eNOS at Thr497, PKCalpha at Ser657 and PKCbeta2 at Ser660 in apolipoprotein E (ApoE)-deficient mouse aortas but not TRPV1-deficient or ApoE/TRPV1 double-knockout mice.	evodiamine	10-20	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	194-199
23774672-13	2013	Inactivation of c-Jun N-terminal kinases (JNK) suppressed evodiamine-mediated autophagy accompanied by increased apoptosis.	evodiamine	58-68	mitogen-activated protein kinase 8	Homo sapiens	42-45
24028645-2	2013	RESULTS: In BAECs, treatment with the TRPV1 ligand evodiamine decreased the phosphorylation of eNOS at Thr497, protein kinase Calpha (PKCalpha) at Serine 657 (Ser657) and PKCbeta2 at Ser660.	evodiamine	51-61	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	38-43
24028645-2	2013	RESULTS: In BAECs, treatment with the TRPV1 ligand evodiamine decreased the phosphorylation of eNOS at Thr497, protein kinase Calpha (PKCalpha) at Serine 657 (Ser657) and PKCbeta2 at Ser660.	evodiamine	51-61	protein kinase C, alpha	Mus musculus	134-142
24028645-4	2013	Inhibition of TRPV1 activation by the pharmacological antagonists, removal of extracellular Ca(2+) or pharmacological inhibition of PI3K/Akt/calmodulin-dependent protein kinase II/AMP-activated protein kinase signalling pathway abolished the evodiamine-induced alterations in phosphorylation of eNOS at Thr497, PKCalpha at Ser657, PKCbeta2 at Ser660 and PP2B activity, as well as the formation of a PP2B-PKC complex.	evodiamine	242-252	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	14-19
24028645-6	2013	Moreover, evodiamine decreased the phosphorylation of eNOS at Thr497, PKCalpha at Ser657 and PKCbeta2 at Ser660 in apolipoprotein E (ApoE)-deficient mouse aortas but not TRPV1-deficient or ApoE/TRPV1 double-knockout mice.	evodiamine	10-20	protein kinase C, alpha	Mus musculus	70-78
24028645-6	2013	Moreover, evodiamine decreased the phosphorylation of eNOS at Thr497, PKCalpha at Ser657 and PKCbeta2 at Ser660 in apolipoprotein E (ApoE)-deficient mouse aortas but not TRPV1-deficient or ApoE/TRPV1 double-knockout mice.	evodiamine	10-20	apolipoprotein E	Mus musculus	115-131
23708383-4	2013	In vitro, evodiamine inhibited cell migration and invasion abilities through downregulation of MMP-9, urokinase-type plasminogen activator (uPA) and uPAR expression.	evodiamine	10-20	matrix metallopeptidase 9	Homo sapiens	95-100
23774672-14	2013	Furthermore, evodiamine-mediated JNK activation was abolished by BAPTA-AM, an intracellular calcium scavenger, suggesting that evodiamine mediates autophagy via a calcium-JNK signaling pathway.	evodiamine	13-23	mitogen-activated protein kinase 8	Homo sapiens	33-36
23774672-14	2013	Furthermore, evodiamine-mediated JNK activation was abolished by BAPTA-AM, an intracellular calcium scavenger, suggesting that evodiamine mediates autophagy via a calcium-JNK signaling pathway.	evodiamine	13-23	mitogen-activated protein kinase 8	Homo sapiens	171-174
23774672-14	2013	Furthermore, evodiamine-mediated JNK activation was abolished by BAPTA-AM, an intracellular calcium scavenger, suggesting that evodiamine mediates autophagy via a calcium-JNK signaling pathway.	evodiamine	127-137	mitogen-activated protein kinase 8	Homo sapiens	33-36
23774672-14	2013	Furthermore, evodiamine-mediated JNK activation was abolished by BAPTA-AM, an intracellular calcium scavenger, suggesting that evodiamine mediates autophagy via a calcium-JNK signaling pathway.	evodiamine	127-137	mitogen-activated protein kinase 8	Homo sapiens	171-174
23774672-15	2013	Collectively, these results suggest that evodiamine induces intracellular calcium/JNK signaling-mediated autophagy and calcium/mitochondria-mediated apoptosis in glioma cells.	evodiamine	41-51	mitogen-activated protein kinase 8	Homo sapiens	82-85
23708383-4	2013	In vitro, evodiamine inhibited cell migration and invasion abilities through downregulation of MMP-9, urokinase-type plasminogen activator (uPA) and uPAR expression.	evodiamine	10-20	plasminogen activator, urokinase	Homo sapiens	102-138
23708383-4	2013	In vitro, evodiamine inhibited cell migration and invasion abilities through downregulation of MMP-9, urokinase-type plasminogen activator (uPA) and uPAR expression.	evodiamine	10-20	plasminogen activator, urokinase	Homo sapiens	140-143
23708383-4	2013	In vitro, evodiamine inhibited cell migration and invasion abilities through downregulation of MMP-9, urokinase-type plasminogen activator (uPA) and uPAR expression.	evodiamine	10-20	plasminogen activator, urokinase receptor	Homo sapiens	149-153
23708383-5	2013	Evodiamine-induced G0/G1 arrest and apoptosis were associated with a decrease in Bcl-2, cyclin D1 and cyclin-dependent kinase 6 (CDK6) expression and an increase in Bax and p27Kip1 expression.	evodiamine	0-10	BCL2 apoptosis regulator	Homo sapiens	81-86
23708383-5	2013	Evodiamine-induced G0/G1 arrest and apoptosis were associated with a decrease in Bcl-2, cyclin D1 and cyclin-dependent kinase 6 (CDK6) expression and an increase in Bax and p27Kip1 expression.	evodiamine	0-10	cyclin D1	Homo sapiens	88-97
23708383-5	2013	Evodiamine-induced G0/G1 arrest and apoptosis were associated with a decrease in Bcl-2, cyclin D1 and cyclin-dependent kinase 6 (CDK6) expression and an increase in Bax and p27Kip1 expression.	evodiamine	0-10	cyclin dependent kinase 6	Homo sapiens	102-127
23708383-5	2013	Evodiamine-induced G0/G1 arrest and apoptosis were associated with a decrease in Bcl-2, cyclin D1 and cyclin-dependent kinase 6 (CDK6) expression and an increase in Bax and p27Kip1 expression.	evodiamine	0-10	cyclin dependent kinase 6	Homo sapiens	129-133
23708383-5	2013	Evodiamine-induced G0/G1 arrest and apoptosis were associated with a decrease in Bcl-2, cyclin D1 and cyclin-dependent kinase 6 (CDK6) expression and an increase in Bax and p27Kip1 expression.	evodiamine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	165-168
23708383-5	2013	Evodiamine-induced G0/G1 arrest and apoptosis were associated with a decrease in Bcl-2, cyclin D1 and cyclin-dependent kinase 6 (CDK6) expression and an increase in Bax and p27Kip1 expression.	evodiamine	0-10	cyclin dependent kinase inhibitor 1B	Homo sapiens	173-180
23708383-6	2013	Moreover, evodiamine regulated p-ERK and p-p38 MAPK expression.	evodiamine	10-20	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	31-36
23708383-6	2013	Moreover, evodiamine regulated p-ERK and p-p38 MAPK expression.	evodiamine	10-20	mitogen-activated protein kinase 14	Homo sapiens	43-51
23708383-7	2013	Evodiamine-induced apoptosis was enhanced by its combination with the extracellular signal-regulated kinase (ERK) inhibitor PD98059 or the p38 mitogen-activated protein kinase (p38 MAPK) inhibitor SB203580.	evodiamine	0-10	mitogen-activated protein kinase 1	Homo sapiens	70-107
23708383-7	2013	Evodiamine-induced apoptosis was enhanced by its combination with the extracellular signal-regulated kinase (ERK) inhibitor PD98059 or the p38 mitogen-activated protein kinase (p38 MAPK) inhibitor SB203580.	evodiamine	0-10	mitogen-activated protein kinase 1	Homo sapiens	109-112
23708383-7	2013	Evodiamine-induced apoptosis was enhanced by its combination with the extracellular signal-regulated kinase (ERK) inhibitor PD98059 or the p38 mitogen-activated protein kinase (p38 MAPK) inhibitor SB203580.	evodiamine	0-10	mitogen-activated protein kinase 14	Homo sapiens	139-175
23708383-7	2013	Evodiamine-induced apoptosis was enhanced by its combination with the extracellular signal-regulated kinase (ERK) inhibitor PD98059 or the p38 mitogen-activated protein kinase (p38 MAPK) inhibitor SB203580.	evodiamine	0-10	mitogen-activated protein kinase 14	Homo sapiens	177-185
23840656-6	2013	Evodiamine inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with concentration of 1x10(-6) and 1x10(-5) M. Evodiamine also induced apoptosis via up-regulation of caspase 7 activation, PARP cleavage (Bik and Bax expression).	evodiamine	0-10	caspase 7	Homo sapiens	207-216
23774672-0	2013	Evodiamine, a plant alkaloid, induces calcium/JNK-mediated autophagy and calcium/mitochondria-mediated apoptosis in human glioblastoma cells.	evodiamine	0-10	mitogen-activated protein kinase 8	Homo sapiens	46-49
23774672-13	2013	Inactivation of c-Jun N-terminal kinases (JNK) suppressed evodiamine-mediated autophagy accompanied by increased apoptosis.	evodiamine	58-68	mitogen-activated protein kinase 8	Homo sapiens	16-40
23840656-6	2013	Evodiamine inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with concentration of 1x10(-6) and 1x10(-5) M. Evodiamine also induced apoptosis via up-regulation of caspase 7 activation, PARP cleavage (Bik and Bax expression).	evodiamine	0-10	collagen type XI alpha 2 chain	Homo sapiens	229-233
23840656-6	2013	Evodiamine inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with concentration of 1x10(-6) and 1x10(-5) M. Evodiamine also induced apoptosis via up-regulation of caspase 7 activation, PARP cleavage (Bik and Bax expression).	evodiamine	0-10	BCL2 interacting killer	Homo sapiens	244-247
23840656-6	2013	Evodiamine inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with concentration of 1x10(-6) and 1x10(-5) M. Evodiamine also induced apoptosis via up-regulation of caspase 7 activation, PARP cleavage (Bik and Bax expression).	evodiamine	0-10	BCL2 associated X, apoptosis regulator	Homo sapiens	252-255
23840656-6	2013	Evodiamine inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with concentration of 1x10(-6) and 1x10(-5) M. Evodiamine also induced apoptosis via up-regulation of caspase 7 activation, PARP cleavage (Bik and Bax expression).	evodiamine	152-162	caspase 7	Homo sapiens	207-216
23840656-6	2013	Evodiamine inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with concentration of 1x10(-6) and 1x10(-5) M. Evodiamine also induced apoptosis via up-regulation of caspase 7 activation, PARP cleavage (Bik and Bax expression).	evodiamine	152-162	collagen type XI alpha 2 chain	Homo sapiens	229-233
23840656-6	2013	Evodiamine inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with concentration of 1x10(-6) and 1x10(-5) M. Evodiamine also induced apoptosis via up-regulation of caspase 7 activation, PARP cleavage (Bik and Bax expression).	evodiamine	152-162	BCL2 interacting killer	Homo sapiens	244-247
23840656-6	2013	Evodiamine inhibited the proliferation of MCF-7 and MDA-MB-231 cells in a concentration-dependent manner with concentration of 1x10(-6) and 1x10(-5) M. Evodiamine also induced apoptosis via up-regulation of caspase 7 activation, PARP cleavage (Bik and Bax expression).	evodiamine	152-162	BCL2 associated X, apoptosis regulator	Homo sapiens	252-255
23840656-7	2013	The expression of ER alpha and beta in protein and mRNA levels was down-regulated by evodiamine according to data from immunoblotting and RT-PCR analysis.	evodiamine	85-95	estrogen receptor 1	Homo sapiens	18-26
23840656-8	2013	Overall, our results indicate that evodiamine mediates degradation of ER and induces caspase-dependent pathway leading to inhibit proliferation of breast cancer cell lines.	evodiamine	35-45	estrogen receptor 1	Homo sapiens	70-72
23762305-10	2013	ERCC1 mRNA expression levels was markedly suppressed by the presentation of PPI (P = 0.001) and slightly suppressed by the presentation of EVO (P = 0.04); whereas, TS mRNA expression levels was markedly decreased by the presentation of EVO (P = 0.017) and slightly decreased by the presentation of PPI (P = 0.047).	evodiamine	139-142	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
23762305-10	2013	ERCC1 mRNA expression levels was markedly suppressed by the presentation of PPI (P = 0.001) and slightly suppressed by the presentation of EVO (P = 0.04); whereas, TS mRNA expression levels was markedly decreased by the presentation of EVO (P = 0.017) and slightly decreased by the presentation of PPI (P = 0.047).	evodiamine	236-239	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	0-5
23762305-11	2013	CONCLUSION: PPI and EVO both could inhibit the activity of freshly-removed gastric tumor, and they could enhance the anticancer effect of Pt and 5-FU by reducing the mRNA expression levels of ERCC1 and TS.	evodiamine	20-23	ERCC excision repair 1, endonuclease non-catalytic subunit	Homo sapiens	192-197
22767428-5	2013	CYP3A4, CYP2C9 and CYP1A2 were identified to be the main CYP isoforms involved in the metabolism of evodiamine in human liver microsomes.	evodiamine	100-110	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
22767428-5	2013	CYP3A4, CYP2C9 and CYP1A2 were identified to be the main CYP isoforms involved in the metabolism of evodiamine in human liver microsomes.	evodiamine	100-110	cytochrome P450 family 2 subfamily C member 9	Homo sapiens	8-14
22767428-5	2013	CYP3A4, CYP2C9 and CYP1A2 were identified to be the main CYP isoforms involved in the metabolism of evodiamine in human liver microsomes.	evodiamine	100-110	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	19-25
22767428-5	2013	CYP3A4, CYP2C9 and CYP1A2 were identified to be the main CYP isoforms involved in the metabolism of evodiamine in human liver microsomes.	evodiamine	100-110	peptidylprolyl isomerase G	Homo sapiens	0-3
23032719-0	2013	Evodiamine inhibits STAT3 signaling by inducing phosphatase shatterproof 1 in hepatocellular carcinoma cells.	evodiamine	0-10	signal transducer and activator of transcription 3	Homo sapiens	20-25
23025809-0	2013	Essential role of transient receptor potential vanilloid type 1 in evodiamine-mediated protection against atherosclerosis.	evodiamine	67-77	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	18-63
23025809-1	2013	AIM: We investigated whether transient receptor potential vanilloid type 1 (TRPV1) was involved in the therapeutic effect of evodiamine, a main bioactive component in the fruit of Evodiae rutaecarpa, on the development of atherosclerosis in apolipoprotein E-deficient (ApoE(-/-)) mice and ApoE(-/-)TRPV1(-/-) mice.	evodiamine	125-135	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	29-74
23025809-1	2013	AIM: We investigated whether transient receptor potential vanilloid type 1 (TRPV1) was involved in the therapeutic effect of evodiamine, a main bioactive component in the fruit of Evodiae rutaecarpa, on the development of atherosclerosis in apolipoprotein E-deficient (ApoE(-/-)) mice and ApoE(-/-)TRPV1(-/-) mice.	evodiamine	125-135	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	76-81
23025809-3	2013	RESULTS: Chronic administration with evodiamine (10 mg kg(-1) body weight) reduced the size of atherosclerotic lesions and alleviated the hyperlipidaemia and systemic inflammation, as well as hepatic macrovesicular steatosis, in ApoE(-/-) mice.	evodiamine	37-47	apolipoprotein E	Mus musculus	229-233
23025809-4	2013	Treating ApoE(-/-) mice with evodiamine enhanced hepatic cholesterol clearance, as revealed by upregulation of hepatic low-density lipoprotein receptor and ATP-binding cassette (ABC) transporters ABCG5, ABCG8 and cholesterol 7alpha-hydrolase.	evodiamine	29-39	apolipoprotein E	Mus musculus	9-13
23025809-4	2013	Treating ApoE(-/-) mice with evodiamine enhanced hepatic cholesterol clearance, as revealed by upregulation of hepatic low-density lipoprotein receptor and ATP-binding cassette (ABC) transporters ABCG5, ABCG8 and cholesterol 7alpha-hydrolase.	evodiamine	29-39	low density lipoprotein receptor	Mus musculus	119-151
23025809-4	2013	Treating ApoE(-/-) mice with evodiamine enhanced hepatic cholesterol clearance, as revealed by upregulation of hepatic low-density lipoprotein receptor and ATP-binding cassette (ABC) transporters ABCG5, ABCG8 and cholesterol 7alpha-hydrolase.	evodiamine	29-39	ATP binding cassette subfamily G member 5	Mus musculus	196-201
23025809-4	2013	Treating ApoE(-/-) mice with evodiamine enhanced hepatic cholesterol clearance, as revealed by upregulation of hepatic low-density lipoprotein receptor and ATP-binding cassette (ABC) transporters ABCG5, ABCG8 and cholesterol 7alpha-hydrolase.	evodiamine	29-39	ATP binding cassette subfamily G member 8	Mus musculus	203-208
23025809-6	2013	Moreover, genetic deletion of TRPV1 abrogated the evodiamine-evoked atheroprotection but not anti-obesity effect in ApoE(-/-) mice.	evodiamine	50-60	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	30-35
23025809-7	2013	CONCLUSION: Evodiamine may confer novel TRPV1-dependent atheroprotection and TRPV1-independent anti-obesity action.	evodiamine	12-22	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	40-45
23135406-8	2013	In addition, we showed for the first time that evodiamine promoted autophagosome formation by enhancing the conversion of microtubule-associated protein 1 light chain 3 (LC3)-I to LC3-II and upregulating the expression of autophagy-specific genes (Atgs).	evodiamine	47-57	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	170-173
23135406-8	2013	In addition, we showed for the first time that evodiamine promoted autophagosome formation by enhancing the conversion of microtubule-associated protein 1 light chain 3 (LC3)-I to LC3-II and upregulating the expression of autophagy-specific genes (Atgs).	evodiamine	47-57	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	180-183
23135406-9	2013	Moreover, 3-methyladenine (3-MA), an autophagy inhibitor, attenuated evodiamine-induced autophagy through decreasing the conversion of LC3-I to LC3-II.	evodiamine	69-79	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	135-138
23135406-9	2013	Moreover, 3-methyladenine (3-MA), an autophagy inhibitor, attenuated evodiamine-induced autophagy through decreasing the conversion of LC3-I to LC3-II.	evodiamine	69-79	microtubule-associated protein 1 light chain 3 alpha	Mus musculus	144-147
23032719-4	2013	We found that evodiamine suppressed both constitutive and interleukin-6 (IL-6)-induced activation of STAT3 tyrosine 705 (Tyr(705)) effectively.	evodiamine	14-24	interleukin 6	Homo sapiens	58-71
23032719-4	2013	We found that evodiamine suppressed both constitutive and interleukin-6 (IL-6)-induced activation of STAT3 tyrosine 705 (Tyr(705)) effectively.	evodiamine	14-24	interleukin 6	Homo sapiens	73-77
23032719-4	2013	We found that evodiamine suppressed both constitutive and interleukin-6 (IL-6)-induced activation of STAT3 tyrosine 705 (Tyr(705)) effectively.	evodiamine	14-24	signal transducer and activator of transcription 3	Homo sapiens	101-106
23032719-5	2013	The phosphorylation of Janus-activated kinase 2 (JAK2), Src and extracellular regulated protein kinases 1/2 (ERK1/2) were also suppressed by evodiamine.	evodiamine	141-151	Janus kinase 2	Homo sapiens	23-47
23032719-5	2013	The phosphorylation of Janus-activated kinase 2 (JAK2), Src and extracellular regulated protein kinases 1/2 (ERK1/2) were also suppressed by evodiamine.	evodiamine	141-151	Janus kinase 2	Homo sapiens	49-53
23032719-5	2013	The phosphorylation of Janus-activated kinase 2 (JAK2), Src and extracellular regulated protein kinases 1/2 (ERK1/2) were also suppressed by evodiamine.	evodiamine	141-151	SRC proto-oncogene, non-receptor tyrosine kinase	Homo sapiens	56-59
23032719-5	2013	The phosphorylation of Janus-activated kinase 2 (JAK2), Src and extracellular regulated protein kinases 1/2 (ERK1/2) were also suppressed by evodiamine.	evodiamine	141-151	mitogen-activated protein kinase 3	Homo sapiens	64-107
23032719-5	2013	The phosphorylation of Janus-activated kinase 2 (JAK2), Src and extracellular regulated protein kinases 1/2 (ERK1/2) were also suppressed by evodiamine.	evodiamine	141-151	mitogen-activated protein kinase 3	Homo sapiens	109-115
23032719-6	2013	Interestingly, treatment of cells with sodium pervanadate abrogated the inhibition of evodiamine on IL-6-induced STAT3 (Tyr(705)) activation indicating the involvement of protein tyrosine phosphatases.	evodiamine	86-96	interleukin 6	Homo sapiens	100-104
23032719-6	2013	Interestingly, treatment of cells with sodium pervanadate abrogated the inhibition of evodiamine on IL-6-induced STAT3 (Tyr(705)) activation indicating the involvement of protein tyrosine phosphatases.	evodiamine	86-96	signal transducer and activator of transcription 3	Homo sapiens	113-118
23032719-8	2013	Moreover, inhibition of SHP-1 gene by small interference RNA abolished the ability of evodiamine to inhibit IL-6-induced STAT3 (Tyr(705)) activation.	evodiamine	86-96	interleukin 6	Homo sapiens	108-112
23032719-8	2013	Moreover, inhibition of SHP-1 gene by small interference RNA abolished the ability of evodiamine to inhibit IL-6-induced STAT3 (Tyr(705)) activation.	evodiamine	86-96	signal transducer and activator of transcription 3	Homo sapiens	121-126
23032719-9	2013	Evodiamine also suppressed STAT3 DNA binding activity and down-regulated the expression of STAT3-mediated genes leading to the suppression of proliferation, induction of cell apoptosis and cell cycle arrest.	evodiamine	0-10	signal transducer and activator of transcription 3	Homo sapiens	27-32
23032719-9	2013	Evodiamine also suppressed STAT3 DNA binding activity and down-regulated the expression of STAT3-mediated genes leading to the suppression of proliferation, induction of cell apoptosis and cell cycle arrest.	evodiamine	0-10	signal transducer and activator of transcription 3	Homo sapiens	91-96
23032719-11	2013	In summary, evodiamine blocked STAT3 signaling pathway by inducing SHP-1 and exhibited anticancer effect in vitro and in vivo.	evodiamine	12-22	signal transducer and activator of transcription 3	Homo sapiens	31-36
22900043-4	2012	Additionally, evodiamine could significantly inhibit the accumulation of LC3-II and p62, and the dot-like aggregation of EGFP-LC3.	evodiamine	14-24	nucleoporin 62	Homo sapiens	84-87
22367117-13	2012	Additionally, Beclin-1 is involved in evodiamine-induced             autophagy and the pro-apoptotic mechanisms of evodiamine may be associated with             down-regulation of Bcl-2 and up-regulation of Bax expression.	evodiamine	38-48	beclin 1	Homo sapiens	14-22
22367117-13	2012	Additionally, Beclin-1 is involved in evodiamine-induced             autophagy and the pro-apoptotic mechanisms of evodiamine may be associated with             down-regulation of Bcl-2 and up-regulation of Bax expression.	evodiamine	38-48	BCL2 apoptosis regulator	Homo sapiens	180-185
22367117-13	2012	Additionally, Beclin-1 is involved in evodiamine-induced             autophagy and the pro-apoptotic mechanisms of evodiamine may be associated with             down-regulation of Bcl-2 and up-regulation of Bax expression.	evodiamine	115-125	beclin 1	Homo sapiens	14-22
22367117-13	2012	Additionally, Beclin-1 is involved in evodiamine-induced             autophagy and the pro-apoptotic mechanisms of evodiamine may be associated with             down-regulation of Bcl-2 and up-regulation of Bax expression.	evodiamine	115-125	BCL2 apoptosis regulator	Homo sapiens	180-185
22367117-13	2012	Additionally, Beclin-1 is involved in evodiamine-induced             autophagy and the pro-apoptotic mechanisms of evodiamine may be associated with             down-regulation of Bcl-2 and up-regulation of Bax expression.	evodiamine	115-125	BCL2 associated X, apoptosis regulator	Homo sapiens	207-210
22087636-4	2012	The results revealed that Sinomenine, Oxymartrine and Evodiamine inhibited the production of IL-1alpha; Stachydrine, Chuanxionggzine and Evodiamine inhibited the secretion of TXB(2); Sinomenine and Oxymartrine down-regulated ET-1 expression; Fangchinoline and Evodiamine decreased the level of E-selectin.	evodiamine	54-64	interleukin 1 alpha	Homo sapiens	93-102
21647174-0	2012	Berberine and evodiamine influence serotonin transporter (5-HTT) expression via the 5-HTT-linked polymorphic region.	evodiamine	14-24	solute carrier family 6 member 4	Homo sapiens	35-56
21647174-0	2012	Berberine and evodiamine influence serotonin transporter (5-HTT) expression via the 5-HTT-linked polymorphic region.	evodiamine	14-24	solute carrier family 6 member 4	Homo sapiens	58-63
21647174-0	2012	Berberine and evodiamine influence serotonin transporter (5-HTT) expression via the 5-HTT-linked polymorphic region.	evodiamine	14-24	solute carrier family 6 member 4	Homo sapiens	84-89
21647174-2	2012	Both berberine and evodiamine, alone and in combination, increased 5-HTT mRNA and protein expression significantly across the various alleles.	evodiamine	19-29	solute carrier family 6 member 4	Homo sapiens	67-72
21647174-4	2012	Berberine and evodiamine increased 5-HTT promoter activity differently depending on the genetic variation of the 5-HTTLPR polymorphism.	evodiamine	14-24	solute carrier family 6 member 4	Homo sapiens	35-40
22402246-3	2012	We report here the anti-proliferative activity against human leukaemia cells K562, THP-1, CCRF-CEM and CCRF-CEM/C1 and the inhibitory mechanism on human topoisomerases I and II, important anti-cancer drugs targets, of evodiamine.	evodiamine	218-228	GLI family zinc finger 2	Homo sapiens	83-88
22402246-5	2012	The results suggest evodiamine is a dual catalytic inhibitor of topoisomerases I and II, with IC(50) of 60.74 and 78.81 muM, respectively.	evodiamine	20-30	latexin	Homo sapiens	120-123
22367117-0	2012	Cytotoxic effect of evodiamine in SGC-7901 human gastric adenocarcinoma             cells via simultaneous induction of apoptosis and autophagy.	evodiamine	20-30	sarcoglycan beta	Homo sapiens	34-37
22367117-4	2012	This study was conducted to investigate the synchronized role             of autophagy and apoptosis in evodiamine-induced cytotoxic activity on SGC-7901             human gastric adenocarcinoma cells and further to elucidate the underlying molecular             mechanisms.	evodiamine	104-114	sarcoglycan beta	Homo sapiens	145-148
22367117-5	2012	The MTT assay was used to examine the cytotoxicity of evodiamine against             SGC-7901 gastric adenocarcinoma cells.	evodiamine	54-64	sarcoglycan beta	Homo sapiens	85-88
22367117-10	2012	Here, we found that evodiamine significantly inhibited             the proliferation of SGC-7901 cells and induced G2/M phase cell cycle arrest.	evodiamine	20-30	sarcoglycan beta	Homo sapiens	88-91
22367117-11	2012	Furthermore, both autophagy and apoptosis were activated during the evodiamine-induced             death of SGC-7901 cells.	evodiamine	68-78	sarcoglycan beta	Homo sapiens	108-111
22367117-12	2012	Evodiamine-induced autophagy is partially involved in             the death of SGC-7901 cells which was confirmed by using the autophagy inhibitor             3-methyladenine (3-MA).	evodiamine	0-10	sarcoglycan beta	Homo sapiens	79-82
22087636-4	2012	The results revealed that Sinomenine, Oxymartrine and Evodiamine inhibited the production of IL-1alpha; Stachydrine, Chuanxionggzine and Evodiamine inhibited the secretion of TXB(2); Sinomenine and Oxymartrine down-regulated ET-1 expression; Fangchinoline and Evodiamine decreased the level of E-selectin.	evodiamine	137-147	endothelin 1	Homo sapiens	225-229
22087636-4	2012	The results revealed that Sinomenine, Oxymartrine and Evodiamine inhibited the production of IL-1alpha; Stachydrine, Chuanxionggzine and Evodiamine inhibited the secretion of TXB(2); Sinomenine and Oxymartrine down-regulated ET-1 expression; Fangchinoline and Evodiamine decreased the level of E-selectin.	evodiamine	137-147	selectin E	Homo sapiens	294-304
22087636-4	2012	The results revealed that Sinomenine, Oxymartrine and Evodiamine inhibited the production of IL-1alpha; Stachydrine, Chuanxionggzine and Evodiamine inhibited the secretion of TXB(2); Sinomenine and Oxymartrine down-regulated ET-1 expression; Fangchinoline and Evodiamine decreased the level of E-selectin.	evodiamine	137-147	endothelin 1	Homo sapiens	225-229
22087636-4	2012	The results revealed that Sinomenine, Oxymartrine and Evodiamine inhibited the production of IL-1alpha; Stachydrine, Chuanxionggzine and Evodiamine inhibited the secretion of TXB(2); Sinomenine and Oxymartrine down-regulated ET-1 expression; Fangchinoline and Evodiamine decreased the level of E-selectin.	evodiamine	137-147	selectin E	Homo sapiens	294-304
22211100-0	2012	Enhanced antitumor efficacy of gemcitabine by evodiamine on pancreatic cancer via regulating PI3K/Akt pathway.	evodiamine	46-56	AKT serine/threonine kinase 1	Homo sapiens	98-101
22211100-5	2012	In conclusion, evodiamine can augment the therapeutic effect of gemcitabine in pancreatic cancer through direct or indirect negative regulation of the PI3K/Akt pathway.	evodiamine	15-25	AKT serine/threonine kinase 1	Homo sapiens	156-159
22942745-0	2012	Binding mode pediction of evodiamine within vanilloid receptor TRPV1.	evodiamine	26-36	transient receptor potential cation channel subfamily V member 1	Homo sapiens	63-68
22942745-2	2012	It has been reported that evodiamine acts as an agonist of the vanilloid receptor Transient receptor potential vanilloid-1 (TRPV1).	evodiamine	26-36	transient receptor potential cation channel subfamily V member 1	Homo sapiens	82-122
22942745-2	2012	It has been reported that evodiamine acts as an agonist of the vanilloid receptor Transient receptor potential vanilloid-1 (TRPV1).	evodiamine	26-36	transient receptor potential cation channel subfamily V member 1	Homo sapiens	124-129
22942745-3	2012	However, the precise interaction between evodiamine and TRPV1 was still not fully understood.	evodiamine	41-51	transient receptor potential cation channel subfamily V member 1	Homo sapiens	56-61
22942745-5	2012	We then performed docking and molecular dynamics simulation to gain a better understanding of the probable binding modes of evodiamine within the TRPV1 binding pocket.	evodiamine	124-134	transient receptor potential cation channel subfamily V member 1	Homo sapiens	146-151
22942745-8	2012	This study is the first to shed light on the structural determinants required for the interaction between TRPV1 and evodiamine, and gives new suggestions for the rational design of novel TRPV1 ligands.	evodiamine	116-126	transient receptor potential cation channel subfamily V member 1	Homo sapiens	106-111
22942745-8	2012	This study is the first to shed light on the structural determinants required for the interaction between TRPV1 and evodiamine, and gives new suggestions for the rational design of novel TRPV1 ligands.	evodiamine	116-126	transient receptor potential cation channel subfamily V member 1	Homo sapiens	187-192
22451268-2	2012	In ECs, treatment with evodiamine, the activator of TRPV1, increased the phosphorylation of AMPK, acetyl-CoA carboxylase (ACC) and eNOS, as revealed by western blot analysis.	evodiamine	23-33	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	52-57
22451268-2	2012	In ECs, treatment with evodiamine, the activator of TRPV1, increased the phosphorylation of AMPK, acetyl-CoA carboxylase (ACC) and eNOS, as revealed by western blot analysis.	evodiamine	23-33	nitric oxide synthase 3, endothelial cell	Mus musculus	131-135
22451268-3	2012	Inhibition of AMPK activation by compound C or dominant-negative AMPK mutant abrogated the evodiamine-induced increase in phosphorylation of AMPK and eNOS and NO bioavailability, as well as tube formation in ECs.	evodiamine	91-101	nitric oxide synthase 3, endothelial cell	Mus musculus	150-154
22451268-4	2012	Immunoprecipitation and two-hybrid analysis demonstrated that AMPK mediated the evodiamine-induced increase in the formation of a TRPV1-eNOS complex.	evodiamine	80-90	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	130-135
22451268-4	2012	Immunoprecipitation and two-hybrid analysis demonstrated that AMPK mediated the evodiamine-induced increase in the formation of a TRPV1-eNOS complex.	evodiamine	80-90	nitric oxide synthase 3, endothelial cell	Mus musculus	136-140
22451268-5	2012	Additionally, TRPV1 activation by evodiamine increased the phosphorylation of AMPK and eNOS in aortas of wild-type mice but did not activate eNOS in aortas of TRPV1-deficient mice.	evodiamine	34-44	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	14-19
22451268-5	2012	Additionally, TRPV1 activation by evodiamine increased the phosphorylation of AMPK and eNOS in aortas of wild-type mice but did not activate eNOS in aortas of TRPV1-deficient mice.	evodiamine	34-44	nitric oxide synthase 3, endothelial cell	Mus musculus	87-91
22451268-7	2012	Moreover, evodiamine-induced phosphorylation of AMPK and eNOS in aortas of apolipoprotein E deficient (ApoE(-/-)) mice was abrogated in TRPV1-deficient ApoE(-/-) mice.	evodiamine	10-20	nitric oxide synthase 3, endothelial cell	Mus musculus	57-61
22451268-7	2012	Moreover, evodiamine-induced phosphorylation of AMPK and eNOS in aortas of apolipoprotein E deficient (ApoE(-/-)) mice was abrogated in TRPV1-deficient ApoE(-/-) mice.	evodiamine	10-20	apolipoprotein E	Mus musculus	75-91
22451268-7	2012	Moreover, evodiamine-induced phosphorylation of AMPK and eNOS in aortas of apolipoprotein E deficient (ApoE(-/-)) mice was abrogated in TRPV1-deficient ApoE(-/-) mice.	evodiamine	10-20	apolipoprotein E	Mus musculus	103-107
22451268-7	2012	Moreover, evodiamine-induced phosphorylation of AMPK and eNOS in aortas of apolipoprotein E deficient (ApoE(-/-)) mice was abrogated in TRPV1-deficient ApoE(-/-) mice.	evodiamine	10-20	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	136-141
22451268-7	2012	Moreover, evodiamine-induced phosphorylation of AMPK and eNOS in aortas of apolipoprotein E deficient (ApoE(-/-)) mice was abrogated in TRPV1-deficient ApoE(-/-) mice.	evodiamine	10-20	apolipoprotein E	Mus musculus	152-156
22900043-6	2012	Evodiamine inhibited IAV-induced autophagy was also dependent on its action on the AMPK/TSC2/mTOR signal pathway.	evodiamine	0-10	TSC complex subunit 2	Homo sapiens	88-92
22900043-6	2012	Evodiamine inhibited IAV-induced autophagy was also dependent on its action on the AMPK/TSC2/mTOR signal pathway.	evodiamine	0-10	mechanistic target of rapamycin kinase	Homo sapiens	93-97
21887472-7	2011	The time required to reverse             the apoptotic effects of Evo was between 16 and 20 h. We also demonstrated that             promotion of mitotic slippage by a CDK1 inhibitor enhanced apoptosis.	evodiamine	66-69	cyclin dependent kinase 1	Homo sapiens	168-172
20888792-0	2010	Evodiamine as a novel antagonist of aryl hydrocarbon receptor.	evodiamine	0-10	aryl hydrocarbon receptor	Homo sapiens	36-61
21493704-2	2011	METHODS AND RESULTS: In ECs, TRPV1 ligands (evodiamine or capsaicin) promoted NO production, eNOS phosphorylation, and the formation of a TRPV1-eNOS complex, which were all abrogated by the TRPV1 antagonist capsazepine.	evodiamine	44-54	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	29-34
21493704-2	2011	METHODS AND RESULTS: In ECs, TRPV1 ligands (evodiamine or capsaicin) promoted NO production, eNOS phosphorylation, and the formation of a TRPV1-eNOS complex, which were all abrogated by the TRPV1 antagonist capsazepine.	evodiamine	44-54	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	138-143
21493704-2	2011	METHODS AND RESULTS: In ECs, TRPV1 ligands (evodiamine or capsaicin) promoted NO production, eNOS phosphorylation, and the formation of a TRPV1-eNOS complex, which were all abrogated by the TRPV1 antagonist capsazepine.	evodiamine	44-54	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	138-143
21294641-0	2011	Acid sphingomyelinase contributes to evodiamine-induced apoptosis in human gastric cancer SGC-7901 cells.	evodiamine	37-47	sphingomyelin phosphodiesterase 1	Homo sapiens	0-21
21294641-6	2011	Protein expression of aSMase, which was exposed to evodiamine, was shown to be increased by western blot analysis and could have been responsible for inducing caspase-independent apoptosis.	evodiamine	51-61	sphingomyelin phosphodiesterase 1	Homo sapiens	22-28
21294641-7	2011	Our results indicate that evodiamine stimulates upregulation of aSMase expression and hydrolysis of sphingomyelin into ceramide, which might be one of the mechanisms by which apoptosis occurs in SGC-7901 cells.	evodiamine	26-36	sphingomyelin phosphodiesterase 1	Homo sapiens	64-70
21356280-4	2011	The major alkaloidal ingredients, berberine and evodiamine, inhibited AP-1 activities and/or NF-kappaB activation, and further suppressed hepatocellular transformation.	evodiamine	48-58	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	70-74
21356280-5	2011	In conclusion, ZJW and its constituents, berberine and evodiamine, suppressed tumor promotion primarily through AP-1 and/or NF-kappaB pathways in HepG2 cells.	evodiamine	55-65	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	112-116
21799692-4	2011	Three alkaloids, although to differing extents, all concentration dependent, inhibited H1N1-induced RANTES production with Evo consistently being the most potent among these active components.	evodiamine	123-126	chemokine (C-C motif) ligand 5	Mus musculus	100-106
21799692-8	2011	Evo and Rut, but not DeHE, also had the ability to inhibit cell migration toward RANTES and MCP-1, respectively.	evodiamine	0-3	chemokine (C-C motif) ligand 5	Mus musculus	81-87
21799692-8	2011	Evo and Rut, but not DeHE, also had the ability to inhibit cell migration toward RANTES and MCP-1, respectively.	evodiamine	0-3	mast cell protease 1	Mus musculus	92-97
22393744-6	2011	The excretion of Coptidis Rhizoma, Paeoniae Radix Alba was negative correlated with that of evodiamine, rutaecarpine; meanwhile, the most superior proportion was also caculated which promote the representative ingredient excrete from bile.	evodiamine	92-102	afamin	Homo sapiens	50-54
21246637-0	2011	Evodiamine inhibits 12-O-tetradecanoylphorbol-13-acetate-induced activator protein 1 transactivation and cell transformation in human hepatocytes.	evodiamine	0-10	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	65-84
21246637-7	2011	EVO inhibited the TPA-induced AP-1 transactivation and colony formation, with EC50 values of 82 muM and 8.2 muM, respectively.	evodiamine	0-3	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	30-34
21246637-9	2011	These results suggested that EVO treatment suppressed the TPA-induced AP-1 activity via the ERKs pathway.	evodiamine	29-32	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	70-74
21246637-10	2011	In conclusion, EVO inhibited the AP-1 activity and cellular transformation in human hepatocytes, suggesting that EVO was a potential agent for antitumor therapy.	evodiamine	15-18	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	33-37
21246637-10	2011	In conclusion, EVO inhibited the AP-1 activity and cellular transformation in human hepatocytes, suggesting that EVO was a potential agent for antitumor therapy.	evodiamine	113-116	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	33-37
21278785-0	2011	Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(DeltaE9) transgenic mouse models of Alzheimer"s disease.	evodiamine	0-10	presenilin 1	Mus musculus	63-66
21278785-1	2011	AIM: To investigate the effect of evodiamine (a quinolone alkaloid from the fruit of Evodia rutaecarpa) on the progression of Alzheimer"s disease in SAMP8 and APP(swe)/PS1(DeltaE9) transgenic mouse models.	evodiamine	34-44	presenilin 1	Mus musculus	168-171
21278785-9	2011	Furthermore, the dose of evodiamine significantly decreased the expression of IL-1beta, IL-6, TNF-alpha, and COX-2 that were involved in the inflammation due to Alzheimer"s disease.	evodiamine	25-35	interleukin 1 alpha	Mus musculus	78-86
21278785-9	2011	Furthermore, the dose of evodiamine significantly decreased the expression of IL-1beta, IL-6, TNF-alpha, and COX-2 that were involved in the inflammation due to Alzheimer"s disease.	evodiamine	25-35	interleukin 6	Mus musculus	88-92
21278785-9	2011	Furthermore, the dose of evodiamine significantly decreased the expression of IL-1beta, IL-6, TNF-alpha, and COX-2 that were involved in the inflammation due to Alzheimer"s disease.	evodiamine	25-35	tumor necrosis factor	Mus musculus	94-103
21278785-9	2011	Furthermore, the dose of evodiamine significantly decreased the expression of IL-1beta, IL-6, TNF-alpha, and COX-2 that were involved in the inflammation due to Alzheimer"s disease.	evodiamine	25-35	cytochrome c oxidase II, mitochondrial	Mus musculus	109-114
20888792-6	2010	These results suggested that evodiamine was able to bind to the AhR as ligand and exhibit antagonistic effects.	evodiamine	29-39	aryl hydrocarbon receptor	Homo sapiens	64-67
20888792-2	2010	In this study, we investigated the interaction between evodiamine and the aryl hydrocarbon receptor (AhR).	evodiamine	55-65	aryl hydrocarbon receptor	Homo sapiens	74-99
20888792-2	2010	In this study, we investigated the interaction between evodiamine and the aryl hydrocarbon receptor (AhR).	evodiamine	55-65	aryl hydrocarbon receptor	Homo sapiens	101-104
20888792-3	2010	Molecular modeling results revealed that evodiamine directly interacted with the AhR.	evodiamine	41-51	aryl hydrocarbon receptor	Homo sapiens	81-84
20888792-4	2010	Cytosolic receptor binding assay also provided the evidence that evodiamine could interact with the AhR with the K(i) value of 28.4+-4.9nM.	evodiamine	65-75	aryl hydrocarbon receptor	Homo sapiens	100-103
20888792-5	2010	In addition, we observed that evodiamine suppressed the 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induced nuclear translocation of the AhR and the expression of CYP1A1 dose-dependently.	evodiamine	30-40	aryl hydrocarbon receptor	Homo sapiens	136-139
20888792-5	2010	In addition, we observed that evodiamine suppressed the 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induced nuclear translocation of the AhR and the expression of CYP1A1 dose-dependently.	evodiamine	30-40	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	162-168
20503248-10	2010	Furthermore, by using the TUNEL assay, evodiamine-induced apoptosis was observed at 48 h and extended to 72 h. Western blotting demonstrated that evodiamine treatment induced the activation of caspase-8, caspase-9, caspase-3, and the cleavage of poly ADP-ribose polymerase (PARP).	evodiamine	146-156	caspase 9	Homo sapiens	204-213
20647931-5	2010	Western blot indicated that evodiamine treatment decreased the expression of procaspase-8, procaspase-9, and procaspase-3 in lovo cells, accompanied by the activation of caspase-8, caspase-9, and caspase-3.	evodiamine	28-38	caspase 3	Homo sapiens	109-121
20647931-5	2010	Western blot indicated that evodiamine treatment decreased the expression of procaspase-8, procaspase-9, and procaspase-3 in lovo cells, accompanied by the activation of caspase-8, caspase-9, and caspase-3.	evodiamine	28-38	caspase 8	Homo sapiens	80-89
20647931-5	2010	Western blot indicated that evodiamine treatment decreased the expression of procaspase-8, procaspase-9, and procaspase-3 in lovo cells, accompanied by the activation of caspase-8, caspase-9, and caspase-3.	evodiamine	28-38	caspase 9	Homo sapiens	94-103
20647931-5	2010	Western blot indicated that evodiamine treatment decreased the expression of procaspase-8, procaspase-9, and procaspase-3 in lovo cells, accompanied by the activation of caspase-8, caspase-9, and caspase-3.	evodiamine	28-38	caspase 3	Homo sapiens	112-121
20647931-7	2010	Moreover, western blot assay also suggested that evodiamine-induced S phase arrest in lovo cells was associated with a marked decrease in the protein expression of cyclinA, cyclinA-dependent kinase 2, and cdc25c.	evodiamine	49-59	cyclin A2	Homo sapiens	164-171
20647931-7	2010	Moreover, western blot assay also suggested that evodiamine-induced S phase arrest in lovo cells was associated with a marked decrease in the protein expression of cyclinA, cyclinA-dependent kinase 2, and cdc25c.	evodiamine	49-59	cyclin A2	Homo sapiens	173-180
20647931-7	2010	Moreover, western blot assay also suggested that evodiamine-induced S phase arrest in lovo cells was associated with a marked decrease in the protein expression of cyclinA, cyclinA-dependent kinase 2, and cdc25c.	evodiamine	49-59	cell division cycle 25C	Homo sapiens	205-211
20647931-8	2010	In-vivo antineoplastic characteristics of evodiamine were examined in a human colon carcinoma lovo xenograft model and results showed that evodiamine increased the number of TUNEL-positive cells accompanied by the downregulated expression of procaspase-8, procaspase-9, and procaspase-3.	evodiamine	139-149	caspase 3	Homo sapiens	274-286
20503248-0	2010	Anti-proliferative effects of evodiamine on human thyroid cancer cell line ARO.	evodiamine	30-40	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	75-78
20503248-6	2010	In the present study, the mechanism by which evodiamine inhibited the undifferentiated thyroid cancer cell line ARO was examined.	evodiamine	45-55	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	112-115
20503248-10	2010	Furthermore, by using the TUNEL assay, evodiamine-induced apoptosis was observed at 48 h and extended to 72 h. Western blotting demonstrated that evodiamine treatment induced the activation of caspase-8, caspase-9, caspase-3, and the cleavage of poly ADP-ribose polymerase (PARP).	evodiamine	146-156	caspase 3	Homo sapiens	215-224
20503248-8	2010	According to the flow cytometric analysis, evodiamine treatment resulted in G2/M arrest and DNA fragmentation in ARO cells.	evodiamine	43-53	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	113-116
20503248-10	2010	Furthermore, by using the TUNEL assay, evodiamine-induced apoptosis was observed at 48 h and extended to 72 h. Western blotting demonstrated that evodiamine treatment induced the activation of caspase-8, caspase-9, caspase-3, and the cleavage of poly ADP-ribose polymerase (PARP).	evodiamine	146-156	poly(ADP-ribose) polymerase 1	Homo sapiens	246-272
20503248-10	2010	Furthermore, by using the TUNEL assay, evodiamine-induced apoptosis was observed at 48 h and extended to 72 h. Western blotting demonstrated that evodiamine treatment induced the activation of caspase-8, caspase-9, caspase-3, and the cleavage of poly ADP-ribose polymerase (PARP).	evodiamine	39-49	caspase 8	Homo sapiens	193-202
20503248-10	2010	Furthermore, by using the TUNEL assay, evodiamine-induced apoptosis was observed at 48 h and extended to 72 h. Western blotting demonstrated that evodiamine treatment induced the activation of caspase-8, caspase-9, caspase-3, and the cleavage of poly ADP-ribose polymerase (PARP).	evodiamine	39-49	caspase 9	Homo sapiens	204-213
20503248-10	2010	Furthermore, by using the TUNEL assay, evodiamine-induced apoptosis was observed at 48 h and extended to 72 h. Western blotting demonstrated that evodiamine treatment induced the activation of caspase-8, caspase-9, caspase-3, and the cleavage of poly ADP-ribose polymerase (PARP).	evodiamine	39-49	caspase 3	Homo sapiens	215-224
20503248-10	2010	Furthermore, by using the TUNEL assay, evodiamine-induced apoptosis was observed at 48 h and extended to 72 h. Western blotting demonstrated that evodiamine treatment induced the activation of caspase-8, caspase-9, caspase-3, and the cleavage of poly ADP-ribose polymerase (PARP).	evodiamine	39-49	poly(ADP-ribose) polymerase 1	Homo sapiens	246-272
20503248-10	2010	Furthermore, by using the TUNEL assay, evodiamine-induced apoptosis was observed at 48 h and extended to 72 h. Western blotting demonstrated that evodiamine treatment induced the activation of caspase-8, caspase-9, caspase-3, and the cleavage of poly ADP-ribose polymerase (PARP).	evodiamine	39-49	poly(ADP-ribose) polymerase 1	Homo sapiens	274-278
20503248-10	2010	Furthermore, by using the TUNEL assay, evodiamine-induced apoptosis was observed at 48 h and extended to 72 h. Western blotting demonstrated that evodiamine treatment induced the activation of caspase-8, caspase-9, caspase-3, and the cleavage of poly ADP-ribose polymerase (PARP).	evodiamine	146-156	caspase 8	Homo sapiens	193-202
20503248-10	2010	Furthermore, by using the TUNEL assay, evodiamine-induced apoptosis was observed at 48 h and extended to 72 h. Western blotting demonstrated that evodiamine treatment induced the activation of caspase-8, caspase-9, caspase-3, and the cleavage of poly ADP-ribose polymerase (PARP).	evodiamine	146-156	poly(ADP-ribose) polymerase 1	Homo sapiens	274-278
20503248-11	2010	These results suggested that evodiamine inhibited the growth of the ARO cells, arrested them at M phase, and induced apoptosis through caspases signaling.	evodiamine	29-39	cytochrome P450 family 19 subfamily A member 1	Homo sapiens	68-71
20503248-11	2010	These results suggested that evodiamine inhibited the growth of the ARO cells, arrested them at M phase, and induced apoptosis through caspases signaling.	evodiamine	29-39	caspase 8	Homo sapiens	135-143
19799972-3	2010	We have shown that treatment with 8 microM berberine or 4 microM evodiamine resulted in a major inhibition of HWP differentiation accompanied by up-regulation of both GATA binding protein 2 and 3 (GATA-2 and GATA-3) mRNA and protein expression, suggesting that both compounds may have excellent potential as agents to prevent obesity.	evodiamine	65-75	GATA binding protein 2	Homo sapiens	167-195
19799972-3	2010	We have shown that treatment with 8 microM berberine or 4 microM evodiamine resulted in a major inhibition of HWP differentiation accompanied by up-regulation of both GATA binding protein 2 and 3 (GATA-2 and GATA-3) mRNA and protein expression, suggesting that both compounds may have excellent potential as agents to prevent obesity.	evodiamine	65-75	GATA binding protein 2	Homo sapiens	197-203
19799972-3	2010	We have shown that treatment with 8 microM berberine or 4 microM evodiamine resulted in a major inhibition of HWP differentiation accompanied by up-regulation of both GATA binding protein 2 and 3 (GATA-2 and GATA-3) mRNA and protein expression, suggesting that both compounds may have excellent potential as agents to prevent obesity.	evodiamine	65-75	GATA binding protein 3	Homo sapiens	208-214
18955035-0	2009	Intragastric administration of evodiamine suppresses NPY and AgRP gene expression in the hypothalamus and decreases food intake in rats.	evodiamine	31-41	neuropeptide Y	Rattus norvegicus	53-56
19106818-0	2009	Evodiamine represses hypoxia-induced inflammatory proteins expression and hypoxia-inducible factor 1alpha accumulation in RAW264.7.	evodiamine	0-10	hypoxia inducible factor 1, alpha subunit	Mus musculus	74-105
19106818-4	2009	We showed that evodiamine repressed not only COX-2 and iNOS expression but also prostaglandin E2 release in a concentration-dependent manner under hypoxic conditions.	evodiamine	15-25	cytochrome c oxidase II, mitochondrial	Mus musculus	45-50
19106818-4	2009	We showed that evodiamine repressed not only COX-2 and iNOS expression but also prostaglandin E2 release in a concentration-dependent manner under hypoxic conditions.	evodiamine	15-25	nitric oxide synthase 2, inducible	Mus musculus	55-59
19106818-5	2009	Furthermore, our studies indicated that COX-2 mRNA was inhibited by evodiamine, implying that transcriptional activity is involved in the mechanistic pathway.	evodiamine	68-78	cytochrome c oxidase II, mitochondrial	Mus musculus	40-45
19106818-7	2009	In addition, our studies have confirmed that evodiamine inhibited HIF-1alpha, which accounted for the transcriptional activity of COX-2, rather than nuclear factor kappaB in RAW264.7 cells.	evodiamine	45-55	hypoxia inducible factor 1, alpha subunit	Mus musculus	66-76
19106818-7	2009	In addition, our studies have confirmed that evodiamine inhibited HIF-1alpha, which accounted for the transcriptional activity of COX-2, rather than nuclear factor kappaB in RAW264.7 cells.	evodiamine	45-55	cytochrome c oxidase II, mitochondrial	Mus musculus	130-135
19106818-9	2009	We found that hypoxia-evoked phosphorylation of Akt and p70S6K was blocked after evodiamine treatment, in addition to the inhibition of phosphorylation of 4E-BP.	evodiamine	81-91	thymoma viral proto-oncogene 1	Mus musculus	48-51
19106818-9	2009	We found that hypoxia-evoked phosphorylation of Akt and p70S6K was blocked after evodiamine treatment, in addition to the inhibition of phosphorylation of 4E-BP.	evodiamine	81-91	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	56-62
19106818-10	2009	These results suggest that the mechanism of repression of hypoxia-induced COX-2 expression by evodiamine is through the inhibition of HIF-1alpha at the translational level and is primarily mediated via dephosphorylation of Akt and p70S6K.	evodiamine	94-104	cytochrome c oxidase II, mitochondrial	Mus musculus	74-79
19106818-10	2009	These results suggest that the mechanism of repression of hypoxia-induced COX-2 expression by evodiamine is through the inhibition of HIF-1alpha at the translational level and is primarily mediated via dephosphorylation of Akt and p70S6K.	evodiamine	94-104	hypoxia inducible factor 1, alpha subunit	Mus musculus	134-144
19106818-10	2009	These results suggest that the mechanism of repression of hypoxia-induced COX-2 expression by evodiamine is through the inhibition of HIF-1alpha at the translational level and is primarily mediated via dephosphorylation of Akt and p70S6K.	evodiamine	94-104	thymoma viral proto-oncogene 1	Mus musculus	223-226
19106818-10	2009	These results suggest that the mechanism of repression of hypoxia-induced COX-2 expression by evodiamine is through the inhibition of HIF-1alpha at the translational level and is primarily mediated via dephosphorylation of Akt and p70S6K.	evodiamine	94-104	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	231-237
19241441-5	2009	Evodiamine and rutaecarpine decreased the LIGHT-induced production of ROS, IL-8, monocyte chemoattractant protein-1 (MCP-1), TNF-alpha, and IL-6, as well as the expression of chemokine receptor (CCR) 1, CCR2 and ICAM-1 and the phosphorylation of the ERK 1/2 and p38 MAPK.	evodiamine	0-10	C-X-C motif chemokine ligand 8	Homo sapiens	75-79
20005289-0	2010	Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition.	evodiamine	0-10	AKT serine/threonine kinase 1	Homo sapiens	74-77
20005289-0	2010	Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition.	evodiamine	0-10	Fas ligand	Homo sapiens	90-95
20005289-0	2010	Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways and augmented by ubiquitin-proteasome inhibition.	evodiamine	0-10	nuclear factor kappa B subunit 1	Homo sapiens	96-105
20005289-2	2010	We have previously reported that evodiamine has a marked inhibitory effect on IL-1 sensitive human melanoma A375-S2 cells proliferation, and this action might be through inactivation of PI3K signaling.	evodiamine	33-43	interleukin 1 alpha	Homo sapiens	78-82
20005289-5	2010	Evodiamine also led to IkappaBalpha phosphorylation and degradation that reflect translocation of NF-kappaB.	evodiamine	0-10	NFKB inhibitor alpha	Homo sapiens	23-35
20005289-5	2010	Evodiamine also led to IkappaBalpha phosphorylation and degradation that reflect translocation of NF-kappaB.	evodiamine	0-10	nuclear factor kappa B subunit 1	Homo sapiens	98-107
20005289-7	2010	In addition, MG132 reduced ERK phosphorylation, increased caspase-3 activation, Fas-L expression and Bcl-2 cleavage in evodiamine-treated A375-S2 cells.	evodiamine	119-129	BCL2 apoptosis regulator	Homo sapiens	101-106
20005289-8	2010	These results suggested the PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways might account for the responses of A375-S2 cell death induced by evodiamine, and these signals could be augmented by ubiquitin-proteasome pathway.	evodiamine	149-159	AKT serine/threonine kinase 1	Homo sapiens	33-36
20005289-8	2010	These results suggested the PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways might account for the responses of A375-S2 cell death induced by evodiamine, and these signals could be augmented by ubiquitin-proteasome pathway.	evodiamine	149-159	Fas ligand	Homo sapiens	49-54
20005289-8	2010	These results suggested the PI3K/Akt/caspase and Fas-L/NF-kappaB signaling pathways might account for the responses of A375-S2 cell death induced by evodiamine, and these signals could be augmented by ubiquitin-proteasome pathway.	evodiamine	149-159	nuclear factor kappa B subunit 1	Homo sapiens	55-64
19854188-0	2009	Evodiamine inhibits adipogenesis via the EGFR-PKCalpha-ERK signaling pathway.	evodiamine	0-10	epidermal growth factor receptor	Homo sapiens	41-45
19854188-0	2009	Evodiamine inhibits adipogenesis via the EGFR-PKCalpha-ERK signaling pathway.	evodiamine	0-10	protein kinase C alpha	Homo sapiens	46-54
19854188-0	2009	Evodiamine inhibits adipogenesis via the EGFR-PKCalpha-ERK signaling pathway.	evodiamine	0-10	mitogen-activated protein kinase 1	Homo sapiens	55-58
19854188-2	2009	The evodiamine effect was not blocked by the specific TRPV1 antagonist capsazepine in 3T3-L1 preadipocytes, whereas its effect was greatly curtailed by inhibitors of protein kinase C (PKC) and epidermal growth factor receptor (EGFR).	evodiamine	4-14	protein kinase C alpha	Homo sapiens	184-187
19854188-2	2009	The evodiamine effect was not blocked by the specific TRPV1 antagonist capsazepine in 3T3-L1 preadipocytes, whereas its effect was greatly curtailed by inhibitors of protein kinase C (PKC) and epidermal growth factor receptor (EGFR).	evodiamine	4-14	epidermal growth factor receptor	Homo sapiens	227-231
19854188-3	2009	Signal analyses showed that evodiamine stimulated the phosphorylation of EGFR, PKCalpha, and ERK, all of which were reduced by an EGFR inhibitor.	evodiamine	28-38	epidermal growth factor receptor	Homo sapiens	73-77
19854188-3	2009	Signal analyses showed that evodiamine stimulated the phosphorylation of EGFR, PKCalpha, and ERK, all of which were reduced by an EGFR inhibitor.	evodiamine	28-38	protein kinase C alpha	Homo sapiens	79-87
19854188-3	2009	Signal analyses showed that evodiamine stimulated the phosphorylation of EGFR, PKCalpha, and ERK, all of which were reduced by an EGFR inhibitor.	evodiamine	28-38	mitogen-activated protein kinase 1	Homo sapiens	93-96
19854188-3	2009	Signal analyses showed that evodiamine stimulated the phosphorylation of EGFR, PKCalpha, and ERK, all of which were reduced by an EGFR inhibitor.	evodiamine	28-38	epidermal growth factor receptor	Homo sapiens	130-134
19854188-4	2009	Silencing experiments of EGFR mRNA supported the involvement of these signaling molecules in the inhibitory effect of evodiamine.	evodiamine	118-128	epidermal growth factor receptor	Homo sapiens	25-29
19854188-5	2009	An unidentified mechanism whereby evodiamine inhibits adipogenesis via the EGFR-PKCalpha-ERK signaling pathway was revealed.	evodiamine	34-44	epidermal growth factor receptor	Homo sapiens	75-79
19854188-5	2009	An unidentified mechanism whereby evodiamine inhibits adipogenesis via the EGFR-PKCalpha-ERK signaling pathway was revealed.	evodiamine	34-44	protein kinase C alpha	Homo sapiens	80-88
19854188-5	2009	An unidentified mechanism whereby evodiamine inhibits adipogenesis via the EGFR-PKCalpha-ERK signaling pathway was revealed.	evodiamine	34-44	mitogen-activated protein kinase 1	Homo sapiens	89-92
19639602-6	2009	After administration of ZFR cells with EVO or RUT (10(-4) M) for 60 and 120 min, Western blot analysis was employed to explore the influence of EVO and RUT on the expression of cytochrome P450 side chain cleavage enzyme (P450scc) and steroidogenic acute regulatory protein (StAR).	evodiamine	144-147	cytochrome P450, family 11, subfamily a, polypeptide 1	Rattus norvegicus	177-219
19639602-9	2009	These results suggest that EVO and RUT inhibit corticosterone production in rat ZFR cells via a mechanism involving: (1) a decreased activity of cAMP-related pathways; (2) a decreased activity of the steroidogenic enzymes, that is, 3beta-hydroxysteroid dehydrogenase (3beta-HSD) and 11beta-hydroxylase (P450c11), during steroidogenesis; and (3) an inhibition of StAR protein expression.	evodiamine	27-30	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Rattus norvegicus	232-266
19639602-9	2009	These results suggest that EVO and RUT inhibit corticosterone production in rat ZFR cells via a mechanism involving: (1) a decreased activity of cAMP-related pathways; (2) a decreased activity of the steroidogenic enzymes, that is, 3beta-hydroxysteroid dehydrogenase (3beta-HSD) and 11beta-hydroxylase (P450c11), during steroidogenesis; and (3) an inhibition of StAR protein expression.	evodiamine	27-30	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1	Rattus norvegicus	268-277
19639602-9	2009	These results suggest that EVO and RUT inhibit corticosterone production in rat ZFR cells via a mechanism involving: (1) a decreased activity of cAMP-related pathways; (2) a decreased activity of the steroidogenic enzymes, that is, 3beta-hydroxysteroid dehydrogenase (3beta-HSD) and 11beta-hydroxylase (P450c11), during steroidogenesis; and (3) an inhibition of StAR protein expression.	evodiamine	27-30	cytochrome P450, family 11, subfamily b, polypeptide 1	Rattus norvegicus	303-310
19639602-9	2009	These results suggest that EVO and RUT inhibit corticosterone production in rat ZFR cells via a mechanism involving: (1) a decreased activity of cAMP-related pathways; (2) a decreased activity of the steroidogenic enzymes, that is, 3beta-hydroxysteroid dehydrogenase (3beta-HSD) and 11beta-hydroxylase (P450c11), during steroidogenesis; and (3) an inhibition of StAR protein expression.	evodiamine	27-30	steroidogenic acute regulatory protein	Rattus norvegicus	362-366
19241441-5	2009	Evodiamine and rutaecarpine decreased the LIGHT-induced production of ROS, IL-8, monocyte chemoattractant protein-1 (MCP-1), TNF-alpha, and IL-6, as well as the expression of chemokine receptor (CCR) 1, CCR2 and ICAM-1 and the phosphorylation of the ERK 1/2 and p38 MAPK.	evodiamine	0-10	C-C motif chemokine ligand 2	Homo sapiens	81-115
19241441-5	2009	Evodiamine and rutaecarpine decreased the LIGHT-induced production of ROS, IL-8, monocyte chemoattractant protein-1 (MCP-1), TNF-alpha, and IL-6, as well as the expression of chemokine receptor (CCR) 1, CCR2 and ICAM-1 and the phosphorylation of the ERK 1/2 and p38 MAPK.	evodiamine	0-10	C-C motif chemokine ligand 2	Homo sapiens	117-122
19241441-5	2009	Evodiamine and rutaecarpine decreased the LIGHT-induced production of ROS, IL-8, monocyte chemoattractant protein-1 (MCP-1), TNF-alpha, and IL-6, as well as the expression of chemokine receptor (CCR) 1, CCR2 and ICAM-1 and the phosphorylation of the ERK 1/2 and p38 MAPK.	evodiamine	0-10	tumor necrosis factor	Homo sapiens	125-134
19241441-5	2009	Evodiamine and rutaecarpine decreased the LIGHT-induced production of ROS, IL-8, monocyte chemoattractant protein-1 (MCP-1), TNF-alpha, and IL-6, as well as the expression of chemokine receptor (CCR) 1, CCR2 and ICAM-1 and the phosphorylation of the ERK 1/2 and p38 MAPK.	evodiamine	0-10	interleukin 6	Homo sapiens	140-144
19241441-5	2009	Evodiamine and rutaecarpine decreased the LIGHT-induced production of ROS, IL-8, monocyte chemoattractant protein-1 (MCP-1), TNF-alpha, and IL-6, as well as the expression of chemokine receptor (CCR) 1, CCR2 and ICAM-1 and the phosphorylation of the ERK 1/2 and p38 MAPK.	evodiamine	0-10	C-C motif chemokine receptor 1	Homo sapiens	175-201
19241441-5	2009	Evodiamine and rutaecarpine decreased the LIGHT-induced production of ROS, IL-8, monocyte chemoattractant protein-1 (MCP-1), TNF-alpha, and IL-6, as well as the expression of chemokine receptor (CCR) 1, CCR2 and ICAM-1 and the phosphorylation of the ERK 1/2 and p38 MAPK.	evodiamine	0-10	C-C motif chemokine receptor 2	Homo sapiens	203-207
19241441-5	2009	Evodiamine and rutaecarpine decreased the LIGHT-induced production of ROS, IL-8, monocyte chemoattractant protein-1 (MCP-1), TNF-alpha, and IL-6, as well as the expression of chemokine receptor (CCR) 1, CCR2 and ICAM-1 and the phosphorylation of the ERK 1/2 and p38 MAPK.	evodiamine	0-10	intercellular adhesion molecule 1	Homo sapiens	212-218
19241441-5	2009	Evodiamine and rutaecarpine decreased the LIGHT-induced production of ROS, IL-8, monocyte chemoattractant protein-1 (MCP-1), TNF-alpha, and IL-6, as well as the expression of chemokine receptor (CCR) 1, CCR2 and ICAM-1 and the phosphorylation of the ERK 1/2 and p38 MAPK.	evodiamine	0-10	mitogen-activated protein kinase 3	Homo sapiens	250-257
19241441-5	2009	Evodiamine and rutaecarpine decreased the LIGHT-induced production of ROS, IL-8, monocyte chemoattractant protein-1 (MCP-1), TNF-alpha, and IL-6, as well as the expression of chemokine receptor (CCR) 1, CCR2 and ICAM-1 and the phosphorylation of the ERK 1/2 and p38 MAPK.	evodiamine	0-10	mitogen-activated protein kinase 1	Homo sapiens	262-265
19241441-7	2009	These findings indicate that the inhibitory effects of evodiamine and rutaecarpine on LIGHT-induced migration and the activation of CCR1, CCR2, ICAM-1, ERK, and p38 MAPK occurs via decreased ROS production and NADPH oxidase activation.	evodiamine	55-65	C-C motif chemokine receptor 1	Homo sapiens	132-136
19241441-7	2009	These findings indicate that the inhibitory effects of evodiamine and rutaecarpine on LIGHT-induced migration and the activation of CCR1, CCR2, ICAM-1, ERK, and p38 MAPK occurs via decreased ROS production and NADPH oxidase activation.	evodiamine	55-65	C-C motif chemokine receptor 2	Homo sapiens	138-142
19241441-7	2009	These findings indicate that the inhibitory effects of evodiamine and rutaecarpine on LIGHT-induced migration and the activation of CCR1, CCR2, ICAM-1, ERK, and p38 MAPK occurs via decreased ROS production and NADPH oxidase activation.	evodiamine	55-65	intercellular adhesion molecule 1	Homo sapiens	144-150
19241441-7	2009	These findings indicate that the inhibitory effects of evodiamine and rutaecarpine on LIGHT-induced migration and the activation of CCR1, CCR2, ICAM-1, ERK, and p38 MAPK occurs via decreased ROS production and NADPH oxidase activation.	evodiamine	55-65	mitogen-activated protein kinase 1	Homo sapiens	152-155
19241441-7	2009	These findings indicate that the inhibitory effects of evodiamine and rutaecarpine on LIGHT-induced migration and the activation of CCR1, CCR2, ICAM-1, ERK, and p38 MAPK occurs via decreased ROS production and NADPH oxidase activation.	evodiamine	55-65	mitogen-activated protein kinase 1	Homo sapiens	161-164
18955035-0	2009	Intragastric administration of evodiamine suppresses NPY and AgRP gene expression in the hypothalamus and decreases food intake in rats.	evodiamine	31-41	agouti related neuropeptide	Rattus norvegicus	61-65
18955035-10	2009	Our results show that intragastric administration of Evo (40 mg/kg) decreased rate of food intake and body weight increase following rat growth, reduced orexigenic neuropeptide Y (NPY) and agouti-gene related protein (AgRP) mRNA levels and NPY peptide level in the arcuate nucleus (ARC) of the hypothalamus, but it increases the circulating level of leptin.	evodiamine	53-56	neuropeptide Y	Rattus norvegicus	164-178
18955035-10	2009	Our results show that intragastric administration of Evo (40 mg/kg) decreased rate of food intake and body weight increase following rat growth, reduced orexigenic neuropeptide Y (NPY) and agouti-gene related protein (AgRP) mRNA levels and NPY peptide level in the arcuate nucleus (ARC) of the hypothalamus, but it increases the circulating level of leptin.	evodiamine	53-56	neuropeptide Y	Rattus norvegicus	180-183
18955035-10	2009	Our results show that intragastric administration of Evo (40 mg/kg) decreased rate of food intake and body weight increase following rat growth, reduced orexigenic neuropeptide Y (NPY) and agouti-gene related protein (AgRP) mRNA levels and NPY peptide level in the arcuate nucleus (ARC) of the hypothalamus, but it increases the circulating level of leptin.	evodiamine	53-56	agouti related neuropeptide	Rattus norvegicus	189-216
18955035-10	2009	Our results show that intragastric administration of Evo (40 mg/kg) decreased rate of food intake and body weight increase following rat growth, reduced orexigenic neuropeptide Y (NPY) and agouti-gene related protein (AgRP) mRNA levels and NPY peptide level in the arcuate nucleus (ARC) of the hypothalamus, but it increases the circulating level of leptin.	evodiamine	53-56	agouti related neuropeptide	Rattus norvegicus	218-222
18955035-10	2009	Our results show that intragastric administration of Evo (40 mg/kg) decreased rate of food intake and body weight increase following rat growth, reduced orexigenic neuropeptide Y (NPY) and agouti-gene related protein (AgRP) mRNA levels and NPY peptide level in the arcuate nucleus (ARC) of the hypothalamus, but it increases the circulating level of leptin.	evodiamine	53-56	neuropeptide Y	Rattus norvegicus	240-243
18955035-12	2009	These data suggest that Evo decreases food intake, and therefore body weight, partly by down-regulating NPY and AgRP mRNA expression and peptide expression in the ARC of the hypothalamus.	evodiamine	24-27	neuropeptide Y	Rattus norvegicus	104-107
18955035-12	2009	These data suggest that Evo decreases food intake, and therefore body weight, partly by down-regulating NPY and AgRP mRNA expression and peptide expression in the ARC of the hypothalamus.	evodiamine	24-27	agouti related neuropeptide	Rattus norvegicus	112-116
18484413-2	2008	This study reported that reactive oxygen species (ROS) and nitric oxide (NO) generations were induced by evodiamine time-dependently; while they acted in synergy to trigger mitochondria-dependent apoptosis by induction of mitochondrial membrane permeabilization (MMP) through increasing the Bax/Bcl-2 or Bcl-x(L) ratio.	evodiamine	105-115	BCL2 associated X, apoptosis regulator	Homo sapiens	291-294
18718084-3	2008	Cell proliferation was detected by MTT method, while the concentration of IL-2 was detected by ELISA, mRNA levels of bcl-2 and cdk2 in cells treated with evodiamine were detected by RT-PCR, the apoptosis rate and intracellular reactive oxygen species (ROS) concentration were analyzed by FCM, and the protein levels of BCL-2, CDK2 and BAX were determined by fluorescence microscope.	evodiamine	154-164	B cell leukemia/lymphoma 2	Mus musculus	117-122
18718084-3	2008	Cell proliferation was detected by MTT method, while the concentration of IL-2 was detected by ELISA, mRNA levels of bcl-2 and cdk2 in cells treated with evodiamine were detected by RT-PCR, the apoptosis rate and intracellular reactive oxygen species (ROS) concentration were analyzed by FCM, and the protein levels of BCL-2, CDK2 and BAX were determined by fluorescence microscope.	evodiamine	154-164	cyclin-dependent kinase 2	Mus musculus	127-131
18718084-3	2008	Cell proliferation was detected by MTT method, while the concentration of IL-2 was detected by ELISA, mRNA levels of bcl-2 and cdk2 in cells treated with evodiamine were detected by RT-PCR, the apoptosis rate and intracellular reactive oxygen species (ROS) concentration were analyzed by FCM, and the protein levels of BCL-2, CDK2 and BAX were determined by fluorescence microscope.	evodiamine	154-164	B cell leukemia/lymphoma 2	Mus musculus	319-324
18718084-3	2008	Cell proliferation was detected by MTT method, while the concentration of IL-2 was detected by ELISA, mRNA levels of bcl-2 and cdk2 in cells treated with evodiamine were detected by RT-PCR, the apoptosis rate and intracellular reactive oxygen species (ROS) concentration were analyzed by FCM, and the protein levels of BCL-2, CDK2 and BAX were determined by fluorescence microscope.	evodiamine	154-164	cyclin-dependent kinase 2	Mus musculus	326-330
18718084-3	2008	Cell proliferation was detected by MTT method, while the concentration of IL-2 was detected by ELISA, mRNA levels of bcl-2 and cdk2 in cells treated with evodiamine were detected by RT-PCR, the apoptosis rate and intracellular reactive oxygen species (ROS) concentration were analyzed by FCM, and the protein levels of BCL-2, CDK2 and BAX were determined by fluorescence microscope.	evodiamine	154-164	BCL2-associated X protein	Mus musculus	335-338
18718084-5	2008	At 0.75 micromol/L, evodiamine inhibited the secretion of IL-2, decreased the mRNA level of bcl-2 and cdk2, and induced apoptosis of thymocytes and splenocytes (p &lt; 0.05).	evodiamine	20-30	interleukin 2	Mus musculus	58-62
18718084-5	2008	At 0.75 micromol/L, evodiamine inhibited the secretion of IL-2, decreased the mRNA level of bcl-2 and cdk2, and induced apoptosis of thymocytes and splenocytes (p &lt; 0.05).	evodiamine	20-30	B cell leukemia/lymphoma 2	Mus musculus	92-97
18718084-5	2008	At 0.75 micromol/L, evodiamine inhibited the secretion of IL-2, decreased the mRNA level of bcl-2 and cdk2, and induced apoptosis of thymocytes and splenocytes (p &lt; 0.05).	evodiamine	20-30	cyclin-dependent kinase 2	Mus musculus	102-106
18718084-9	2008	It is concluded that evodiamine inhibits proliferation and induces apoptosis of thymocytes and splenocytes from different germline mice, and at the same time decreases secretion of IL-2 through down-regulating bcl-2 and cdk2 levels.	evodiamine	21-31	interleukin 2	Mus musculus	181-185
18718084-9	2008	It is concluded that evodiamine inhibits proliferation and induces apoptosis of thymocytes and splenocytes from different germline mice, and at the same time decreases secretion of IL-2 through down-regulating bcl-2 and cdk2 levels.	evodiamine	21-31	B cell leukemia/lymphoma 2	Mus musculus	210-215
18718084-9	2008	It is concluded that evodiamine inhibits proliferation and induces apoptosis of thymocytes and splenocytes from different germline mice, and at the same time decreases secretion of IL-2 through down-regulating bcl-2 and cdk2 levels.	evodiamine	21-31	cyclin-dependent kinase 2	Mus musculus	220-224
18484413-2	2008	This study reported that reactive oxygen species (ROS) and nitric oxide (NO) generations were induced by evodiamine time-dependently; while they acted in synergy to trigger mitochondria-dependent apoptosis by induction of mitochondrial membrane permeabilization (MMP) through increasing the Bax/Bcl-2 or Bcl-x(L) ratio.	evodiamine	105-115	BCL2 apoptosis regulator	Homo sapiens	295-300
18484413-2	2008	This study reported that reactive oxygen species (ROS) and nitric oxide (NO) generations were induced by evodiamine time-dependently; while they acted in synergy to trigger mitochondria-dependent apoptosis by induction of mitochondrial membrane permeabilization (MMP) through increasing the Bax/Bcl-2 or Bcl-x(L) ratio.	evodiamine	105-115	BCL2 like 1	Homo sapiens	304-312
18484413-3	2008	Autophagy was also stimulated by evodiamine, as demonstrated by the positive autophagosome-specific dye monodansylcadaverine (MDC) staining as well as the expressions of autophagy-related proteins, Beclin 1 and LC3.	evodiamine	33-43	beclin 1	Homo sapiens	198-206
18484413-3	2008	Autophagy was also stimulated by evodiamine, as demonstrated by the positive autophagosome-specific dye monodansylcadaverine (MDC) staining as well as the expressions of autophagy-related proteins, Beclin 1 and LC3.	evodiamine	33-43	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	211-214
18058680-4	2007	Rutaecarpine and evodiamine showed quite high toxicity with IC (50) values from 2.64 to 4.53 microM and were weak modulators of p-gp activity.	evodiamine	17-27	phosphoglycolate phosphatase	Homo sapiens	128-132
17884939-3	2008	When UCP1-knockout mice were fed a high-fat diet with 0.03% evodiamine (wt/wt) for 2 months, the increases in body weight, adiposity, and the serum levels of leptin and insulin were reduced in a manner indistinguishable from control mice fed a high-fat diet with evodiamine, suggesting that evodiamine triggered a UCP1-independent mechanism to prevent diet-induced obesity.	evodiamine	60-70	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	5-9
17884939-3	2008	When UCP1-knockout mice were fed a high-fat diet with 0.03% evodiamine (wt/wt) for 2 months, the increases in body weight, adiposity, and the serum levels of leptin and insulin were reduced in a manner indistinguishable from control mice fed a high-fat diet with evodiamine, suggesting that evodiamine triggered a UCP1-independent mechanism to prevent diet-induced obesity.	evodiamine	60-70	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	314-318
17884939-3	2008	When UCP1-knockout mice were fed a high-fat diet with 0.03% evodiamine (wt/wt) for 2 months, the increases in body weight, adiposity, and the serum levels of leptin and insulin were reduced in a manner indistinguishable from control mice fed a high-fat diet with evodiamine, suggesting that evodiamine triggered a UCP1-independent mechanism to prevent diet-induced obesity.	evodiamine	263-273	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	5-9
17884939-3	2008	When UCP1-knockout mice were fed a high-fat diet with 0.03% evodiamine (wt/wt) for 2 months, the increases in body weight, adiposity, and the serum levels of leptin and insulin were reduced in a manner indistinguishable from control mice fed a high-fat diet with evodiamine, suggesting that evodiamine triggered a UCP1-independent mechanism to prevent diet-induced obesity.	evodiamine	263-273	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	5-9
17884939-4	2008	By using preadipocyte cultures, we found that evodiamine, but not capsaicin, increased phosphorylation of ERK/MAPK, reduced the expression of transcription factors such as peroxisome proliferator-activated receptor-gamma, and strongly inhibited adipocyte differentiation.	evodiamine	46-56	mitogen-activated protein kinase 1	Mus musculus	106-109
17884939-4	2008	By using preadipocyte cultures, we found that evodiamine, but not capsaicin, increased phosphorylation of ERK/MAPK, reduced the expression of transcription factors such as peroxisome proliferator-activated receptor-gamma, and strongly inhibited adipocyte differentiation.	evodiamine	46-56	peroxisome proliferator activated receptor gamma	Mus musculus	172-220
17884939-5	2008	Evodiamine treatment also reduced insulin-stimulated phosphorylation of Akt, a crucial regulator of adipocyte differentiation; and the reduction of phosphorylated-Akt and augmentation of phosphorylated ERK were reversed by blockade of the MAPK kinase/MAPK signaling pathway, restoring adipogenesis in the cultures.	evodiamine	0-10	thymoma viral proto-oncogene 1	Mus musculus	72-75
17884939-5	2008	Evodiamine treatment also reduced insulin-stimulated phosphorylation of Akt, a crucial regulator of adipocyte differentiation; and the reduction of phosphorylated-Akt and augmentation of phosphorylated ERK were reversed by blockade of the MAPK kinase/MAPK signaling pathway, restoring adipogenesis in the cultures.	evodiamine	0-10	thymoma viral proto-oncogene 1	Mus musculus	163-166
17884939-5	2008	Evodiamine treatment also reduced insulin-stimulated phosphorylation of Akt, a crucial regulator of adipocyte differentiation; and the reduction of phosphorylated-Akt and augmentation of phosphorylated ERK were reversed by blockade of the MAPK kinase/MAPK signaling pathway, restoring adipogenesis in the cultures.	evodiamine	0-10	mitogen-activated protein kinase 1	Mus musculus	202-205
17884939-6	2008	The changes in ERK and Akt phosphorylation levels were also observed in white adipose tissues of UCP1-knockout mice fed the evodiamine diet.	evodiamine	124-134	mitogen-activated protein kinase 1	Mus musculus	15-18
17884939-6	2008	The changes in ERK and Akt phosphorylation levels were also observed in white adipose tissues of UCP1-knockout mice fed the evodiamine diet.	evodiamine	124-134	thymoma viral proto-oncogene 1	Mus musculus	23-26
17884939-6	2008	The changes in ERK and Akt phosphorylation levels were also observed in white adipose tissues of UCP1-knockout mice fed the evodiamine diet.	evodiamine	124-134	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	97-101
17884939-7	2008	These findings suggest that evodiamine has a potential to prevent the development of diet-induced obesity in part by inhibiting adipocyte differentiation through ERK activation and its negative cross talk with the insulin signaling pathway.	evodiamine	28-38	mitogen-activated protein kinase 1	Mus musculus	162-165
18324518-0	2008	Nitric oxide activated by p38 and NF-kappaB facilitates apoptosis and cell cycle arrest under oxidative stress in evodiamine-treated human melanoma A375-S2 cells.	evodiamine	114-124	mitogen-activated protein kinase 14	Homo sapiens	26-29
18324518-0	2008	Nitric oxide activated by p38 and NF-kappaB facilitates apoptosis and cell cycle arrest under oxidative stress in evodiamine-treated human melanoma A375-S2 cells.	evodiamine	114-124	nuclear factor kappa B subunit 1	Homo sapiens	34-43
18324518-6	2008	It was concluded that p38 and NF-kappaB were critical to the NO producing system, which contributed greatly to the apoptosis and cell cycle arrest in evodiamine-incubated cells.	evodiamine	150-160	mitogen-activated protein kinase 14	Homo sapiens	22-25
18324518-6	2008	It was concluded that p38 and NF-kappaB were critical to the NO producing system, which contributed greatly to the apoptosis and cell cycle arrest in evodiamine-incubated cells.	evodiamine	150-160	nuclear factor kappa B subunit 1	Homo sapiens	30-39
17213816-7	2007	Two modulators of the Akt/NF-kappaB pathway, caffeic acid phenethyl ester and evodiamine, were observed to decrease HIF-1alpha expression.	evodiamine	78-88	AKT serine/threonine kinase 1	Homo sapiens	22-25
17884939-0	2008	Evodiamine improves diet-induced obesity in a uncoupling protein-1-independent manner: involvement of antiadipogenic mechanism and extracellularly regulated kinase/mitogen-activated protein kinase signaling.	evodiamine	0-10	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	46-66
17884939-1	2008	Evodiamine is an alkaloidal compound with antiobesity effects that have been thought to be due to uncoupling protein-1 (UCP1) thermogenesis similar to the effects of capsaicin, but the underlying mechanisms are poorly understood.	evodiamine	0-10	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	98-124
17213816-7	2007	Two modulators of the Akt/NF-kappaB pathway, caffeic acid phenethyl ester and evodiamine, were observed to decrease HIF-1alpha expression.	evodiamine	78-88	hypoxia inducible factor 1 subunit alpha	Homo sapiens	116-126
17340628-0	2007	Anti-proliferative effects of evodiamine on human prostate cancer cell lines DU145 and PC3.	evodiamine	30-40	proprotein convertase subtilisin/kexin type 1	Homo sapiens	87-90
17340628-3	2007	In the present study, the action mechanisms of EVO on the growth of androgen-independent prostate cancer cells (DU145 and PC3 cells) were explored.	evodiamine	47-50	proprotein convertase subtilisin/kexin type 1	Homo sapiens	122-125
17340628-4	2007	EVO dramatically inhibited the growth and elevated cytotoxicity of DU145 and PC3 cells.	evodiamine	0-3	proprotein convertase subtilisin/kexin type 1	Homo sapiens	77-80
17340628-7	2007	TUNEL examination showed that EVO-induced apoptosis was observed at 72 h. EVO elevated the activities of caspase 3, 8, and 9 in DU145 cells, while in PC3 cells only the activities of caspase 3 and 9 were elevated.	evodiamine	30-33	caspase 3	Homo sapiens	105-114
17340628-7	2007	TUNEL examination showed that EVO-induced apoptosis was observed at 72 h. EVO elevated the activities of caspase 3, 8, and 9 in DU145 cells, while in PC3 cells only the activities of caspase 3 and 9 were elevated.	evodiamine	30-33	proprotein convertase subtilisin/kexin type 1	Homo sapiens	150-153
17340628-7	2007	TUNEL examination showed that EVO-induced apoptosis was observed at 72 h. EVO elevated the activities of caspase 3, 8, and 9 in DU145 cells, while in PC3 cells only the activities of caspase 3 and 9 were elevated.	evodiamine	30-33	caspase 3	Homo sapiens	183-192
17340628-7	2007	TUNEL examination showed that EVO-induced apoptosis was observed at 72 h. EVO elevated the activities of caspase 3, 8, and 9 in DU145 cells, while in PC3 cells only the activities of caspase 3 and 9 were elevated.	evodiamine	74-77	caspase 3	Homo sapiens	105-114
17340628-8	2007	EVO also triggered the processing of caspase 3 and 9 in both DU145 and PC3 cells.	evodiamine	0-3	caspase 3	Homo sapiens	37-46
17340628-8	2007	EVO also triggered the processing of caspase 3 and 9 in both DU145 and PC3 cells.	evodiamine	0-3	proprotein convertase subtilisin/kexin type 1	Homo sapiens	71-74
17340628-9	2007	We demonstrate that roscovitine treatment result in the reversion of G2/M arrest in response to EVO in both DU145 and PC3.	evodiamine	96-99	proprotein convertase subtilisin/kexin type 1	Homo sapiens	118-121
17340628-10	2007	However, inhibitory effect of roscovitine on EVO-induced apoptosis could only be observed in DU145 rather than PC3.	evodiamine	45-48	proprotein convertase subtilisin/kexin type 1	Homo sapiens	111-114
17340628-12	2007	Whereas EVO-triggered PC3 apoptosis might be independent of G2/M arrest.	evodiamine	8-11	proprotein convertase subtilisin/kexin type 1	Homo sapiens	22-25
17340628-13	2007	These results suggested that EVO inhibited the growth of prostate cancer cell lines, DU145 and PC3, through an accumulation at G2/M phase and an induction of apoptosis.	evodiamine	29-32	proprotein convertase subtilisin/kexin type 1	Homo sapiens	95-98
16985074-7	2006	We next showed that evodiamine induced the substantial amount of apoptosis both in Bcl-2- and Akt-overexpressing U937 cells but not in human peripheral blood mononuclear cells.	evodiamine	20-30	BCL2 apoptosis regulator	Homo sapiens	83-88
17202687-4	2007	Evodiamine and rutaecarpine inhibited TNF-alpha and IL-4 protein expression in RBL-2H3 cells induced by IgE-antigen complex, although these did not inhibit degranulation of RBL-2H3 cells induced by IgE-antigen complex and rat peritoneal mast cells induced by compound 48/80.	evodiamine	0-10	tumor necrosis factor	Rattus norvegicus	38-47
17202687-4	2007	Evodiamine and rutaecarpine inhibited TNF-alpha and IL-4 protein expression in RBL-2H3 cells induced by IgE-antigen complex, although these did not inhibit degranulation of RBL-2H3 cells induced by IgE-antigen complex and rat peritoneal mast cells induced by compound 48/80.	evodiamine	0-10	interleukin 4	Rattus norvegicus	52-56
17202687-4	2007	Evodiamine and rutaecarpine inhibited TNF-alpha and IL-4 protein expression in RBL-2H3 cells induced by IgE-antigen complex, although these did not inhibit degranulation of RBL-2H3 cells induced by IgE-antigen complex and rat peritoneal mast cells induced by compound 48/80.	evodiamine	0-10	RB transcriptional corepressor like 2	Rattus norvegicus	79-84
16280136-8	2006	After the collection of conditioned media, the VEGF expression of remaining CL1 cells were determined by Western analyses and revealed that evodiamine decreased VEGF expression.	evodiamine	140-150	vascular endothelial growth factor A	Homo sapiens	47-51
16395600-4	2006	Administration of a vasodilator, evodiamine, transiently increased Tskin in Ucp1+/+ and Ucp1-/- mice similarly; whereas the induction of vasodilation caused a greater and more prolonged reduction in Trectal in Ucp1-/- mice than in Ucp1+/+ mice.	evodiamine	33-43	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	76-80
16395600-4	2006	Administration of a vasodilator, evodiamine, transiently increased Tskin in Ucp1+/+ and Ucp1-/- mice similarly; whereas the induction of vasodilation caused a greater and more prolonged reduction in Trectal in Ucp1-/- mice than in Ucp1+/+ mice.	evodiamine	33-43	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	88-92
16395600-4	2006	Administration of a vasodilator, evodiamine, transiently increased Tskin in Ucp1+/+ and Ucp1-/- mice similarly; whereas the induction of vasodilation caused a greater and more prolonged reduction in Trectal in Ucp1-/- mice than in Ucp1+/+ mice.	evodiamine	33-43	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	88-92
16395600-4	2006	Administration of a vasodilator, evodiamine, transiently increased Tskin in Ucp1+/+ and Ucp1-/- mice similarly; whereas the induction of vasodilation caused a greater and more prolonged reduction in Trectal in Ucp1-/- mice than in Ucp1+/+ mice.	evodiamine	33-43	uncoupling protein 1 (mitochondrial, proton carrier)	Mus musculus	88-92
16280136-6	2006	The gene expression of vascular endothelial growth factor (VEGF) and the p44/p42 mitogen-activated protein kinase (MAPK, ERK) that correlated with endothelial cells angiogenesis were inhibited by evodiamine.	evodiamine	196-206	vascular endothelial growth factor A	Homo sapiens	23-57
16280136-6	2006	The gene expression of vascular endothelial growth factor (VEGF) and the p44/p42 mitogen-activated protein kinase (MAPK, ERK) that correlated with endothelial cells angiogenesis were inhibited by evodiamine.	evodiamine	196-206	vascular endothelial growth factor A	Homo sapiens	59-63
16280136-6	2006	The gene expression of vascular endothelial growth factor (VEGF) and the p44/p42 mitogen-activated protein kinase (MAPK, ERK) that correlated with endothelial cells angiogenesis were inhibited by evodiamine.	evodiamine	196-206	interferon induced protein 44	Homo sapiens	73-76
16280136-6	2006	The gene expression of vascular endothelial growth factor (VEGF) and the p44/p42 mitogen-activated protein kinase (MAPK, ERK) that correlated with endothelial cells angiogenesis were inhibited by evodiamine.	evodiamine	196-206	cyclin dependent kinase 20	Homo sapiens	77-80
16280136-6	2006	The gene expression of vascular endothelial growth factor (VEGF) and the p44/p42 mitogen-activated protein kinase (MAPK, ERK) that correlated with endothelial cells angiogenesis were inhibited by evodiamine.	evodiamine	196-206	mitogen-activated protein kinase 1	Homo sapiens	115-119
16280136-6	2006	The gene expression of vascular endothelial growth factor (VEGF) and the p44/p42 mitogen-activated protein kinase (MAPK, ERK) that correlated with endothelial cells angiogenesis were inhibited by evodiamine.	evodiamine	196-206	mitogen-activated protein kinase 1	Homo sapiens	121-124
16280136-7	2006	We found that the evodiamine-treated CL1 cells derived conditioned medium showed decreased VEGF release and reduced ability of inducing in vitro tube formation.	evodiamine	18-28	vascular endothelial growth factor A	Homo sapiens	91-95
16280136-8	2006	After the collection of conditioned media, the VEGF expression of remaining CL1 cells were determined by Western analyses and revealed that evodiamine decreased VEGF expression.	evodiamine	140-150	vascular endothelial growth factor A	Homo sapiens	161-165
16280136-9	2006	Moreover, administration of recombinant human VEGF(165) (rhVEGF(165)) induced tube formation and ERK phosphorylation by HUVECs, and partially attenuated inhibitory effect of evodiamine.	evodiamine	174-184	vascular endothelial growth factor A	Homo sapiens	46-50
15930731-0	2005	Evodiamine induced human melanoma A375-S2 cell death partially through interleukin 1 mediated pathway.	evodiamine	0-10	interleukin 1 alpha	Homo sapiens	71-84
16499090-7	2005	CONCLUSION: PKC lies upstream and exhibits regulatory effect on ERK and Bcl-2 in evodiamine-induced cell death.	evodiamine	81-91	mitogen-activated protein kinase 1	Homo sapiens	64-67
16499090-7	2005	CONCLUSION: PKC lies upstream and exhibits regulatory effect on ERK and Bcl-2 in evodiamine-induced cell death.	evodiamine	81-91	BCL2 apoptosis regulator	Homo sapiens	72-77
16499090-6	2005	Evodiamine inhibited PKC activity, down-regulated the expression of ERK, phospho-ERK and Bcl-2, and staurosporine was capable of augmenting these effects induced by evodiamine.	evodiamine	0-10	mitogen-activated protein kinase 1	Homo sapiens	68-71
16499090-6	2005	Evodiamine inhibited PKC activity, down-regulated the expression of ERK, phospho-ERK and Bcl-2, and staurosporine was capable of augmenting these effects induced by evodiamine.	evodiamine	0-10	mitogen-activated protein kinase 1	Homo sapiens	81-84
16499090-6	2005	Evodiamine inhibited PKC activity, down-regulated the expression of ERK, phospho-ERK and Bcl-2, and staurosporine was capable of augmenting these effects induced by evodiamine.	evodiamine	0-10	BCL2 apoptosis regulator	Homo sapiens	89-94
16499090-6	2005	Evodiamine inhibited PKC activity, down-regulated the expression of ERK, phospho-ERK and Bcl-2, and staurosporine was capable of augmenting these effects induced by evodiamine.	evodiamine	165-175	mitogen-activated protein kinase 1	Homo sapiens	81-84
15705600-8	2005	In a time- and concentration-dependent manner, evodiamine also promoted the phosphorylations of Raf-1 kinase and Bcl-2.	evodiamine	47-57	Raf-1 proto-oncogene, serine/threonine kinase	Homo sapiens	96-101
15930731-1	2005	We have reported that caspase cascade accompanied by the regulation of Bax/Bcl-2 and MAPK signaling were involved in evodiamine-induced A375-S2 cell death.	evodiamine	117-127	BCL2 associated X, apoptosis regulator	Homo sapiens	71-74
15930731-1	2005	We have reported that caspase cascade accompanied by the regulation of Bax/Bcl-2 and MAPK signaling were involved in evodiamine-induced A375-S2 cell death.	evodiamine	117-127	BCL2 apoptosis regulator	Homo sapiens	75-80
15930731-1	2005	We have reported that caspase cascade accompanied by the regulation of Bax/Bcl-2 and MAPK signaling were involved in evodiamine-induced A375-S2 cell death.	evodiamine	117-127	mitogen-activated protein kinase 1	Homo sapiens	85-89
15930731-2	2005	In this study, pretreatment with interleukin 1 (IL-1) receptor antagonist (IL-1Ra) rescued the cell viability loss and reversed the ratio of terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)-positive cells induced by evodiamine.	evodiamine	245-255	interleukin 1 receptor antagonist	Homo sapiens	33-73
15930731-2	2005	In this study, pretreatment with interleukin 1 (IL-1) receptor antagonist (IL-1Ra) rescued the cell viability loss and reversed the ratio of terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL)-positive cells induced by evodiamine.	evodiamine	245-255	interleukin 1 receptor antagonist	Homo sapiens	75-81
15930731-3	2005	IL-1Ra was capable of attenuating the expression of Fas-ligand (Fas-L) and the cleavage of procaspas-8 and -3 caused by evodiamine.	evodiamine	120-130	interleukin 1 receptor antagonist	Homo sapiens	0-6
15930731-4	2005	Subsequently, IL-1Ra reduced evodiamine-induced DNA degradation, p53 activation and up-regulation of Bax/Bcl-2 ratio.	evodiamine	29-39	interleukin 1 receptor antagonist	Homo sapiens	14-20
15930731-4	2005	Subsequently, IL-1Ra reduced evodiamine-induced DNA degradation, p53 activation and up-regulation of Bax/Bcl-2 ratio.	evodiamine	29-39	BCL2 associated X, apoptosis regulator	Homo sapiens	101-104
15930731-4	2005	Subsequently, IL-1Ra reduced evodiamine-induced DNA degradation, p53 activation and up-regulation of Bax/Bcl-2 ratio.	evodiamine	29-39	BCL2 apoptosis regulator	Homo sapiens	105-110
15930731-6	2005	In conclusion, IL-1-induced death cascade in melanoma A375-S2 cell might be one of the targets for natural product evodiamine, and increased Fas-L expression via IL-1 mediated pathway stands at the initiation phase, leading to consequent events that culminate in the death of the cells.	evodiamine	115-125	interleukin 1 alpha	Homo sapiens	15-19
15705600-8	2005	In a time- and concentration-dependent manner, evodiamine also promoted the phosphorylations of Raf-1 kinase and Bcl-2.	evodiamine	47-57	BCL2 apoptosis regulator	Homo sapiens	113-118
15821341-0	2005	Roles of SIRT1 and phosphoinositide 3-OH kinase/protein kinase C pathways in evodiamine-induced human melanoma A375-S2 cell death.	evodiamine	77-87	sirtuin 1	Homo sapiens	9-14
15821341-0	2005	Roles of SIRT1 and phosphoinositide 3-OH kinase/protein kinase C pathways in evodiamine-induced human melanoma A375-S2 cell death.	evodiamine	77-87	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	19-47
15821341-2	2005	After treatment with evodiamine for the indicated time periods, anti-apoptotic protein SIRT1 expression was decreased; p53 expression and its phosphorylation were both enhanced, whereas transient induction of downstream p21 was not enough to promote cell cycle arrest.	evodiamine	21-31	tumor protein p53	Homo sapiens	119-122
15821341-2	2005	After treatment with evodiamine for the indicated time periods, anti-apoptotic protein SIRT1 expression was decreased; p53 expression and its phosphorylation were both enhanced, whereas transient induction of downstream p21 was not enough to promote cell cycle arrest.	evodiamine	21-31	H3 histone pseudogene 16	Homo sapiens	220-223
15821341-2	2005	After treatment with evodiamine for the indicated time periods, anti-apoptotic protein SIRT1 expression was decreased; p53 expression and its phosphorylation were both enhanced, whereas transient induction of downstream p21 was not enough to promote cell cycle arrest.	evodiamine	21-31	sirtuin 1	Homo sapiens	87-92
15821341-3	2005	Inhibition of the phosphoinositide 3-OH kinase (PI3-K)/protein kinase C (PKC) survival pathway as well as subsequent inhibition of the ERK cascade might contribute to evodiamine-induced cell death.	evodiamine	167-177	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Homo sapiens	18-46
15305207-0	2004	Evodiamine functions as an agonist for the vanilloid receptor TRPV1.	evodiamine	0-10	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	62-67
15821341-3	2005	Inhibition of the phosphoinositide 3-OH kinase (PI3-K)/protein kinase C (PKC) survival pathway as well as subsequent inhibition of the ERK cascade might contribute to evodiamine-induced cell death.	evodiamine	167-177	mitogen-activated protein kinase 1	Homo sapiens	135-138
15821341-4	2005	In addition, p53 activation in response to evodiamine administration was correlated with the activation of the PI3-K/PKC pro-apoptotic pathway, but did not require ERK participation.	evodiamine	43-53	tumor protein p53	Homo sapiens	13-16
15821341-5	2005	The inhibition of the PI3-K/PKC survival pathway might be responsible for SIRT1 inactivation and increased Bax/Bcl-2 expression ratio in evodiamine-induced cell death.	evodiamine	137-147	sirtuin 1	Homo sapiens	74-79
15821341-5	2005	The inhibition of the PI3-K/PKC survival pathway might be responsible for SIRT1 inactivation and increased Bax/Bcl-2 expression ratio in evodiamine-induced cell death.	evodiamine	137-147	BCL2 associated X, apoptosis regulator	Homo sapiens	107-110
15821341-5	2005	The inhibition of the PI3-K/PKC survival pathway might be responsible for SIRT1 inactivation and increased Bax/Bcl-2 expression ratio in evodiamine-induced cell death.	evodiamine	137-147	BCL2 apoptosis regulator	Homo sapiens	111-116
15305207-6	2004	We conclude that evodiamine represents a novel class of agonists for rat TRPV1, albeit 3-19-fold less potent than capsaicin, and thus represents a new potential class of lead molecules for drug development.	evodiamine	17-27	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	73-78
15643547-1	2004	Previous investigations have indicated that the pharmacological activities of evodiamine, a major alkaloidal component of the dried, unripe fruit of Evodia rutaecarpa Bentham (Rutaceae), are associated with the stimulation of calcitonin gene-related peptide (CGRP) release and that CGRP protects the myocardium against ischemia-reperfusion injury.	evodiamine	78-88	calcitonin-related polypeptide alpha	Rattus norvegicus	259-263
15643547-1	2004	Previous investigations have indicated that the pharmacological activities of evodiamine, a major alkaloidal component of the dried, unripe fruit of Evodia rutaecarpa Bentham (Rutaceae), are associated with the stimulation of calcitonin gene-related peptide (CGRP) release and that CGRP protects the myocardium against ischemia-reperfusion injury.	evodiamine	78-88	calcitonin-related polypeptide alpha	Rattus norvegicus	282-286
15643547-6	2004	markedly increased the content of CGRP in plasma concomitantly with a significant reduction in infarct size, the activity of serum creatine kinase, and TNF-alpha level, and the effects of evodiamine were completely abolished by capsazepine (5.0 mg/kg, s.c.), a competitive vanilloid receptor antagonist.	evodiamine	188-198	calcitonin-related polypeptide alpha	Rattus norvegicus	34-38
15643547-7	2004	These results suggest that evodiamine exerts a protection against myocardial ischemia-reperfusion injury in rats and that the protective effects of evodiamine are related to stimulation of CGRP release via activation of vanilloid receptors.	evodiamine	148-158	calcitonin-related polypeptide alpha	Rattus norvegicus	189-193
15305207-2	2004	Here, we characterize evodiamine as an agonist for rat TRPV1 expressed heterologously in CHO cells.	evodiamine	22-32	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	55-60
15305207-3	2004	Evodiamine bound to rat TRPV1 with a Ki of 5.95 +/- 0.87 microM, as measured by inhibition of [3H] RTX binding (capsaicin, Ki = 1.8 +/- 0.3 microM).	evodiamine	0-10	transient receptor potential cation channel, subfamily V, member 1	Rattus norvegicus	24-29
15146552-13	2004	Evodiamine elevated caspase-3, and caspase-9 activities and the processing of caspase-3 and caspase-9.	evodiamine	0-10	caspase 9	Homo sapiens	92-101
15102520-10	2004	Moreover, treatment of CCRF-CEM cells with evodiamine was associated with increased levels of pro-apoptotic protein Bax, activation of caspase-3, and proteolytic cleavage of poly (ADP-ribose) polymerase, an endogenous caspase-3 substrate.	evodiamine	43-53	BCL2 associated X, apoptosis regulator	Homo sapiens	116-119
15102520-10	2004	Moreover, treatment of CCRF-CEM cells with evodiamine was associated with increased levels of pro-apoptotic protein Bax, activation of caspase-3, and proteolytic cleavage of poly (ADP-ribose) polymerase, an endogenous caspase-3 substrate.	evodiamine	43-53	caspase 3	Homo sapiens	135-144
15102520-10	2004	Moreover, treatment of CCRF-CEM cells with evodiamine was associated with increased levels of pro-apoptotic protein Bax, activation of caspase-3, and proteolytic cleavage of poly (ADP-ribose) polymerase, an endogenous caspase-3 substrate.	evodiamine	43-53	poly(ADP-ribose) polymerase 1	Homo sapiens	174-202
15102520-10	2004	Moreover, treatment of CCRF-CEM cells with evodiamine was associated with increased levels of pro-apoptotic protein Bax, activation of caspase-3, and proteolytic cleavage of poly (ADP-ribose) polymerase, an endogenous caspase-3 substrate.	evodiamine	43-53	caspase 3	Homo sapiens	218-227
15102520-12	2004	Furthermore, several biological events including the Bcl-2 phosphorylation, Bax up-regulation and increase of caspase-3 activity could explain evodiamine-induced cell apoptosis.	evodiamine	143-153	BCL2 apoptosis regulator	Homo sapiens	53-58
15102520-12	2004	Furthermore, several biological events including the Bcl-2 phosphorylation, Bax up-regulation and increase of caspase-3 activity could explain evodiamine-induced cell apoptosis.	evodiamine	143-153	BCL2 associated X, apoptosis regulator	Homo sapiens	76-79
15102520-12	2004	Furthermore, several biological events including the Bcl-2 phosphorylation, Bax up-regulation and increase of caspase-3 activity could explain evodiamine-induced cell apoptosis.	evodiamine	143-153	caspase 3	Homo sapiens	110-119
15146552-13	2004	Evodiamine elevated caspase-3, and caspase-9 activities and the processing of caspase-3 and caspase-9.	evodiamine	0-10	caspase 3	Homo sapiens	20-29
15146552-13	2004	Evodiamine elevated caspase-3, and caspase-9 activities and the processing of caspase-3 and caspase-9.	evodiamine	0-10	caspase 9	Homo sapiens	35-44
15146552-13	2004	Evodiamine elevated caspase-3, and caspase-9 activities and the processing of caspase-3 and caspase-9.	evodiamine	0-10	caspase 3	Homo sapiens	78-87
15056871-0	2004	Inhibition by evodiamine of hepatocyte growth factor-induced invasion and migration of tumor cells.	evodiamine	14-24	hepatocyte growth factor	Mus musculus	28-52
15056871-4	2004	In this study, the effects of evodiamine on HGF-induced invasion and migration of tumor cell lines, colon 26-L5 carcinoma, B16-F10 melanoma and Lewis lung carcinoma (LLC) were examined.	evodiamine	30-40	hepatocyte growth factor	Mus musculus	44-47
15056871-6	2004	Evodiamine inhibited the HGF-stimulated tumor cell invasion and migration in a concentration-dependent manner, and achieved complete suppression at 30 microM in all of the cell lines tested.	evodiamine	0-10	hepatocyte growth factor	Mus musculus	25-28
15056871-7	2004	When tumor cells were seeded on fibronectin-coated plates with evodiamine, their spreading on the plate was obviously inhibited, while their adhesiveness to fibronectin was unaffected.	evodiamine	63-73	fibronectin 1	Mus musculus	32-43
15056871-9	2004	These results suggest that evodiamine suppressed HGF-stimulated invasion and migration of tumor cells partly through inhibition of cell spreading.	evodiamine	27-37	hepatocyte growth factor	Mus musculus	49-52
12708481-3	2003	The results showed that evodiamine induced oligonucleosomal fragmentation of DNA in HeLa cells and increased the activity of caspase-3, but not that of caspase-1, in vitro.	evodiamine	24-34	caspase 3	Homo sapiens	125-134
14704127-8	2004	Caspase-3 and -8 were activated in apoptosis induced by evodiamine 15 micromol/L.	evodiamine	56-66	caspase 3	Homo sapiens	0-16
14704127-9	2004	However, over 24-h incubation of A375-S2 cells, evodiamine 15 micromol/L initiated necrosis related to p38 and ERK (extracellular signal-regulated kinases) activities.	evodiamine	48-58	mitogen-activated protein kinase 1	Homo sapiens	103-106
14704127-9	2004	However, over 24-h incubation of A375-S2 cells, evodiamine 15 micromol/L initiated necrosis related to p38 and ERK (extracellular signal-regulated kinases) activities.	evodiamine	48-58	mitogen-activated protein kinase 1	Homo sapiens	111-114
14704127-9	2004	However, over 24-h incubation of A375-S2 cells, evodiamine 15 micromol/L initiated necrosis related to p38 and ERK (extracellular signal-regulated kinases) activities.	evodiamine	48-58	mitogen-activated protein kinase 1	Homo sapiens	116-154
14704127-11	2004	CONCLUSION: Evodiamine induces caspase-3,8-dependent apoptosis in HeLa cells which is related to G2/M arrest of the cell cycle.	evodiamine	12-22	caspase 3	Homo sapiens	31-40
14704127-12	2004	On the other hand, in A375-S2 cells, evodiamine initiates caspase-3,8-mediated apoptosis at early stages and the induction of MAPK-mediated necrosis at later stages of cell culture.	evodiamine	37-47	caspase 3	Homo sapiens	58-67
14704127-12	2004	On the other hand, in A375-S2 cells, evodiamine initiates caspase-3,8-mediated apoptosis at early stages and the induction of MAPK-mediated necrosis at later stages of cell culture.	evodiamine	37-47	mitogen-activated protein kinase 1	Homo sapiens	126-130
14600398-3	2003	Although caspase-1 and -10 inhibitors failed to block cell death, pan-caspase inhibitor and caspase-3, -8, and -9 inhibitors had marked inhibitory effects on apoptosis induced by 15 microM evodiamine.	evodiamine	189-199	caspase 3	Homo sapiens	92-113
14600398-4	2003	Furthermore, evodiamine-induced activation of caspase-3 resulted in the down-regulation of anti-apoptotic Bcl-2 expression and up-regulation of proapoptotic Bax expression.	evodiamine	13-23	caspase 3	Homo sapiens	46-55
14600398-4	2003	Furthermore, evodiamine-induced activation of caspase-3 resulted in the down-regulation of anti-apoptotic Bcl-2 expression and up-regulation of proapoptotic Bax expression.	evodiamine	13-23	BCL2 apoptosis regulator	Homo sapiens	106-111
14600398-4	2003	Furthermore, evodiamine-induced activation of caspase-3 resulted in the down-regulation of anti-apoptotic Bcl-2 expression and up-regulation of proapoptotic Bax expression.	evodiamine	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	157-160
14600398-6	2003	Moreover, evodiamine increased the phosphorylation of p38 and decreased the expression and phosphorylation of ERK in caspase-independent necrosis.	evodiamine	10-20	mitogen-activated protein kinase 1	Homo sapiens	54-57
14600398-6	2003	Moreover, evodiamine increased the phosphorylation of p38 and decreased the expression and phosphorylation of ERK in caspase-independent necrosis.	evodiamine	10-20	mitogen-activated protein kinase 1	Homo sapiens	110-113
14600398-7	2003	Consequently, evodiamine induced the caspase- and Bax-mediated apoptosis at an early stage, but, initiated MAPKs-dependent necrosis at a later stage.	evodiamine	14-24	BCL2 associated X, apoptosis regulator	Homo sapiens	50-53
12708481-4	2003	Both evodiamine-induced DNA fragmentation and caspase-3 activity were effectively inhibited by a caspase-3 inhibitor, z-DEVD-fmk (z-Asp-Glu-Val-Asp-fmk).	evodiamine	5-15	caspase 3	Homo sapiens	46-55
12708481-4	2003	Both evodiamine-induced DNA fragmentation and caspase-3 activity were effectively inhibited by a caspase-3 inhibitor, z-DEVD-fmk (z-Asp-Glu-Val-Asp-fmk).	evodiamine	5-15	caspase 3	Homo sapiens	97-106
12708481-5	2003	In addition, evodiamine increased the expression of the apoptosis inducer Bax, but decreased the expression of the apoptosis suppressor Bcl-2 in mitochondria.	evodiamine	13-23	BCL2 associated X, apoptosis regulator	Homo sapiens	74-77
12708481-5	2003	In addition, evodiamine increased the expression of the apoptosis inducer Bax, but decreased the expression of the apoptosis suppressor Bcl-2 in mitochondria.	evodiamine	13-23	BCL2 apoptosis regulator	Homo sapiens	136-141
12708481-6	2003	Taken together, our data indicated that evodiamine alters the balance of Bcl-2 and Bax gene expression and induces apoptosis through the caspase pathway in HeLa cells.	evodiamine	40-50	BCL2 apoptosis regulator	Homo sapiens	73-78
12708481-6	2003	Taken together, our data indicated that evodiamine alters the balance of Bcl-2 and Bax gene expression and induces apoptosis through the caspase pathway in HeLa cells.	evodiamine	40-50	BCL2 associated X, apoptosis regulator	Homo sapiens	83-86
12708481-6	2003	Taken together, our data indicated that evodiamine alters the balance of Bcl-2 and Bax gene expression and induces apoptosis through the caspase pathway in HeLa cells.	evodiamine	40-50	caspase 1	Homo sapiens	137-144
12464363-7	2002	After administration of evodiamine (0.67-6.00 mg/kg), both gastric emptying and gastrointestinal transit were inhibited, whereas the plasma concentration of CCK was increased in a dose-dependent manner.	evodiamine	24-34	cholecystokinin	Rattus norvegicus	157-160
12464363-8	2002	The selective CCK(1) receptor antagonists, devazepide and lorglumide, effectively attenuated the evodiamine-induced inhibition of gastric emptying and gastrointestinal transit.	evodiamine	97-107	cholecystokinin	Rattus norvegicus	14-17
12464363-9	2002	L-365,260 (3R-(+)-N-(2,3-dihydro-1-methyl-2-oxo-5-phenyl-1H-1,4-benzodiazepine-3-yl)-N"-(3-methylphenyl)-urea), a selective CCK(2) receptor antagonist, did not alter the evodiamine-induced inhibition of gastric emptying and gastrointestinal transit.	evodiamine	170-180	cholecystokinin B receptor	Rattus norvegicus	124-139
12464363-10	2002	These results suggest that evodiamine inhibits both gastric emptying and gastrointestinal transit in male rats via a mechanism involving CCK release and CCK(1) receptor activation.	evodiamine	27-37	cholecystokinin	Rattus norvegicus	137-140
12464363-10	2002	These results suggest that evodiamine inhibits both gastric emptying and gastrointestinal transit in male rats via a mechanism involving CCK release and CCK(1) receptor activation.	evodiamine	27-37	cholecystokinin	Rattus norvegicus	153-156
12567888-6	2002	Caspase-3 inhibitor, z-Asp-Glu-Val-Asp-fmk (z-DEVD-fmk) was shown to partially inhibit evodiamine-induced apoptosis.	evodiamine	87-97	caspase 3	Homo sapiens	0-9
12567888-9	2002	Evodiamine-induced apoptosis is partially dependent on caspase-3 pathway in HeLa cells.	evodiamine	0-10	caspase 3	Homo sapiens	55-64
11530944-7	2001	The results demonstrated that evodiamine decreased the basal level of and Ang II-induced release level of aldosterone in rat ZG cells.	evodiamine	30-40	angiotensinogen	Rattus norvegicus	74-80
11530944-9	2001	This suggest that evodiamine affects aldosterone release in rat adrenal glomerulosa cells by acting on Ang II-associated pathway and reducing the activity of 11 beta-hydroxylase (an enzyme which coverts deoxycorticosterone to corticosterone) during the steroidogenesis of aldosterone.	evodiamine	18-28	angiotensinogen	Rattus norvegicus	103-109
10599984-9	1999	These results suggest that evodiamine reduces testosterone secretion in rat TICs via a mechanism involving reduced activity of cAMP-related pathways and 17beta-hydroxysteroid dehydrogenase (17beta-HSD).	evodiamine	27-37	aldo-keto reductase family 1, member C12	Rattus norvegicus	153-188
10599984-9	1999	These results suggest that evodiamine reduces testosterone secretion in rat TICs via a mechanism involving reduced activity of cAMP-related pathways and 17beta-hydroxysteroid dehydrogenase (17beta-HSD).	evodiamine	27-37	aldo-keto reductase family 1, member C12	Rattus norvegicus	190-200